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Objectives: To evaluate the clinical and cost-
effectiveness of capecitabine and tegafur with uracil
(UFT/LV) as first-line treatments for patients with
metastatic colorectal cancer, as compared with 5-
fluorouracil/folinic acid (5-FU/FA) regimens.
Data sources: Electronic databases, reference lists of
relevant articles and sponsor submissions were also
consulted.
Review methods: Systematic searches, selection
against criteria and quality assessment were performed
to obtain data from relevant studies. Costs were
estimated through resource-use data taken from the
published trials and the unpublished sponsor
submissions. Unit costs were taken from published
sources, where available. An economic evaluation was
undertaken to compare the cost-effectiveness of
capecitabine and UFT/LV with three intravenous 5-
FU/LV regimens widely used in the UK: the Mayo, the
modified de Gramont regimen and the inpatient de
Gramont regimens.
Results: The evidence suggests that treatment with
capecitabine improves overall response rates and has
an improved adverse effect profile in comparison with
5-FU/LV treatment with the Mayo regimen, with the
exception of hand–foot syndrome. Time to disease
progression or death after treatment with UFT/LV in
one study appears to be shorter than after treatment
with 5-FU/LV with the Mayo regimen, although it also
had an improved adverse effect profile. Neither
capecitabine nor UFT/LV appeared to improve health-
related quality of life. Little information on patient
preference was available for UFT/LV, but there was
indicated a strong preference for this over 5-FU/LV.
The total cost of capecitabine and UFT/LV treatments
were estimated at £2111 and £3375, respectively,
compared with the total treatment cost for the Mayo
regimen of £3579. Cost estimates were also presented
for the modified de Gramont and inpatient de Gramont
regimens. These were £3684 and £6155, respectively.
No survival advantage was shown in the RCTs of the
oral drugs against the Mayo regimen. Cost savings of
capecitabine and UFT/LV over the Mayo regimen were
estimated to be £1461 and £209, respectively. Drug
acquisition costs were higher for the oral therapies
than for the Mayo regimen, but were offset by lower
administration costs. Adverse event treatment costs
were similar across the three regimens. It was inferred
that there was no survival difference between the oral
drugs and the de Gramont regimens. Cost savings of
capecitabine and UFT/LV over the modified de
Gramont regimen were estimated to be £1353 and
£101, respectively, and over the inpatient de Gramont
regimen were estimated to be £4123 and £2870,
respectively. 
Conclusions: The results show that there are cost
savings associated with the use of oral therapies. No
survival difference has been proven between the oral
drugs and the Mayo regimen. In addition, no evidence
of a survival difference between the Mayo regimen and
the de Gramont regimens has been identified.
However, improved progression-free survival and an
improved adverse event profile have been shown for
the de Gramont regimen over the Mayo regimen.
Further research is recommended into the following
areas: quality of life data should be included in trials of
colorectal cancer treatments; the place of effective oral
treatments in the treatment of colorectal cancer, the
safety mechanisms needed to ensure compliance and
the monitoring of adverse effects; the optimum
duration of treatment; the measurement of patient
preference; and a phase III comparative trial of
capecitabine and UFT/LV versus modified de Gramont
treatment to determine whether there was any survival
advantage and to collate the necessary economic data.
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Glossary
Adjuvant chemotherapy Chemotherapy given
after apparently curative surgery to increase
the chance of cure.
Advanced disease Cancer which has spread
either locally or to distant sites such that a
curative complete resection cannot be
performed.
Cost-effectiveness Measures the net cost of
providing a service and the outcomes obtained.
Cost minimisation If health effects are known
to be equal, only costs are analysed and the
least costly alternative is chosen.
Duration of response Period from first day of
treatment until the date progressive disease was
first noted.
Failure-free survival The length of time from
the start of treatment to either the first
evidence of disease progression, unacceptable
toxicity or death.
First-line treatment Treatment of patients for
advanced disease who have not previously
received chemotherapy for advanced disease (but
may have received previous adjuvant therapy).
Friction-cost method A valuation of work time
lost based on the assumption that in short
periods of illnesses (a friction period) the
productivity losses associated with the loss of a
single worker are less than the productivity of
that worker had she/he been able to work.
Progression-free survival The length of time
from the start of treatment to either the first
evidence of disease progression or death.
Response rate See Appendix 1.
Second-line treatment Treatment of patients
who have previously received chemotherapy for
advanced disease.
Time to progression From date of
randomisation to the first recorded observation
of progressive disease or the occurrence of
death from any cause.
Time to treatment failure As for time to
disease progression but additionally including
toxicity-related premature withdrawals, failure
to return and treatment refusals as events.
Glossary and list of abbreviations
List of abbreviations
5-FU 5-fluorouracil
AIO Arbeitsgemeinschaft
Internische Onkologie
AUC area under the curve
BMS Bristol-Myers Squibb
BNF British National
Formulary
CI confidence interval
CR complete response
continued
viii
Glossary and list of abbreviations
List of abbreviations continued
DPD dihydropyrimidine 
dehydrogenase
ECOG Eastern Cooperative
Oncology Group
EORTC European Organization
QLQ-C30 for Research and
Treatment of Cancer
Quality of Life
Questionnaire
FA folinic acid (leucovorin,
calcium folinate)
FDA Food and Drug
Administration
FLIC Functional Living Index –
Cancer
IRC Independent Review
Committee
ITT intention to treat
i.v. intravenous
LV leucovorin (folinic acid,
calcium folinate)
LYG life-year gained
MAOP Mid-Atlantic Oncology
Program
MdG modified de Gramont
MRC Medical Research Council
NCCTG National Colorectal
Cancer Treatment Group
NCIC National Cancer Institute
of Canada
NICE National Institute for
Clinical Excellence
NS not significant
PD progressive disease
PR partial response
PSSRU Personal and Social
Services Research Unit
PVI protracted venous infusion
RCT randomised controlled trial
SWOG Southwest Oncology Group
QoL quality of life
UFT tegafur with uracil
(Uftoral®)
VAT value added tax
All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or 
it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case 
the abbreviation is defined in the figure legend or at the end of the table.
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Description of proposed service
The service evaluated in this review is the use of
capecitabine and tegafur with uracil (UFT/LV) as
first-line treatments for patient with metastatic
colorectal cancer.
Epidemiology
Colorectal cancer (cancers of the colon and rectum
combined) accounts for 13% of all cancers in
England and Wales and is the second most
common cancer in the UK, after lung cancer. In
1997, 28,900 cases of colorectal cancer were
diagnosed in England and Wales, of which about
two-thirds were in the colon and one-third in the
rectum. Incidence increases with age. The median
age of patients at diagnosis is just under 70 years.
Approximately 80% of patients with colorectal
cancer undergo surgery and, of these, 40% will
remain disease-free in the long term.
Approximately 20% of patients with colorectal
cancer present with advanced disease and, of
these, approximately 50% will have liver
metastases. Median survival after diagnosis of
metastatic disease is approximately 6–9 months.
Patients may have a variety of symptoms, both
physical and psychological, which detract from
their quality of life and often require hospital
admission.
Colorectal cancer is a significant cause of
premature mortality, with 48% of deaths occurring
in the under-75 age group. It is also a significant
cause of morbidity. The main aims of treatment
for patients with metastatic colorectal cancer are to
relieve symptoms, increase survival and improve
quality of life. 
Number and quality of studies
and direction of evidence
Two published randomised controlled trials
(RCTs) of capecitabine, along with one separate
report pooling data from the same two studies,
met the inclusion criteria. These studies compared
treatment with capecitabine to treatment with the
Mayo clinic 5-fluorouracil/leucovorin (5-FU/LV)
regimen. Duration of response, time to disease
progression or death, time to treatment failure
and overall survival were found not to be
significantly different between the two treatments.
Overall response rates, assessed by the
investigator, were significantly greater in both
trials in the capecitabine group, whereas overall
response rates, as assessed by an independent
review committee, were found to be significantly
greater for the capecitabine group in one of the
trials and pooled data. With regard to toxicity,
patients in the capecitabine group reported less
diarrhoea, stomatitis, nausea and alopecia of all
grades than those in the 5-FU/LV groups. Those in
the capecitabine group also had significantly less
grade 3–4 neutropenia and less frequent
hospitalisation for adverse events. Hand–foot
syndrome and grade 3 hyperbilirubinaemia was
significantly greater in the capecitabine group.
Despite this improved toxicity profile, the
reported health-related quality of life did not
differ significantly between the capecitabine and
5-FU/LV groups in either trial.
Two RCTs of treatment with Uftoral®/leucovorin
(UFT/LV) met the inclusion criteria. One trial
compared UFT/LV with the standard Mayo 
5-FU/LV regimen and the other compared
UFT/LV with a modification of the Mayo regimen.
There were no significant differences with regard
to overall response rates, duration of response or
survival between UFT/LV and 5-FU/LV in either
trial. Time to disease progression was significantly
inferior for the UFT/LV group than the 5-FU/LV
group in one study, although there was no
difference in time to disease progression between
UFT/LV and 5-FU/LV in the second study.
Treatment with UFT/LV was associated with
significantly less diarrhoea, nausea/vomiting,
mucositis, neutropenia and thrombocytopenia of
all grades compared with 5-FU/LV in one study
and fewer episodes of stomatitis/mucositis,
neutropenia, thrombocytopenia and anaemia of
any grade in the other study. With regard to grade
3–4 toxicity, mucositis, neutropenia,
thrombocytopenia and anaemia were much less
frequent in the UFT/LV group in one study and
grade 3–4 stomatitis/mucositis and neutropenia
were much less common in the second study.
Executive summary
xSignificantly increased bilirubin was more
common among UFT/LV patients than in those
treated with 5-FU/LV in the first study. As with the
capecitabine studies, despite this improved toxicity
profile, reported health-related quality of life did
not differ significantly between the UFT/LV and 
5-FU/LV groups in either trial.
Economic evidence reviewed in this analysis
includes a pharmacoeconomic study of UFT costs
in South America and two resource-use studies,
one relating to evidence from the Hoff
capecitabine trial and the other to results from the
UFT/LV trial by Carmichael. None of the evidence
identified was directly applicable to the situation
of England and Wales. Two sponsor submissions
received by the National Institute for Clinical
Excellence (NICE) from Roche and Bristol-Myers
Squibb were also reviewed. 
Summary of benefits
There is good evidence to suggest that treatment
with capecitabine improves overall response rates
and has an improved adverse effect profile in
comparison with 5-FU/LV treatment with the Mayo
regimen, with the exception of hand–foot
syndrome. There is no evidence comparing
capecitabine with infusional 5-FU schedules such
as the de Gramont or modified de Gramont
regimens, both commonly used as standard
treatment in the UK. 
Time to disease progression or death after
treatment with UFT/LV in one study appears to be
shorter than after treatment with 5-FU/LV with the
Mayo regimen. There is no evidence comparing
UFT/LV with treatment with the de Gramont or
modified de Gramont regimen. Treatment with
UFT/LV had an improved adverse effect profile
compared with 5-FU/LV treatment with the Mayo
regimen.
Neither capecitabine nor UFT/LV appeared to
improve health-related quality of life. Information
on patient preference was available for UFT/LV
only from a small crossover trial. Patients
appeared strongly to prefer treatment with
UFT/LV over 5-FU/LV.
Costs
Costs were estimated through resource-use data
taken from the published trials and the
unpublished sponsor submissions. Unit costs were
taken from published sources, where available.
The total cost of capecitabine and UFT/LV
treatments were estimated at £2111 and £3375
respectively, compared with the total treatment
cost for the Mayo regimen of £3579. Cost
estimates were also presented for the modified de
Gramont and inpatient de Gramont regimens.
These were £3684 and £6155, respectively. 
Cost-effectiveness
An economic evaluation was undertaken to
compare the cost-effectiveness of capecitabine and
UFT/LV with three intravenous 5-FU/LV regimens
widely used in the UK: the Mayo, the modified de
Gramont regimen and the inpatient de Gramont
regimens. 
No survival advantage was shown in the RCTs of
the oral drugs against the Mayo regimen. Cost
minimisation analyses were therefore undertaken
for both oral therapies against the Mayo regimen.
Cost savings of capecitabine and UFT/LV over the
Mayo regimen were estimated to be £1461 and
£209, respectively. Drug acquisition costs were
higher for the oral therapies than for the Mayo
regimen, but were offset by lower administration
costs. Adverse event treatment costs were similar
across the three regimens.
No direct evidence comparing either capecitabine
or UFT/LV treatment with de Gramont regimens
was identified and therefore an indirect
comparison was undertaken for the purposes of
economic evaluation. On the basis that no proven
survival difference between the Mayo and the de
Gramont regimens was identified, it was inferred
that there was no survival difference between the
oral drugs and the de Gramont regimens. Cost
minimisation analyses of the oral therapies against
the de Gramont regimens were performed. Cost
savings of capecitabine and UFT/LV over the
modified de Gramont regimen were estimated to
be £1353 and £101, respectively. Cost savings of
capecitabine and UFT/LV over the inpatient de
Gramont regimen were estimated to be £4123 and
£2870, respectively.
Cost-effectiveness analyses were also undertaken,
for illustrative purposes, to explore the impact of
adopting an assumption of survival benefit of de
Gramont regimens over the oral regimens.
Infusional regimens have been shown to be more
effective than bolus regimens in terms of
progression-free survival, tumour response and
toxicity. The impact of a potential difference in
Executive summary
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progression-free survival between the oral drugs
and the infusional regimens was explored in terms
of the impact on the cost per progression-free life
year gained. The results are illustrative only.
Further direct evidence on the survival benefits
and costs of oral therapies relative to infusional
regimens is required before any robust conclusions
can be drawn from this type of analysis.
Conclusion
The results show that there are cost savings
associated with the use of oral therapies. No
survival difference has been proven between the
oral drugs and the Mayo regimen. In addition, no
evidence of a survival difference between the Mayo
regimen and the de Gramont regimens has been
identified. However, improved progression-free
survival and an improved adverse event profile
have been shown for the de Gramont regimen
over the Mayo regimen and these need to be
taken into consideration. These issues can only be
indirectly addressed in the absence of direct
randomised comparisons between the oral drugs
and optimum infusional 5-FU regimens. 
Need for further research
The following points have been identified as areas
requiring further research:
 Quality of life data should be included in trials
of colorectal cancer treatments. Well-validated
instruments should be used and this research
should be conducted by independent
researchers. It may be necessary to use more
than one instrument in order to identify
differences in quality of life and then the
components of quality of life that vary with
different treatments.
 More research is needed to determine the place
of effective oral treatments in the treatment of
colorectal cancer. This should focus on when
such treatments should be given alone and
when they should be given in combination with
other chemotherapeutic agents. Research is
needed on the combination of oral agents with
other chemotherapy agents (notably irinotecan
and oxaliplatin) and novel agents.
 Some types of patients may benefit more from
oral treatment than others. Research is needed
to determine what safety mechanisms are
needed in order to ensure compliance and the
monitoring of adverse effects.
 The optimum duration of treatment needs to be
determined with respect to, for example,
disease progression, response, unacceptable
toxicity or death. Intermittent treatment with a
pause after 12 weeks for those with stable or
responding disease also needs to be considered.
 The issue of patient preference must be given
careful consideration in future trials and all
trials should incorporate the measurement of
patient preference.
 In order to make a precise estimate of the cost-
effectiveness of capecitabine and UFT/LV versus
modified de Gramont treatment, a phase III
comparative trial would be necessary to
determine whether there was any survival
advantage and to collate the necessary
economic data. This would also give clinicians
clear information on survival to present to
patients who can then make an informed choice
with regard to treatment.

The overall aim of this review is to evaluate theclinical and cost-effectiveness of capecitabine
and tegafur with uracil as first-line treatments for
patients with metastatic colorectal cancer, as
compared with 5-fluorouracil/folinic acid 
(5-FU/FA) regimens. It reviews these drugs in
relation to their licensed indications. Capecitabine
is indicated for first-line monotherapy for
metastatic colorectal cancer. Tegafur with uracil is
indicated for first-line treatment of metastatic
colorectal cancer in combination with calcium
folinate. This review does not consider the use of
chemotherapy in an adjuvant setting or the use of
these drugs in combination with other
chemotherapy agents or as second-line treatment.
The review does not focus solely on differences
between treatment in overall survival and disease
progression rates as there is also a need to
consider changes in quality of life (QoL)
associated with new drug treatment. The review
therefore includes any significant impacts that
such treatments may have on health-related QoL. 
Progression-free survival is considered to be a
particularly important outcome measure in
relation to the treatment of metastatic colorectal
cancer because disease progression may impair
both physical and emotional health. However,
progression may only become a problem when
symptoms develop. Tumour response (see
Appendix 1) does not necessarily correspond to
subjective benefit in terms of quality of survival,
and subjective improvement (a clinical response) is
possible without an objective response. If survival
advantage is only modest compared with that
provided by alternative regimens, disease-related
symptoms and QoL obviously become particularly
relevant outcome measures.
The following objectives are therefore contained
within the overall aim of the review:
1. to evaluate the clinical effectiveness of the two
drugs in terms of disease progression rates,
tumour response and time to treatment failure
2. to estimate their effects on overall survival,
progression-free survival and QoL adjusted
survival
3. to evaluate their adverse-effect profiles and
toxicities
4. to estimate the incremental cost-effectiveness of
the drugs in comparison to conventional
therapy
5. to estimate the possible overall cost of these
drugs in England and Wales
In undertaking to achieve the above aims, the
review also considers factors such as patient
preference and compliance to treatment. Issues
associated with routinely used intravenous agents
will be considered, such as complications from
catheter use.
Health Technology Assessment 2003; Vol. 7: No. 32
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Chapter 1
Aim of the review

Description of underlying health
problem
Epidemiology of colorectal cancer
Colorectal cancer (cancers of the colon and rectum
combined) accounts for 13% of all cancers in
England and Wales.1 It is the second most common
cancer in the UK after lung cancer. In 1997,
28,900 cases of colorectal cancer were diagnosed
in England and Wales, of which about two-thirds
were in the colon and one-third were in the
rectum.1 Males are more frequently affected than
females, with an age-standardised male:female
ratio of 1.5:1,1 although some studies suggest that
incidence rates for males and females may be
similar.2 The incidence rate per 100,000 (all ages)
is 53.5 for men and 36.7 for women.3 Incidence
increases continuously with age in both sexes for
both colon and rectal cancers.1 The median age of
patients at diagnosis is just under 70 years.4
Risk factors for colorectal cancer are thought to
include diets high in fats and animal proteins and
low in fruit and vegetables and fibre. Other risk
factors associated with developing colon cancer are
lack of physical activity and family history of the
disease. There is some evidence that colon cancer
in women may be related to sex hormones or
reproductive history. The risk of developing
colorectal cancer is also raised for patients with
one or more adenomatous polyps as occurs in
familial adenomatous polyposis and other
hereditary conditions. The incidence of colorectal
cancer is three to four times greater in developed
countries than in developing countries.1 At
present there are no established screening services
for the general population.4
Death rates for England and Wales for 1998 are
illustrated in Table 1.
Large differences in survival exist according to the
stage of disease.2 The overall 5-year survival rate
in England is 35%; however, within Britain, there
is evidence of wide variations in treatment and
outcomes.3 Table 2 shows the modified Dukes’
staging of colorectal cancer with 5-year survival.
On average, patients survive for 3 years after
diagnosis.4 Median survival after diagnosis of
metastatic disease is approximately 6–9 months.
The 5-year survival rate for advanced colorectal
cancer is lower than 5%.6 Patients may develop a
variety of symptoms during this time, both
physical and psychological.7 In about 20% of cases
of colorectal cancer, patients present with
advanced disease and, of these, approximately
50% will have liver metastasis.6
Significance in terms of ill-health
Colorectal cancer is a significant cause of
premature death, with 48% of deaths occurring in
the under-75 age group. It is also a significant
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TABLE 1 Death rates for colorectal cancer in England and
Wales in 19985
Age (years)
0–44 45–64 65–74 75+ Total
Deaths 203 2783 4132 7866 14,984
Rate per 100,000
population 0.6 23.0 93.9 202.3 28.6
TABLE 2 Modified Dukes’ staging of colorectal cancer, with 5-year survivala3
Dukes’ stage Definition Approximate frequency 5-year survival
(modified) at diagnosis (%) (%)
A Cancer localised within bowel wall 11 83
B Cancer which penetrates the bowel wall 35 64
C Cancer spread to the lymph nodes 26 38
D Cancer with distant metastases (most often in the liver) 29 3
a Data from St. Vincent’s Hospital, Dublin. These figures are illustrative only, since stage frequency and survival statistics vary
between published series from different centres.
cause of morbidity. When treating patients with
metastatic colorectal cancer, the main aims of
treatment are to relieve symptoms, increase
survival and improve QoL. Individual patient
preferences for treatment are also important to
consider.
There is some evidence that extended survival is
not always associated with an overall improvement
in QoL. The treatments assessed in this report
provide palliative care and offer no real chance of
long-term survival. For this reason, information
regarding health-related QoL, particularly that
associated with treatment-related toxicity, will be
given careful consideration. Since chemotherapy
can cause disabling adverse effects, assessing QoL
outcomes is essential.
Current service provision
Overview of current service
The NHS Executive document ‘Improving
Outcomes in Colorectal Cancer’ outlines current
service provision for the diagnosis, treatment and
follow-up of patients with colorectal cancer.4
Approximately 80% of patients with colorectal
cancer undergo surgery3 and chemotherapy is
used as an adjuvant treatment after surgery to
improve survival.3 About 50% of patients treated
with curative surgery will go on to develop
advanced disease and of those with advanced
disease, 50% will present with liver metastasis.6
Once metastatic disease develops, curative
treatment is rarely possible. Resection of liver
metastases produces occasional cures in cases
where there is no evidence of extra-hepatic disease
and the position and size of the metastases is
favourable; similarly, resection of isolated lung
metastases may be worthwhile. However, for the
large majority of patients, treatment is aimed at
modest extension of survival with palliation of
symptoms. In this situation, chemotherapy is the
principle active treatment, although palliative
radiotherapy and surgery have a role for some
patients with localised symptoms.
There is clear evidence that chemotherapy
improves survival and prolongs time to disease
progression in patients with advanced colorectal
cancer.8–10 Chemotherapy delays the occurrence or
progression of symptoms by about 6 months and
improves symptoms, weight gain and functional
performance in about 40% of patients.6 However,
patients must be sufficiently fit to receive
chemotherapy. Referral patterns and treatment
policies for patients with advanced colorectal
cancer vary widely in the UK.6
5-Fluorouracil (5-FU) has been the main treatment
for advanced colorectal cancer for over 40 years,
usually in combination with calcium folinate
[calcium leucovorin, leucovorin (LV), folinic acid].
Fluorouracil is a prodrug which is converted
intracellularly into metabolites that inhibit the
enzyme thymidylate synthase. This prevents DNA
synthesis and inhibits RNA and protein
synthesis.11 5-FU is usually given as a bolus
intravenous injection or via infusion as it has
erratic oral bioavailability.11 The addition of
calcium folinate enhances response rates.12
Trials comparing chemotherapy given
immediately on diagnosis of advanced or
recurrent disease with chemotherapy for the
palliation of symptoms have shown that early
chemotherapy increases median survival and that
symptom-free survival increases from a median of
2 months to 10 months (p < 0.001).3
5-FU regimens
A variety of 5-FU-based regimens are currently in
use in the UK. Details of these 5-FU regimens are
listed in Appendix 2, involving mainly bolus
injection or continuous infusion. Bolus regimens
typically require frequent hospital visits.
Continuous infusion regimens require placement
of a venous access device, the use of a portable
infusion pump and intravenous infusion
supplies.13 The use of infusional regimens is
frequently associated with complications such as
infections and thromboses,14 while bleeding and
pneumothorax occur rarely.
Internationally, the most commonly used bolus
regimen is the so-called Mayo Clinic or National
Colorectal Cancer Treatment Group (NCCTG)
schedule and this is also the most frequently used
comparator in clinical trials. It is not used as often
in the UK as in the past and its use as a
comparator in clinical trials is a reflection of
current practice in the USA rather than in the UK.
A meta-analysis comparing continuous infusion of
5-FU with bolus administration found that
continuous infusion administration was superior in
terms of tumour response and resulted in a slight
increase in overall survival.15,16 The results of the
meta-analysis are presented in detail in 
Appendix 3. 
The three infusional regimens currently in use in
the UK are the Lokich, the de Gramont and the
Background
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modified de Gramont, with the de Gramont and
modified de Gramont being more frequently used.
A randomised trial comparing the de Gramont
regimen with the Mayo bolus regimen found the
de Gramont regimen to have significantly better
response rates and progression-free survival than
the Mayo regimen and equivalent median survival
times.17 Grade 3–4 toxicities also occurred in more
patients in the Mayo regimen than in the de
Gramont. The results of this trial are presented in
detail in Appendix 4. 
The de Gramont regimen has been demonstrated
to be equivalent to the Lokich infusional regimen
in terms of survival, QoL and response rates,
although the Lokich regimen was associated with
more central line complications and hand–foot
syndrome18 (palmar–plantar erythrodysasthesia),
which causes unpleasant and painful reddening of
the soles of the feet and palms of the hands. 
Response rates, progression-free survival and
median overall survival for the de Gramont
regimen have been reported in comparisons of
this regimen with other treatment regimens.19,20
The range of reported response rates,
progression-free survival and overall median
survival for the de Gramont regimen from four
studies are reported in Appendix 5. It is difficult
to compare the results of different studies for
several reasons, apart from the fact that they use
different comparators. Some studies report
intention to treat (ITT) analyses whereas others
use per protocol analyses. In one study, de
Gramont and colleagues17 only included patients
with measurable lesions in the response rate
analyses in both arms of the trial. Some values
have been assessed by the investigators themselves
whereas others have used independent assessors.
Finally, the studies were designed to use different
primary outcome measures and are therefore not
directly comparable. However, the figures reported
in Appendix 5 give an overall picture of the range
of values reported in these studies.
The de Gramont regimen is repeated every 14
days. It can be administered on an inpatient or
outpatient basis. A modified de Gramont regimen
has been developed whereby LV and bolus 5-FU
are given only on the first day of treatment,
followed by a higher dose 5-FU infusion over 46
hours. This requires the insertion of a central line
as a day-case procedure, thus enabling most
patients to be treated as outpatients, spending half
a day in the day unit and receiving a home visit
from a district nurse for each course of treatment.
A dose-escalation study was used to confirm the
activity of this regimen and to establish the
optimum dose.21 A pilot study has indicated that
this modified de Gramont regimen is associated
with higher compliance, fewer treatment delays
and significantly higher QoL than the inpatient de
Gramont regimen.22 However, for any regimen
which uses indwelling venous lines, the line itself
may present significant problems. For example, a
report from the Royal Marsden Hospital has
indicated that 11% of Hickman lines used for
protracted venous infusion 5-FU have to be
removed unplanned, most commonly because of
superficial infection, pain, line slippage,
septicaemia or thrombosis.23
Approximately 60% of patients who receive first-
line 5-FU/LV therapy have a response or a period
of stable disease. This is temporary, however, and
drug resistance develops. About 40% of patients
have disease that does not respond to 5-FU.
Second-line treatments may then be used.
Recently, the National Institute for Clinical
Excellence (NICE) recommended that irinotecan
monotherapy may be used as second-line
treatment for patients who have failed an
established 5-FU-containing treatment regimen.24
Combination therapies
Recently interest has centred on the possibility of
combining drugs with different mechanisms to treat
colorectal cancer. Several randomised controlled
trials (RCTs) have demonstrated that combination
chemotherapy with 5-FU/LV and either oxaliplatin
or irinotecan produces a higher response rate,
longer time to progression and in some cases
better overall survival than 5-FU/LV alone.21,20 A
current Medical Research Council (MRC) trial
(CR08; FOCUS) is further examining these
combinations, comparing their effect on overall
survival and QoL when used as routine first-line
therapy for all patients, or as planned second-line
therapy after an initial trial of 5-FU/LV alone. This
trial is expected to report in 2004; meanwhile,
NICE has recommended that oxaliplatin/5-FU/LV
should be considered for patients with metastases
that are confined to the liver and may become
resectable following treatment.24
Variation in services
Patterns for referral vary widely throughout the
country. Performance status will have a bearing on
whether or not a patient is eligible for
chemotherapy. Those with a poor performance
status (3 or 4 on the WHO Performance Scale) are
not able to benefit from chemotherapy. Therefore,
many patients, particularly elderly patients, are
managed in the primary care setting. 
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There is no clear evidence as to which 5-FU
regimen is most frequently used in the UK. As the
de Gramont regimen was recently found to be
superior17 to the Mayo regimen, more clinicians
are now using this or the modified de Gramont
regimen. Treatment regimen may also vary
depending on where patients would like to be
treated. As the de Gramont regimen is relatively
expensive, some centres may not use it.7
Current service cost
The care and treatment of patients with colorectal
cancer in the UK have been estimated to account
for approximately 2% of all bed days and for
between 10 and 20% of all palliative care
provision.25
Description of new intervention
Two new drugs, capecitabine and tegafur with
uracil, have been proposed for first-line treatment
of patients with metastatic colorectal cancer. They
will be discussed separately below. Both drugs are
administered orally. 
Summary of product characteristics
Capecitabine (Roche)
Capecitabine (N-[1-(5-deoxy--D-ribofuranosyl)-5-
fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl]-m-pentyl
carbamate; Ro 09-197) is a cytotoxic
fluoropyrimidine carbamate. It is an oral 5-FU
pro-drug with no anti-tumour activity itself.26 It is
metabolised in the body via three sequential
enzyme steps to produce 5-FU within tumours.
Capecitabine is preferentially activated in tumour
tissue.13
The UK licence for capecitabine is held by Roche
and it is marketed as Xeloda®. Xeloda is available
as blisters of film-coated tablets in two sizes: 
60 × 150 mg (six blisters of 10 tablets) and 
120 × 500 mg (12 blisters of 10 tablets).
Xeloda is indicated for first-line monotherapy of
metastatic colorectal cancer. It is also used in the
treatment of advanced or metastatic breast cancer. 
The recommended dose is 1250 mg/m2
administered twice daily (morning and evening;
equivalent to 2500 mg/m2 total daily dose) for 14
days followed by a 7-day rest period.27
Xeloda is contraindicated in patients with
 a history of severe and unexpected reactions to
fluoropyrimidine therapy
 known hypersensitivity to capecitabine, 5-FU or
any of the excipients
 known dihydropyrimidine dehydrogenase
(DPD) deficiency
 pregnancy and lactation
 severe leucopenia, neutropenia or
thrombocytopenia
 severe hepatic impairment
 severe renal impairment (creatinine clearance
below 30 ml/min)
 treatment with sorivudine or its chemically
related analogues, such as brivudine.
Tegafur with uracil (UFT) (Bristol-Myers Squibb
Company)
Tegafur [FT; ftorafur; 1-(tetrahydro-2-furanyl)-5-
fluorouracil] is a furanyl nucleoside analogue of
FudR.28 Tegafur is a prodrug of fluorouracil and
the addition of uracil inhibits the degradation of
5-FU. Early clinical trials of UFT were conducted
in Japan,29 where it has been licensed for use since
1983 and has been used to treat a variety of solid
tumours.30 The addition of LV (calcium folinate)
acts as a modulator and leads to an improvement
in response rates,28 although this has also been
shown to increase toxicity.31 UFT/LV has been
approved for use in the European Union.32
The UK licence for UFT is held by Bristol-Myers
Squibb and it is marketed as Uftoral®. Uftoral is
available as hard, white, opaque capsules
imprinted with the code TC434. Each capsule
contains tegafur (100 mg) plus uracil (224 mg).
Uftoral is indicated as first-line treatment of
metastatic colorectal cancer, in combination with
calcium folinate in adults. 
The recommended dose of Uftoral is tegafur 
300 mg/m2 (with uracil 672 mg/m2) daily,
combined with 90 mg/day oral calcium folinate,
given in three divided doses (preferably every 
8 hours) for 28 days with subsequent courses
repeated after 7-day intervals giving a treatment
cycle of 35 days.27
Uftoral is contraindicated in patients who
 have a known hypersensitivity to 5-FU, tegafur,
uracil or any of the excipients
 are pregnant or attempting to become pregnant
 are breastfeeding
 are adolescents, children or infants
 have severe hepatic impairment
 present with evidence of bone marrow
suppression from previous radiotherapy or
antineoplastic agents
 have a known deficiency of hepatic CYP2A6.
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Identification of patients
These treatments would only be suitable for
patients able to self-medicate or who live with
someone able to undertake a supervisory role. 
Criteria for treatment
These interventions, capecitabine and UFT/LV,
would be used mainly by people with a WHO
performance status of 2 or less (see Appendix 6). 
These treatments would most likely be supplied in
dedicated oncology centres with consultant
oncologist supervision. Support for home use of
these drugs would be needed via a call centre or
visits from trained nurses.
Degree of diffusion
Both capecitabine and UFT/LV are already in use
as first-line treatment for metastatic colorectal
cancer, but the full extent of use is not known. The
use of these drugs is frequently within the context
of clinical trials. There is significant usage of these
agents in private practice and some usage in NHS
practice whenever a reason for avoidance of a
central line can be substantiated. 
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Methods for reviewing
effectiveness
Identification of studies
The search strategy aimed to identify all literature
relating to the clinical and cost-effectiveness of
capecitabine and UFT for the treatment of
metastatic colorectal cancer. The main searches
were conducted in April and May 2002.
Fifteen electronic bibliographic databases were
searched, covering biomedical, science, social
science, health economic and grey literature. A list
of databases is provided in Appendix 7.
In addition, the reference lists of relevant articles
and sponsor submissions were hand-searched and
various health services research-related resources
were consulted via the Internet. These included
health economics and health technology
assessment organisations, guideline-producing
agencies, generic research and trials registers and
specialist sites. A list of these additional sources is
given in Appendix 7. Citation searches were
conducted on key papers and authors using the
Science and Social Science Citation Index facilities.
A combination of free-text and thesaurus terms
were used. ‘Population’ search terms (e.g. colorectal,
colon, rectum, neoplasm, carcinoma,
adenocarcinoma) were combined with ‘intervention’
terms (e.g. capecitabine, xeloda, fluoropyrimidine,
tegafur, uftoral). Three searches were performed
in MEDLINE: the first was the main MEDLINE
search, the second was for the epidemiology of
colorectal cancer and the third was performed to
identify further references specifically on the two
5-FU regimens (de Gramont and Mayo Clinic).
Copies of the search strategies used in the major
databases are included in Appendix 7. 
No language or date restrictions were applied to
the searches. The search performed in MEDLINE
for the epidemiology of colorectal cancer was
limited to 1990–present to ensure that only recent
data were reviewed. No language or
study/publication-type restrictions were applied to
the main searches. An economic evaluations filter
was used in the main searches performed in
MEDLINE and EMBASE to assist with the
identification of articles for the cost-effectiveness
aspect of the review (see Appendix 7).
Inclusion and exclusion criteria
The titles and abstracts of the papers identified
through the search process outlined above were
assessed for relevance to the study question using
the following criteria.
Inclusion criteria
Subjects: adults with metastatic colorectal cancer.
Intervention: capecitabine or UFT/LV used alone
as first-line treatment.
Comparators: 5-FU/LV regimens for metastatic
colorectal cancer.
Outcome measures to include the following: 
 survival rates
 progression-free survival
 tumour response
 time to treatment failure
 health-related QoL
 adverse events
 patient preference
 compliance
 cost.
Methodology, to include at least one of the
following: 
 systematic reviews or meta-analyses
 RCTs
 non-randomised studies (for outcomes where no
data from RCTs are available)
 economic evaluations.
Full copies were obtained of all those papers which
appeared to be relevant or which could not be
assessed on the basis of the abstract alone.
Exclusion criteria
Papers describing the use of chemotherapy in an
adjuvant setting were excluded. Papers describing
randomised phase II trials were excluded where
phase III evidence was available.
Figure 1 shows a summary of study selection and
exclusion.
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Quality assessment strategy
The RCTs were assessed for quality using the
Jadad criteria.33 Other criteria were used to assess
the quality of the meta-analyses34 and non-
randomised studies.35
Data extraction strategy
Data were extracted by one researcher and checked
by a second using customised data extraction forms.
Any disagreements were resolved by discussion. 
The data extracted from the relevant studies will
be presented separately for the two interventions.
Where available, the following data will be
reviewed in relation to each intervention:
 duration of treatment
 progression-free survival
 overall survival
 tumour response rates
 time to progression or death
 duration of response
 treatment-related deaths
 grade 1–4 toxicities
 QoL
 patient preference.
No meta-analyses of the capecitabine trials were
identified, although a study of pooled data was
identified.36 No meta-analyses of the UFT/LV
trials were identified or undertaken. The two trials
used different 5-FU regimens and also different
dosages of calcium folinate (LV). Meta-analysis was
therefore felt to be inappropriate.
Choice of outcomes
As described above, a variety of end-points form
part of the data extracted from the relevant trials
in this review. Relevant end-points in evaluating
treatments for colorectal cancer include tumour
response rates, progression-free survival and
overall survival. However, it is not clear how these
outcomes relate to each other and which, if any,
are most important. In a meta-analysis of 25
randomised trials of first-line treatment
comparing standard bolus 5-FU treatment with a
variety of experimental fluoropyrimidines, the
authors concluded that an increase in tumour
response rates translated into an increase in
overall survival. However, it was emphasised that
knowledge that a treatment improves tumour
response rates does not necessarily accurately
predict benefit with regard to overall survival.37
In another study, Louvet and colleagues38
suggested that progression-free survival, rather
than overall survival, is the most appropriate
primary end-point for interpreting effectiveness in
studies of metastatic colorectal cancer treatments.
They analysed data from 29 phase III trials and
found significant correlations between
progression-free survival and response rates,
between response rates and overall survival and
between progression-free survival and overall
survival. The strongest correlation was between
response rates and progression-free survival. 
Progression-free survival reflects the effectiveness
of the first-line treatment whereas overall survival
reflects the effectiveness of first-line treatment and
any second-line treatment used. When comparing
treatments where overall survival is equivalent, the
use of other end-points is even more important
than treatments resulting in different survival
times. These end-points include response rates,
time to disease progression, tolerability and
patients’ convenience.39 Because of the
uncertainties surrounding choice of outcome
measure, all outcomes reported in the trials are
included in this review.
Results
Two large phase III RCTs40,41 and one study of
pooled data of capecitabine36 were identified. The
evidence from these trials is summarised below in
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Studies rejected at title
N = 1190
Rejected full papers
N = 204
Studies rejected at abstract
N = 115
Potentially relevant studies 
identified and screened for 
retrieval
N = 1453 from databases
N = 63 from other sources
Total N = 1516
Total abstracts
screened
N = 263
Included studiesa
N = 7
Total full
papers screened
N = 148 (plus 63 
from other sources)
FIGURE 1 Summary of flow of study selection and exclusion:
clinical effectiveness. aThese studies refer to papers of trials of
capecitabine and UFT/LV. Other papers are included in this
report dealing with background information, patient preference,
QoL and toxicity. Studies used in the cost-effectiveness analysis
are listed in Chapter 4.
the next section. No phase III RCTs of
capecitabine were excluded from the review.
Two large phase III RCTs of UFT/LV were
identified.42,43 The results of these trials, together
with supplementary information, are summarised
in the section ‘Quality of research available:
UFT/LV’ (p. 20). No phase III RCTs of UFT/LV
were excluded from the review.
Information on QoL and patient preference is
presented separately within the relevant sections.
Quantity and quality of research
available: capecitabine
Capecitabine is licensed for use as first-line
treatment as monotherapy for patients with
metastatic colorectal cancer. It is also licensed for
use in the treatment of advanced or metastatic
breast cancer. This review will deal only with its use
in the treatment of metastatic colorectal cancer.
Three studies have been identified which deal with
the use of capecitabine as first-line treatment for
metastatic colorectal cancer, two RCTs40,41 and a
study of pooled data from these two RCTs.36 The
capecitabine studies included in this review are
listed in Table 3. 
These studies relate to comparisons between
treatment with capecitabine and an intravenous 
5-FU regimen (Mayo). The two RCTs40,41 were
designed with identical protocols to facilitate
pooling of the data. The third study36 shows the
pooled data from these two trials. 
Study characteristics of included capecitabine
studies
Tables 4 and 5 illustrate the study design and
patient details, respectively. As stated previously,
the RCTs were designed with identical protocols.
Therefore, the inclusion/exclusion criteria 
outlined in Table 4 were identical. Both RCTs 
were adequately powered to demonstrate at 
least equivalence in overall response rates. Apart
from alkaline phosphatase levels in the Hoff
study,40 there was baseline comparability between
the two groups in both RCTs. Baseline levels of
serum alkaline phosphatase were significantly
elevated in the capecitabine group compared 
with the 5-FU/LV group, indicating that the 
5-FU/LV patients were of an inherently better
prognosis.
Table 5 describes the patient details of the
capecitabine studies. For information on the
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TABLE 3 Capecitabine studies included in the review
Study Study site Comparators, dosage Type of study Numbers Funding
and procedure randomised
Hoff et al.,
200140
61 centres in USA,
Canada, Brazil and
Mexico
Capecitabine 1250 mg/m2 twice
daily in 3-week cycles 
(2 weeks of treatment followed
by a 1-week rest period) 
5-FU/LV in Mayo clinic regimen:
rapid intravenous (i.v.) injection
of 20 mg/m2 LV followed by an
i.v. bolus injection of 425 mg/m2
5-FU daily, days 1–5 every 4
weeks
Open label,
phase III RCT
Capecitabine 
n = 302
5-FU/LV 
n = 303
Hoffman-LaRoche
Van
Cutsem 
et al.,
200141
59 centres in
Europe, Australia,
New Zealand,
Taiwan and Israel
Capecitabine 1250 mg/m2 twice
daily in 3-week cycles (2 weeks
of treatment followed by a 
1-week rest period)
5-FU/LV in Mayo clinic regimen:
rapid i.v. injection of 20 mg/m2
LV followed by an i.v. bolus
injection of 425 mg/m2 5-FU
daily, days 1–5 every 4 weeks
Open label,
phase III RCT
Capecitabine 
n = 301
5-FU/LV 
n = 301
Hoffman-LaRoche
Twelves
200236
120 centres
(pooled results of
above two trials)
As above Pooled data
from the above
two phase III
trials
Capecitabine 
n = 603
5-FU/LV 
n = 604
Not reported
Karnofsky performance score, see Appendix 6.
The primary tumour site was the colon in the
majority of patients treated with either
capecitabine or 5-FU/LV and the most common
site of metastasis was the liver.
Study quality of included capecitabine studies
Table 6 shows the study quality of the two
capecitabine RCTs. The Jadad criteria were used
to assess the quality of the RCTs.33 The Jadad
criteria consist of three categories: randomisation
Effectiveness
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TABLE 4 Study design: capecitabine
Study Length of study Inclusion criteria Exclusion criteria Power Baseline 
calculation comparability
Hoff et al.,
200140
Assessments
performed up to
30 weeks for most
patients and 48
weeks for those
receiving
prolonged therapy
Patients with advanced or
metastatic disease and no
previous chemotherapy
for metastatic disease.
Adjuvant chemotherapy
completed at least 6
months before trial
enrolment; histological or
cytological confirmation
of colorectal
adenocarcinoma was
required and also at least
one bidimensionally
measurable indicator
lesion that had not been
irradiated; at least 18
years of age; Karnofsky
performance status
≥ 70%; life expectancy of
at least 3 months
Pregnancy or lactation,
hypersensitivity to 5-FU
or had previous severe
reaction to
fluoropyrimidines, history
of other cancer within
previous 5 years (except
for cured basal cell
carcinoma of the skin or
in situ cervical carcinoma),
experimental drugs or
radiotherapy within 4
weeks before enrolment
or not fully recovered
from recent major
surgery; patients with
organ allografts; CNS
involvement of their
disease, neurological or
psychiatric disorders to
interfere with treatment
compliance, significant
cardiac disease or MI in
last 12 months; serious
uncontrolled infections;
malabsorption syndrome,
lack of physical integrity of
the upper gastrointestinal
tract; abnormalities in
neutrophils, platelets,
serum creatinine or serum
bilirubin, alanine
transferase (ALT),
aspartate transferase
(AST) or alkaline
phosphatase (five times
upper normal limit for
ALT, AST and alkaline
phosphatase allowed for
those with liver
metastases and 10 times
alkaline phosphatase for
patients with bone
metastases)
Sample size was
sufficient to
achieve 80%
power to
demonstrate at
least
equivalence in
overall response
rates
Yes, apart from
serum alkaline
phosphatase
concentrations
at baseline
(significantly
higher in
capecitabine
group than 
5-FU/LV group,
p < 0.0025)
Van
Cutsem 
et al.,
200141
As above As above As above As above Yes
Twelves,
200236
As above As above As above As above Yes
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TABLE 5 Patient details: capecitabine
Study Sex (M/F) Age (years) Performance score Primary site Sites of metastasis
SD, standard deviation. 
Hoff et al.,
200140
Capecitabine: 181/121
5-FU/LV: 197/106
Median (range):
Capecitabine 64.0 (23–86)
5-FU/LV 63.0 (24–87)
Karnofsky performance score:
Capecitabine 5-FU/LV
Mean 88.3 88.5
SD 10.0 9.8
Median 90 90
Range 70–100 70–100
Site of primary tumour (%):
Capecitabine 5-FU/LV
Colon 222 (73.5) 232 (76.6)
Rectal 79 (26.2) 70 (23.1)
Metastatic sites at baseline:
Capecitabine 5-FU/LV
Liver 232 225
Lymph nodes 116 123
Lung 107 107
Peritoneum 41 46
Soft tissue 30 28
Other 94 103
Van Cutsem
et al., 200141
Capecitabine 57/43%
5-FU/LV 57/43%
Median (range):
Capecitabine 64.0 (29–84)
5-FU/LV 63.5 (36–86)
Karnofsky performance score:
Capecitabine 5-FU/LV
Mean 89.7 89.6
SD 9.7 9.7
Median 90 90
Range 70–100 70–100
Site of primary tumour (%):
Capecitabine 5-FU/LV
Colon 66.1 65.1
Rectal 33.6 34.9
Metastatic sites at baseline:
Capecitabine 5-FU/LV
Liver 230 238
Lymph nodes 82 88
Lung 89 89
Peritoneum 37 40
Soft tissue 27 28
Other 40 54
Twelves,
200236
Capecitabine 60/40%
5-FU/LV 61/39%
Median (range):
Capecitabine 64 (23–86)
5FU/LV 63 (24–87)
Karnofsky performance status
(%), mean (range):
Capecitabine 89 (70–100)
5-FU/LV 89 (70–100)
Site of primary tumour (%),
colon/rectal cancer (%):
Capecitabine 5-FU/LV
70/30 71/29
Predominant metastatic sites at
baseline (%):
Capecitabine 5-FU/LV
Liver (%) 77 77
Lung (%) 12 14
(including method to generate the sequence of
randomisation and whether or not the method was
appropriate), double blinding and description of
withdrawals and dropouts. The maximum number
of possible points is five. The Jadad score of both
RCTs was 3, indicating that the studies were of
moderate quality. Neither study was double
blinded, which resulted in loss of points according
to these criteria. However, blinding would be
virtually impossible when comparing an oral drug
with a bolus 5-FU regimen, as the mode of
delivery is different for the two treatments. The
problem of blinding was partly overcome in these
studies by the use of an Independent Review
Committee (IRC) to assess response rates.
The pooled data report36 included the two RCTs.
As they were designed using identical protocols,
pooling was an appropriate method of synthesis.
The trials were of identical size, giving them equal
weight. Meta-analysis techniques were not used in
the synthesis so it is not appropriate to assess the
quality of the study as if it were a meta-analysis but
rather as a large RCT. In this case, the pooled
data would receive a score of 3 according to the
Jaded criteria, again indicating moderate quality.
Assessment of effectiveness of capecitabine
Outcomes for the capecitabine trials are listed in
Table 7 and results are given in Table 8. Primary
outcomes in both trials were tumour response
rates and secondary outcomes included time to
response, duration of response, time to disease
progression and overall survival. Analyses of
efficacy were based on all patients randomised,
indicating an ITT analysis.
Tumour response rates
Information on the definition of response rates can
be found in Appendix 1. Both the Hoff40 and Van
Cutsem41 studies had tumour response rates as a
primary outcome. Both studies reported response
rates as measured by the study investigator and by
an IRC, a panel of radiologists who were blinded
to study treatment, clinical condition of the
patient and investigator’s assessment. 
In the Hoff study,40 overall response rates for the
capecitabine group were significantly greater than
for the 5-FU/LV group when assessed by
investigator or by the IRC. Overall response rates
were 24.8% [95% confidence interval (CI): 20.1 to
30.1%] for capecitabine and 15.5% (95% CI: 11.6
to 20.1%) for 5-FU/LV (p = 0.005) when assessed
by investigator. When assessed by the IRC, overall
response rates were 25.8% (95% CI: 21.0 to 31.2%)
for capecitabine and 11.6% (95% CI: 8.2 to 15.7%)
for 5-FU/LV (p = 0.0001). 
In the Van Cutsem study,41 investigator-assessed
overall response rates were significant for
capecitabine at 26.6% (95% CI: 21.7 to 32.0%)
compared with 5-FU/LV at 17.9% (95% CI: 13.8 to
22.8%) (p = 0.013). However, in the IRC-assessed
group, response rates were 18.9% (95% CI: 14.7 to
23.8%) for capecitabine compared with 15.0% 
(95% CI: 11.1 to 19.5%) for the 5-FU/LV group
(not significant) (NS).
In the Twelves study,36 data from the above two
studies were pooled. Investigator-assessed overall
response rates were significantly better for the
capecitabine arm (25.7% compared with the 5-
FU/LV arm (16.7%) (p < 0.0002). Overall response
rates assessed by the IRC were also significantly
better for the capecitabine arm (22.4%) compared
with 13.2% for the 5-FU/LV group (13.2%) (p <
0.0001). Confidence intervals were not reported.
Duration of response
Both the Hoff40 and the Van Cutsem41 studies
reported no significant difference in mean
Effectiveness
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TABLE 6 Trial quality assessment: capecitabine 
Study Randomised/method Blinding/appropriate method Description of Jadad score
withdrawals and 
dropouts
Hoff et al.,
200140
Yes, computer-generated
randomisation code
Open-label trial, so patients were
not blinded to treatment. An IRC
was blinded to clinical condition of
the patient and investigator’s
assessment and assessed tumour
responses solely on the basis of 
X-ray or scan imaging
Withdrawals and dropouts
well described
3/5
Van Cutsem
et al., 200141
Yes, computer-assisted
randomisation centre
As above Withdrawals and dropouts
well described
3/5
duration of response between the capecitabine and
5-FU/LV groups. In the Hoff study,40 the median
duration of response [complete response (CR) and
partial response (PR)] was 9.1 months in the
capecitabine group (54 events) and 9.5 months in
the 5-FU/LV group (30 events) (p = 0.37). In the
Van Cutsem study,41 the median duration of
response in responding patients (PR or CR) was
7.2 months in the capecitabine group and 9.4
months in the 5-FU/LV group (p = 0.17). Duration
of response was not reported by Twelves.36
Time to disease progression or death
All three studies36,40,41 report no significant
differences in time to disease progression or death
between the capecitabine and 5-FU/LV groups. For
the Hoff study,40 median time to disease progression
or death was 4.3 (95% CI: 4.1 to 5.1) months for the
capecitabine group and 4.7 (95% CI: 4.3 to 5.5)
months for the 5-FU/LV group. The Van Custem
study41 reported median time to disease progression
or death for the capecitabine group as 5.2 months
and for the 5-FU/LV group as 4.7 months.
Time to treatment failure in the three studies was also
not significantly different between the capecitabine
and 5-FU/LV groups. In the Hoff study,40 the
capecitabine group had a time to treatment failure
of 4.1 months and the 5-FU/LV group 3.1 months.
The Van Custem study41 had a time to treatment
failure of 4.2 months for the capecitabine group
and 4.0 months for the 5-FU/LV group.
Survival
Median overall survival was equivalent for the
capecitabine and 5-FU/LV groups in all three
studies.36,40,41 Values were 12.5 and 13.3 months,
respectively, for the Hoff study,40 13.2 and 12.1
months, respectively, for the Van Cutsem study41
and 12.9 and 12.8 months, respectively, for the
Twelves pooled data report.36
Secondary chemotherapy
No information was given for either trial or the
pooled data regarding crossover to other
treatments or information concerning the addition
of other chemotherapeutic agents.
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TABLE 7 Outcomes: capecitabine
Study ITT analysis Primary end-points Secondary end-points Duration of treatment
Hoff et al., 200140 Yes, analyses of
efficacy were based on
all randomised patients
Tumour response rate Time to response,
duration of response,
time to disease
progression, time to
treatment failure, overall
survival and QoL
(results presented
separately)
Capecitabine: mean
daily dose corresponded
to 80% of the
scheduled dose and
mean duration of
treatment was 4.3
months
5-FU/LV: mean daily
dose corresponded to
86% of the scheduled
dose and mean duration
of treatment was 4.6
months
Van Cutsem et al.,
200141
Yes, analyses of
efficacy were based on
all randomised patients
Tumour response rate Time to response,
duration of response,
time to disease
progression, time to
treatment failure, overall
survival and QoL
(results presented
separately)
Capecitabine: median
dose per cycle was
82–100% of that
planned; median
duration of treatment
was 147 days
5-FU/LV: median dose
per cycle was between
95–100% of that
planned and median
duration of treatment
was 140 days
Twelves, 200236 Yes Tumour response rate Time to response, time
to disease progression,
overall survival and time
to treatment failure
Not reported
E
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TABLE 8 Results: capecitabine
Study Response rate Duration of response Median time to disease Survival
progression or death
Hoff et al., 200140 Response rates (%)
Capecitabine 5-FU/LV
(n = 302) (n = 303)
Investigator
Overall response, 
CR or PR 75 (24.8) 47 (15.5)a
CR 3 (1.0) 3 (1.0)
PR 72 (23.8) 44 (14.5)
Stable disease 146 (48.3) 158 (52.1)
PD 57 (18.9) 59 (19.5)
Missing post-baseline 22 (7.3) 38 (12.5)
IRC
Overall response, 
CR or PR 78 (25.8) 35 (11.6)b
CR 1 (0.3) 1 (0.3)
PR 77 (25.5) 34 (11.2)
Stable disease 148 (49.0) 181 (59.7)
progressive disease (PD) 43 (14.2) 36 (11.9)
Missing post-baseline 30 (9.9) 49 (16.2)
Median duration of response (CR
and PR) was 9.1 months in the
capecitabine group (54 events)
and 9.5 months in the 5-FU/LV
group (30 events) (p = 0.37)
Median time to disease progression
or death
Capecitabine 4.3 (95% CI: 4.1 to
5.1) months (269 events)
5-FU/LV 4.7 (95% CI: 4.3 to 5.5)
months (271 events) 
(p = 0.72, log-rank test)
Hazard ratio 1.03 (95% CI: 0.87
to 1.22)
Time to treatment failure
Capecitabine: 4.1 months (227
events)
5-FU/LV: 3.1 months (280 events)
(p = 0.19, log-rank test)
Hazard ratio 0.90 (95% CI: 0.76
to 1.06)
Median overall survival
Capecitabine 12.5 (95% CI: 10.5
to 14.2) months (260 events)
5-FU/LV 13.3 (95% CI: 12.0 to
14.6) months (273 events) 
(p = 0.97, log-rank test)
Hazard ratio 1.00 (95% CI: 0.84
to 1.18)
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TABLE 8 Results: capecitabine (cont’d)
Study Response rate Duration of response Median time to disease Survival
progression or death
a p = 0.005.
b χ2 test showed the response rate for capecitabine to be significantly greater than that achieved with 5-FU/LV (p = 0.0001).
c p = 0.013.
d Confidence intervals and log-rank p values from Hoff et al.44
Van Cutsem 
et al., 200141
Response rates (%)
Capecitabine 5-FU/LV
(n = 301) (n = 301)
Investigator
Overall response, 26.6 17.9c
CR or PR
IRC
Overall response, 57 (18.9) 45 (15.0)
CR or PR
CR 1 (0.3) 2 (0.7)
PR 56 (18.6) 43 (14.3)
Stable disease 171 (56.8) 167 (55.5)
PD 38 (12.6) 51 (16.9)
Missing post-baseline 33 (11.0) 38 (12.6)
Median duration of response in
responding patients (PR or CR)
was 7.2 months in the
capecitabine group and 9.4
months in the 5-FU/LV group 
(p = 0.17)
Median time to disease progression
or death
Capecitabine 5.2 months
5-FU/LV 4.7 months (log-rank 
p = 0.65) 
Hazard ratio: 0.96 (95% CI: 0.81
to 1.14)
Time to treatment failure
Capecitabine 4.2 months
5-FU/LV 4.0 months (log-rank 
p = 0.89)
Median overall survival
Capecitabine 13.2 months
5-FU/LV 12.1 months 
Hazard ratio: 0.92 (95% CI: 0.78
to 1.09) (log-rank p = 0.33)
Twelves, 200236 Response rates (%)
Capecitabine 5-FU/LV
(n = 603) (n = 604)
Investigator
PR + CR (%) 25.7 16.7
(p < 0.0002)
Stable disease (%) 47.8 52.2
IRC
PR + CR (%) 22.4 13.2
(p < 0.0001)
Stable disease (%) 52.9 57.6
Both overall response rates were significantly higher
in favour of capecitabine using two-sided χ2 test
with Schouten correction
Not reported Median time to disease progression
or death
Capecitabine 4.6 months (95%
CI: 4.3 to 5.3)
5-FU/LV 4.7 months (95% CI: 4.3
to 5.4)
Median time to treatment failure
Capecitabine 4.2 months
5-FU/LV 3.6 months
Median time to response
1.7 months for capecitabine and
2.4 months for 5-FU/LV
Median overall survival
Capecitabine 12.9 months (95%
CI: 12.0 to 14.0)d
5-FU/LV 12.8 months (95% CI:
11.8 to 14.0)d
Hazard ratio= 0.96 (95% CI:
0.85 to 1.08); (log rank p = 0.48)d
Effectiveness
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TABLE 9 Toxicity: capecitabine
Study Types of side-effects Treatment-related deaths
Hoff et al.,
200140
Patients with grade 3 and 4 adverse reactions related to treatment; number (%)a
Capecitabine (n = 299) 5-FU/LV (n = 294)
Grade 3 Grade 4 Grade 3 Grade 4
All reactions 121 (40.5) 8 (2.7) 105 (35.7) 14 (4.8)
Total no. of events 199 10 190 19
Diarrhoea 41 (13.7) 5 (1.7) 33 (11.2) 8 (2.7)
Hand–foot syndrome 54 (18.1) NA 2 (0.7) NA
Stomatitis 9 (3.0) 0 45 (15.3) 2 (0.7)
Vomiting 10 (3.3) 1 (0.3) 13 (4.4) 1 (0.3)
Dehydration 6 (2.0) 1 (0.3) 10 (3.4) 1 (0.3)
Sepsis 0 0 1 (0.3) 1 (0.3)
Myocardial infarction 0 0 0 1 (0.3)
Sudden death 0 1 (0.3) 0 0
Pneumonia 0 1 (0.3) 0 1 (0.3)
Septicemia 0 1 (0.3) 0 0
Viral infection 0 0 0 1 (0.3)
Renal failure 0 0 0 1 (0.3)
Respiratory distress 0 0 0 1 (0.3)
Drug toxicity NOS 0 0 0 1 (0.3)
Adverse reactions requiring hospitalisation; number (%)
Capecitabine (n = 299) 5-FU/LV (n = 294)
Total patients hospitalisedb 34 (11.4) 60 (20.4)
Dehydration 8 (2.7) 9 (3.1)
Diarrhoea 12 (4.0) 8 (2.7)
Infection 1 (0.3) 2 (0.7)
Nausea 0 1 (0.3)
Neutropenia 0 4 (1.4)
Neutropenic fever 0 10 (3.4)
Sepsis 0 1 (0.3)
Stomatitis 0 10 (3.4)
Vomiting 3 (1.0) 5 (1.7)
Other 12 (4.0) 12 (4.1)
Lower overall incidence and later onset of grade 3 or 4 adverse reactions
with capecitabine throughout the entire treatment period (p = 0.0037, 
log-rank test) with the difference particularly pronounced during the first 
4–5 months. Fewer patients in the capecitabine group required hospitalisation
for adverse reactions than in the 5-FU/LV group (p = 0.003).
Capecitabine: 3 patients died
from treatment-related
adverse reactions (one each
from gastrointestinal
haemorrhage, pneumonia
and death of unknown cause)
5-FU/LV: two patients died
from treatment-related
adverse reactions (one sepsis
and one upper respiratory
tract infection)
Van Cutsem
et al., 200141
Capecitabine: 3 patients died
from treatment-related
adverse reactions (one each
from gastrointestinal
necrosis, pulmonary
embolism and myocardial
infarction)
5-FU/LV: four patients died
from treatment-related
adverse reactions (cardiac
failure, renal tubular necrosis,
sepsis and enterocolitis)
Patients with grade 3 and 4 adverse reactions related to treatment; number (%)
Capecitabine (n = 297) 5-FU/LV (n = 299)
Grade 3 Grade 4 Grade 3 Grade 4
Diarrhoea 28 (9.4) 4 (1.3) 28 (9.4) 3 (1.0)
Hand–foot syndrome 48 (16.2) NA 1 (0.3) NA
Stomatitis 3 (1.0) 1 (0.3) 39 (13.0) 1 (0.3)
Sepsis 0 1 (0.3) 5 (1.7) 2 (0.7)
Deep venous thrombosis 4 (1.3) 1 (0.3) 0 0
Neutropenic fever 0 0 2 (0.7) 1 (0.3)
NA = not applicable, an adverse reaction is listed if reported at grade 3 in
>5% of patients in at least one of the treatment groups and all adverse grade
3 or 4 reactions reported in ≥ 1% of the patients with at least one grade 4
adverse event
continued
Toxicity
Toxicity in the form of grade 3 and 4 adverse
reactions are listed in Table 9. For information on
toxicity grading, see Appendix 8. 
The Hoff40 study reports that patients in the
capecitabine group had a significantly lower
incidence of any grade of diarrhoea, stomatitis,
nausea and alopecia compared with the 
5-FU/LV group (p < 0.0002). The patients in the
capecitabine group had a significantly higher
incidence of hand–foot syndrome than the 
5-FU/LV group. With regard to grade 3 toxicities,
stomatitis (15.3 versus 3%) and neutropenia
(values not reported) were significantly more
frequent in the 5-FU/LV group (p < 0.0001).
Grade 3 hand–foot syndrome (18.1 versus 0.7%)
(p < 0.00001) and grade 3–4 hyperbilirubinaemia
were more frequently reported in the capecitabine
group than in the 5-FU/LV group. Fewer patients
in the capecitabine group required hospitalisation
for treatment-related toxicity than those in the 
5-FU/LV group (11.4 versus 20.4%) (p = 0.003).
The Van Cutsem41 study also reported significantly
less stomatitis and alopecia of any grade in the
capecitabine group compared with the 5-FU/LV
group (p < 0.00001). Hand–foot syndrome was
again more frequent in the capecitabine group 
(p < 0.00001). The capecitabine group had a lower
incidence of grade 3–4 stomatitis (1 versus 13%) and
neutropenia (values not reported) (p < 0.00001) but
greater incidence of grade 3 hand–foot syndrome
(16.2 versus 0.3%) (p < 0.00001) and uncomplicated
grade 3–4 hyperbilirubinaemia (p < 0.0001). Patients
in the capecitabine group had fewer hospitalisations
due to adverse effects than the 5-FU/LV group 
(11.8 versus 15.7%) (p value not reported).
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TABLE 9 Toxicity: capecitabine (cont’d)
Study Types of side-effects Treatment-related deaths
a NOS = not otherwise specified; NA= not applicable; an adverse reaction is listed if it was reported at grade 3 in ≥ 5% of
patients or grade 4 in any patient.
b Patients could be hospitalised more than once for different adverse events.
Adverse reactions requiring hospitalisation; number (%)
Capecitabine (n = 297) 5-FU/LV (n = 299)
All adverse reactions 35 (11.8) 47 (15.7)
Dehydration 5 (1.7) 0
Diarrhoea 13 (4.4) 14 (4.7)
Hand–foot syndrome 2 (0.7) 0
Infection 0 4 (1.3)
Neutropenia 1 (0.3) 2 (0.7)
Sepsis 1 (0.3) 6 (2.0)
Stomatitis 1 (0.3) 11 (3.7)
Vomiting 1 (0.3) 1 (0.3)
Other 14 (4.7) 11 (3.7)
Twelves, 
et al., 200236
Significantly lower (p < 0.001) incidence of diarrhoea (48 vs 58%), stomatitis
(24 vs 62%), nausea (38 vs 47%) and alopecia (6 vs 21%) for capecitabine
compared with 5-FU/LV. Incidence of vomiting and fatigue was similar in both
treatment groups. Hand–foot syndrome (all grades) was the only adverse
event to occur more frequently with capecitabine than 5-FU/LV. Hand–foot
syndrome led to hospitalisation (0.3%) or withdrawal from treatment (1.7%)
infrequently. Grade 3–4 stomatitis occurred in 2% of capecitabine patients
but 15% of 5-FU/LV patients (p < 0.0001)
Grade 3 or 4 neutropenia was significantly more common in the 5-FU/LV group
than the capecitabine group (21.1 vs 2.2%). Hyperbilirubinaemia was higher
in the capecitabine group with a higher percentage in the capecitabine group
developing total bilirubin levels >1.5 and ≤ 3 times the upper limit of normal
(grade 3: 18.3% for capecitabine vs 3.3% for 5-FU/LV, p < 0.0001). Grade 4
hyperbilirubinaemia showed similar rates in both groups (4.5 vs 2.5%, p =
0.07).
Hospitalisation for treatment-related adverse events was significantly less
frequent in the capecitabine group than the 5-FU/LV group (11.6 vs 18.0%, 
p = 0.0002)
Treatment-related mortality
was 1% in each group.
The Twelves study,36 which pooled data from the
above two trials, reported a significantly lower
incidence of diarrhoea, stomatitis, nausea and
alopecia in the capecitabine group compared with
the 5-FU/LV group. Grade 3–4 neutropenia also
occurred more frequently in the 5-FU/LV group.
Hand–foot syndrome and grade 3
hyperbilirubinaemia occurred more frequently in
the capecitabine group. Hospitalisation for
adverse events was significantly less frequent in the
capecitabine group than the 5-FU/LV group (11.6
versus 18%) (p = 0.002). Treatment-related
mortality was 1% for each group.
Health-related quality of life
QoL was assessed in both RCTs of capecitabine
although the data have not been published. QoL
data were reported in the Roche sponsor
submission to NICE.45 No published health-
related QoL studies for capecitabine were
identified in the literature searches. Both of the
RCTs40,41 measured QoL using the European
Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC
QLQ-C30). The results showed that there was no
significant difference in global QoL between the
capecitabine and 5-FU/LV groups in either trial.
The QoL data are presented in more detail in the
section ‘Quality of life evidence’ (p. 35).
Patient preference
None of the three studies36,40,41 reported
information on patient preference.
Conclusions on effectiveness of capecitabine
Two trials were identified40,41 that compared
capecitabine with 5-FU/LV administered via the
Mayo regimen. An additional study was
identified36 that pooled the data from these two
trials. No studies were identified that compared
capecitabine treatment with the de Gramont or
modified de Gramont 5-FU/LV regimens, both
commonly used regimens in the UK. 
One study41 reported only investigator-assessed
overall response rates to be significantly greater in
the capecitabine group than the 5-FU/LV group.
The other trial40 and the pooled data both found
that investigator-assessed and IRC-assessed overall
response rates were significantly greater in the
capecitabine group than the 5-FU/LV group.
Duration of response, time to disease progression
or death, time to treatment failure and overall
survival were found not to be significantly different
between the capecitabine groups and the 5-FU/LV
groups in the two trials and in the pooled data.
With regard to toxicity, patients in the
capecitabine groups reported less diarrhoea,
stomatitis, nausea and alopecia of all grades than
those in the 5-FU/LV groups. Those in the
capecitabine group also had significantly less
grade 3–4 neutropenia and less frequent
hospitalisation for adverse events. Hand–foot
syndrome and grade 3 hyperbilirubinaemia was
significantly greater in the capecitabine group.
Quantity and quality of research
available: UFT/LV
Tegafur plus uracil administered with folinic acid
(UFT/LV) is licensed for use in the UK as first-line
treatment of metastatic colorectal cancer. Two
phase III RCTs of UFT/LV were identified (011
and 012). Information on these studies was
obtained from a variety of sources. 
Both studies relate to comparison of UFT/LV with
bolus 5-FU. The first, study 01146 (n = 816),
compared UFT/LV with the Mayo regimen. The
second, study 01247 (n = 380), compared UFT/LV
with a modification of the Mayo regimen, where
treatment was repeated every 35 days as opposed
to the standard 28 days in the Mayo regimen. This
non-standard variation of the Mayo regimen is a
less dose-intensive regimen and has not been
tested for efficacy.
The two trials also differ in that study 01146
used different dosages of LV for patients in the
USA and non-US patients. Patients in the 
USA received 75 mg/day and those in other
countries received 90 mg/day. In study 012,47 all
patients received 90 mg/day of LV.
The UFT/LV studies included in this review are
listed in Table 10.
Study characteristics of included UFT/LV studies
Tables 11 and 12 show the study characteristics of
the two included UFT/LV trials.
Inclusion and exclusion criteria were similar
although there were some differences, notably that
study 01247 had an upper age limit of 75 years. 
The Douillard study (study 011)46 was adequately
powered to demonstrate equivalence as non-
inferiority of survival while the Carmichael study
(study 012)47 was adequately powered to
determine time to progression.
Baseline comparability was reported and no
significant differences between the UFT/LV and 
5-FU/LV groups were reported in either of the
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studies, apart from differences in baseline QoL in
the Carmichael study.47
No information on the primary tumour site was
presented for either study. The most common site
of metastases was the liver in both studies.
Study quality of included UFT/LV studies
The Jadad criteria were used to assess the quality
of the RCTs.33 The Jadad criteria consist of three
categories: randomisation (including method to
generate the sequence of randomisation and
whether or not the method was appropriate),
double blinding and description of withdrawals
and dropouts. The maximum number of possible
points is 5. The Jadad score of both RCTs was 3,
indicating moderate quality. Neither study was
double blinded, which resulted in loss of points
according to these criteria. However, blinding
would be virtually impossible when comparing an
oral drug with a bolus 5-FU regimen, as the mode
of delivery is different for the two treatments.
There was no independent assessment of response
rates in either study. Table 13 describes the quality
of the two UFT/LV studies.
Assessment of effectiveness of UFT/LV
Table 14 describes the outcomes used in the
UFT/LV studies and Table 15 shows the results.
The Douillard study46 (study 011) used overall
survival as the primary end-point whereas the
Carmichael study47 (study 012) used time to
disease progression as the primary end-point.
Tumour response rates
In both studies there was no significant difference
between the UFT/LV group and the 5-FU/LV group
with regard to overall tumour response rates.
Response rates were assessed by the sponsor’s
physician and an internal review was conducted.
In the Douillard study,46 overall response rates
were 11.7% for the UFT/LV group and 14.5% for
the 5-FU/LV group, whereas in the Carmichael
study,47 overall response rates were 10.5% for the
UFT/LV group and 9.0% for the 5-FU/LV group.
Duration of response
Both studies reported no significant differences
with regard to duration or response, although
actual values were not reported for either 
study.48
Time to disease progression or death
In the Douillard study,46 time to disease
progression was significantly greater in the 5-
FU/LV group than the UFT/LV group (3.8 versus
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TABLE 10 UFT/LV studies included in the review
Study Study site Comparators, dosage Type of study Numbers Funding
and procedure randomised
Douillard 
et al., 200246
Study 011 
85 sites in the USA,
Canada, Europe
and Israel
UFT (300 mg/m2/day) with
LV (75 or 90 mg/day) given
orally for 28 days every 
35 days (patients in the 
USA received 75 mg/day
and those in other countries
received 90 mg/day)
5-FU (425 mg/m2/day) and
LV (20 mg/m2/day) given i.v.
for 5 days every 28 days
(Mayo Clinic regimen) for
the first two cycles and
repeated at intervals of 
4–5 weeks
Open-label,
phase III RCT
UFT/LV: 409
5-FU/LV: 407
Bristol-Myers Squibb
Carmichael
et al., 200247
Study 012
47 sites in Canada,
Europe, Israel,
Australia and New
Zealand
Oral UFT 300 mg/m2/day
and LV (90 mg/day) both
administered for 28 days
every 35 days
5-FU (425 mg/m2/day) and
LV (20 mg/m2/day both
given i.v. for 5 days every
35 days (not standard Mayo
regimen)
Open-label,
phase III RCT
380 patients
randomised to
study (190 for
each treatment)
Bristol-Myers Squibb
3.5 months, p = 0.01). The actual difference was
therefore 0.3 month (10 days) and the confidence
intervals overlap. Also, the timing of tumour
assessments for patients receiving UFT/LV differed
from that of patients on 5-FU/LV, making it
difficult to compare progression between the arms
of the study. There was no significant difference in
time to disease progression in the Carmichael
study47 between the UFT/LV and the 5-FU/LV
groups (3.4 and 3.3 months, respectively). 
Survival
There were no significant differences in median
survival time between the UFT/LV group and the
Effectiveness
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TABLE 11 Study design: UFT/LV
Study Length of study Inclusion criteria Exclusion criteria Power calculation Baseline 
comparability
Douillard 
et al., 200246
Study 011 
Recruitment
between June 1995
and August 1997
Previously untreated
metastatic colorectal
cancer with evaluable
or measurable
disease; adequate
bone marrow
(absolute granulocyte
count ≥2000/mm3,
platelets
≥100,000/mm3); liver
(bilirubin normal) and
renal function
(creatinine normal);
age ≥18 years;
unsuitable for
definitive surgical
resection, prior
adjuvant
chemotherapy
completed more than
6 months prior to
enrolment; Eastern
Cooperative
Oncology Group
(ECOG) 0–2
Unstable medical
conditions;
concurrent serious
infections, an
oncological
emergency on
presentation;
history of malignant
neoplasms other
than skin cancer or
in situ carcinoma of
the cervix
Study designed
with 80% power
to show
equivalence of
UFT/LV with 
5-FU/LV as non-
inferiority of
survival
No significant
differences reported
in baseline
characteristics
between treatment
groups
Carmichael
et al., 200247
Study 012
Recruitment
between May 1996
and July 1997
Histologically
confirmed metastatic
colorectal
adenocarcinoma with
bidimensionally
measurable disease
or evaluable disease
located outside
previously irradiated
fields (all
measurements 
≥ 1.5 cm); between
18 and 75 years;
completed any prior
colorectal adjuvant
treatment at least 6
months prior to
enrolment;
granulocyte count
≥ 2000/mm3; platelet
count 100,000/mm3;
total bilirubin ≤ 1.5 ×
upper limit of normal;
ECOG 0–2
Concurrent
uncontrolled
medical disorders or
prior malignancies
other than skin
cancer or in situ
carcinoma of the
cervix; oncology
emergency on
presentation
Sample size gave
study 80% power
to detect a hazard
ratio of 1.40
between the two
treatments with
regard to time to
progression
No significant
differences reported
in baseline
characteristics
between treatment
groups apart from
differences in
baseline QoL
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TABLE 12 Patient details: UFT/LV
Study Sex (M/F) Age (years) Performance score Primary site Sites of metastasis
Douillard 
et al., 200246
Study 011 
UFT/LV: 249/160
5-FU/LV: 245/162
Median (range)
UFT/LV: 64 (29–88)
5-FU/LV: 64 (22–90)
ECOG (%) performance status
UFT/LV 5-FU/LV
0 45 43
1 48 49
2 7 8
Not reported Extent of disease (%)
UFT/LV 5-FU/LV
Liver 325 (79) 237 (80)
Lymph node/soft tissue in 120 (29) 124 (30)
primary area
Lymph node/soft tissue outside 23 (6) 18 (4)
primary area
Lung 113 (28) 115 (28)
Visceral, other 29 (7) 30 (7)
Intestine 15 (4) 35 (9)
Ascites 5 (1) 9 (2)
Bone 7 (2) 1 (<1)
Pleural effusion 2 (<1) 4 (1)
Not reported 0 (0) 1 (<1)
Carmichael 
et al., 200247
Study 012
UFT/LV: 128/62
5-FU/LV: 122/68
Median (range)
UFT/LV: 61 (30–77)
5-FU/LV: 62 (29–81)
ECOG (%) performance status
UFT/LV 5-FU/LV
0 39 33
1 47 56
2 14 11
Not reported Extent of disease (%)
UFT/LV 5-FU/LV
Liver 149 (78) 146 (77)
Lymph node/soft tissue in 64 (34) 65 (34)
primary area
Lymph node/soft tissue outside 17 (9) 14 (7)
primary area
Lung 58 (31) 55 (29)
Visceral, other 12 (6) 8 (4)
Intestine 28 (15) 21 (11)
Ascites 4 (2) 8 (4)
Bone 2 (1) 9 (5)
Pleural effusion 6 (3) 4 (2)
Not reported 2 (1) 2 (1)
5-FU/LV group for either study.46,47 Median
survival in the Douillard study (study 011)46 was
12.4 months in the UFT/LV group and 13.4
months in the 5-FU/LV group, whereas in the
Carmichael study (study 012),47 median survival
was 12.2 months in the UFT/LV group and 
10.3 months in the 5-FU/LV group.
Additional analysis of survival was reported by
Benner,49 showing survival for study 011 to be
worse in US study sites.49 As stated previously, the
US sites in study 011 used a different dosage of LV
compared with the non-US sites, which could
potentially be responsible for the difference in
survival. No US sites were included in study 012,
in which all UFT/LV patients received the same
dosage of LV.
Secondary chemotherapy
In the Douillard study,46 secondary chemotherapy
was administered to 52% of patients in the
UFT/LV group and 50% in the 5-FU/LV group,
although data on type of drugs were not 
collected. In the Carmichael study,47 41% of
patients in the UFT/LV group and 39% in the 
5-FU/LV group received secondary chemotherapy,
including fluoropyrimidines, irinotecan and
oxaliplatin.
Toxicity
Table 16 shows the toxicity results for the UFT/LV
trials (see Appendix 8 for toxicity criteria). In the
Douillard study,46 UFT/LV was associated with
significantly less diarrhoea, nausea/vomiting,
mucositis, neutropenia and thrombocytopenia
than 5-FU/LV for all grades. Grade 3–4 toxicity
was also found less commonly with UFT/LV than
with 5-FU/LV for mucositis (1 versus 20%),
neutropenia (1 versus 56%), thrombocytopenia 
(0 versus 2%) and anaemia (3 versus 7%).
Increased bilirubin, without other liver function
abnormalities, was significantly more common in
Effectiveness
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TABLE 13 Trial quality assessment: UFT/LV
Study Randomised/method Blinding/appropriate method Description of Jadad score
withdrawals and 
dropouts
Douillard 
et al., 200246
Study 011
RCT, secure remote
centralised randomisation
procedure
Open-label trial, no blinding
reported 
Withdrawals and dropouts
clearly described
3/5
Carmichael
et al., 200247
Study 012
RCT, secure remote
centralised randomisation
procedure
Open-label study, no blinding
reported
Withdrawals and dropouts
clearly described
3/5
TABLE 14 Outcomes: UFT/LV trials
Study ITT analysis Primary Secondary Duration of treatment
end-points end-points
Douillard 
et al., 200246
Study 011
Analyses of efficacy are
based on data from all
randomised patients
Survival Response rate; time to
disease progression
Median duration of treatment in
weeks (range)
UFT/LV: 16.6 (0.7–120)
5-FU/LV: 16.7 (0.7–69.4)
Mean percentage of planned dose
UFT/LV: 92.6
5-FU/LV: 85.1
Carmichael 
et al., 200247
Study 012
Analyses of efficacy are
based on data from all
randomised patients
Time to disease
progression
Response rates,
median survival 
Median duration of treatment in
weeks (range)
UFT/LV: 17.2 (1.3–51.1) 
5-FU/LV: 15.1 (0.3–67.1)
Mean percentage of planned dose
UFT/LV: 91.8
5-FU/LV: 98.4
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TABLE 15 Results: UFT/LV trials
Study Response rate Duration of response Median time to disease Survival
progression or death
Douillard et al.,
200246
Study 011 
Response rates
UFT/LV 5-FU/LV
(n = 409) (n = 407)
Total tumour response, 48 (11.7) 59 (14.5)
n (%)
CR 8 (2) 8 (2)
PR 40 (10) 51 (13)
Stable disease 148 (36) 168 (41)
PD 167 (41) 130 (32)
Unevaluable 46 (11) 50 (12)
Toxicity/early death 21 21
Not assessed 19 15
Never treated 4 10
Other 2 4
No significant differences
between treatment arms with
regard to duration of response;
values not reported
3.5 months (95% CI: 3.0 to 4.4
months) for UFT/LV and 3.8
months (95% CI: 3.6 to 5.0) for
5-FU/LV (p = 0.01, stratified log-
rank)
Median survival
12.4 months (95% CI: 11.2 to
13.6 months) for UFT/LV group
and 13.4 months (95% CI: 11.6
to 15.4 months) for 5-FU/LV
group (NS)
Hazard ratio for 5-FU/LV over
UFT/LV was 0.964 (95% CI:
0.826 to 1.125); Benner49 for the
Food and Drug Administration
(FDA) states that the hazard ratio
for survival is uncertain because
the survival curves cross at 24
months. The FDA believes that
the highest lower bound that can
be supported is ~0.80.
Carmichael 
et al., 200247
Study 012
Response rates
UFT/LV 5-FU/LV
(n = 190) (n = 190)
Total tumour response, n (%) 20 (10.5) 17 (9)
CR 2 (1) 2 (1)
PR 18 (9) 15 (8)
Stable disease 65 (34) 71 (37)
PD 81 (43) 83 (44)
Unevaluable 24 (13) 19 (10)
Toxicity/early death 11 4
Not assessed 2 4
Never treated 3 4
Other 8 7
No significant differences
between treatment arms with
regard to duration of response;
values not reported
3.4 months (95% CI: 2.6 to 3.8
months) for UFT/LV and 3.3
months (95% CI: 2.5 to 3.7
months) for 5-FU/LV (p = 0.591)
Median survival
12.2 months (95% CI: 10.4 to
13.8) for UFT/LV and 10.3
months (95% CI: 8.2 to 13.0) for
5-FU/LV (p = 0.682) 
Hazard ratio for 5-FU/LV over
UFT/LV was 1.14 (95% CI: 0.92
to 1.42)
UFT/LV patients than those treated with 5-FU/LV
(39 versus 22%) (p < 0.001). No data were
reported regarding amount of hospitalisation due
to treatment-related adverse effects.
In the Carmichael study,47 UFT/LV treatment
resulted in significantly fewer episodes of
stomatitis/mucositis, neutropenia,
thrombocytopenia and anaemia of any grade than
Effectiveness
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TABLE 16 Toxicity for UFT/LV trials
Study Types of side-effects Treatment-related 
deaths
Any (CTC grades 1–4) Severe (CTC grades 3 and 4)
UFT/LV, 5-FU/LV, p-Value UFT/LV, 5-FU/LV, p-Value
N (%) N (%) N (%) N (%)
Douillard 
et al., 200246
Study 011 
Diarrhoea 271 (67) 299 (76) 0.006 86 (21) 63 (16) NS
Nausea/vomiting 273 (67) 296 (75) 0.020 53 (13) 39 (10) NS
Mucositis 97 (24) 297 (75) <0.00 6 (1) 76 (20) <0.00
Neutropenia 52 (13) 302 (77) <0.00 3 (1) 219 (56) <0.00
Thrombocytopenia 84 (21) 123 (31) <0.00 0 (0) 8 (2) 0.003
Anaemia 333 (83) 343 (87) NS 13 (3) 26 (7) 0.032
A total of 65 patients
died within 30 days of
last administration of
treatment drug, 10% in
UFT/LV group and 6%
in 5-FU/LV group. In
the UFT/LV group, 7%
died due to the disease
alone and 3% due to
other causes, including
cardiac arrest,
pulmonary embolism,
aspiration pneumonitis,
lactic acidosis and
disease/toxicity.
In the 5-FU/LV group,
3% died due to disease
alone, 1 died due to 5-
FU/LV toxicity and the
rest due to other
causes including cardiac
and/or respiratory
arrest, pulmonary
embolism and
myocardial infarction
Carmichael
et al., 200247
Study 012
Diarrhoea 102 (54) 111 (60) NS 33 (18) 21 (11) NS
Nausea/vomiting 106 (56) 108 (58) NS 17 (9) 17 (9) NS
Stomatitis/mucositis 34 (18) 102 (55) <0.001 3 (2) 29 (16) <0.001
Neutropenia 21 (11) 120 (67) <0.001 5 (3) 55 (31) <0.001
Thrombocytopenia 33 (18) 50 (28) 0.025 1 (1) 4 (2) NS
Anaemia 143 (76) 160 (89) 0.002 9 (5) 7 (4) NS
UFT/LV treatment resulted in fewer episodes of febrile neutropenia (p < 0.001)
and documented infection (p = 0.40)
10% of patients in the
UFT/LV arm died
within 30 days of
treatment and 9% in
the 5-FU/LV. In the
UFT/LV group death
was due to disease in
all cases. In the 5-
FU/LV arm death was
due to toxicity (partly
or entirely) in 4
patients, disease in 10
patients, disease and
iatrogenic
haematemesis and
melena in 1 patient,
disease and myocardial
infarction in 1 patient
and haemorrhage and
hypovolaemic shock in 
1 patient
the 5-FU/LV treatment. With regard to grade 3–4
adverse events, UFT/LV treatment resulted in
significantly less stomatitis/mucositis (2 versus
16%) and neutropenia (3 versus 31%). A total of
127 patients were hospitalised during the study, 59
(31%) in the UFT/LV group and 68 (37%) in the 
5-FU/LV group. Reasons for hospitalisation were
not reported apart from for five patients, all in the
5-FU/LV group, who were hospitalised for febrile
neutropenia.
Health-related quality of life
Health-related QoL for UFT/LV was included in
both studies.46,47 In the Douillard study46 QoL was
measured using the Functional Living Index –
Cancer (FLIC) and in the Carmichael study47
using EORTC QLQ-C30. No significant
differences in QoL were found between the two
treatment groups in either study. These data are
presented in more detail in the section ‘Quality of
life evidence’ (p. 35). 
QoL was also measured in an unpublished
preliminary report (study CA 146-075). This trial
was an open-label, phase II randomised, non-
comparative study to evaluate health-related QoL,
patient preference and healthcare resource use.
These data are presented in the sponsor
submission48 only and used the EORTC QLQ-C30
to measure health-related QoL at baseline and
every week during the first course of therapy.
Patients were treated with UFT (300 mg/m2/day)
and LV (90 mg/day) administered for 28 days
every 35 days (n = 137) or 5-FU (425 mg/m2/day)
and LV (20 mg/m2/day) intravenously for 5 days
repeated every 4 weeks for two cycles then every
35 days (n = 65). Preliminary data from this trial
show scores for functional and symptom scales to
be either improved or unchanged from baseline in
the UFT/LV group over time but worse in the 
5-FU/LV group. Symptom scores on diarrhoea
worsened for both treatment groups. No
information is given regarding the actual values or
significance.
Patient preference
Borner and colleagues50 reported a crossover trial
of 37 patients with advanced colorectal cancer.
Patients received UFT 300 mg/m2/day plus LV 
90 mg/m2/day for 28 days every 5 weeks or
intravenous 5-FU 425 mg/m2/day plus LV 
20 mg/m2/day for 5 days every 4 weeks. Patients
were crossed-over to the other treatment regimen
for the second treatment cycle. Patients were asked
to complete a therapy preference questionnaire
prior to the first and after the second treatment
cycle. Thirty-six patients were included in the trial
(one was excluded owing to elevated serum
bilirubin) and, of these, 31 completed the
questionnaire. Of those who completed the
questionnaire, 84% preferred the UFT/LV
regimen. Reasons for preference of the 
UFT/LV regimen included being able to take
medication at home, less stomatitis and diarrhoea
and being able to use a tablet instead of an
injection. 
Conclusions on the effectiveness of UFT/LV
Two trials of UFT/LV46,47 were identified in the
literature searches, both comparing UFT/LV with
5-FU/LV treatment, one using the standard Mayo
regimen and one using a modification of the 
Mayo regimen. No studies were identified that
compared UFT/LV treatment with the de Gramont
or modified de Gramont 5-FU/LV regimens, both
in common use in the UK.
The two UFT/LV trials are not comparable for
three main reasons. First, the comparator in the
Douillard study46 was the standard Mayo 5-FU/LV
regimen whereas that in the Carmichael study,47 as
stated above, was a modification of the Mayo 
5-FU/LV regimen that has not yet been tested for
efficacy. Second, the Douillard study46 used two
different doses of leucovorin, depending on the
study site, whereas the Carmichael study47 used
only one dosage. Finally, the primary outcome
measures differ in that the Douillard study46 used
survival and the Carmichael study47 used time to
disease progression as primary outcome 
measures.
There were no significant differences with regard
to overall response rates, duration of response or
survival between UFT/LV and 5-FU/LV in either
trial. Time to disease progression was significantly
inferior for the UFT/LV group than the 5-FU/LV
group in the Douillard study.46 There was no
difference in time to disease progression between
the two groups in the Carmichael study,47
although this is possibly due to the use of a 
non-standard Mayo regimen. The use of this less
dose-intensive regimen may make it less effective,
thereby obscuring any deficit in the effectiveness
of UFT/LV. It is worth noting that survival in the
5-FU/LV group was much lower in this study 
(10.3 months) than in the Douillard study46
(13.4 months) whereas the UFT/LV survival 
was similar in the two studies (12.4 and 
12.2 months).
With regard to toxicity, in the Douillard study,46
UFT/LV was associated with significantly less
diarrhoea, nausea/vomiting, mucositis, neutropenia
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and thrombocytopenia than 5-FU/LV for all grades
and mucositis, neutropenia, thrombocytopenia and
anaemia for grades 3–4. Increased bilirubin, without
other liver function abnormalities, was significantly
more common in UFT/LV patients than those
treated with 5-FU/LV (p < 0.001). No data were
reported regarding amount of hospitalisation due to
treatment-related adverse effects.
In the Carmichael study,47 UFT/LV treatment
resulted in significantly fewer episodes of
stomatitis/mucositis, neutropenia,
thrombocytopenia and anaemia of any 
grade. With regard to grade 3–4 adverse 
events, UFT/LV treatment resulted in 
significantly less stomatitis/mucositis and
neutropenia.
Overview
In this chapter, the published economic literature
is reviewed, along with the economic analyses
included as part of the sponsor submissions from
Roche (capecitabine)45 and Bristol-Myers Squibb
(UFT/LV).48 In addition, we have undertaken our
own economic evaluation. 
Identification of studies
Studies were identified through a systematic search
of medical databases, as detailed in Chapter 3.
Two economic evaluations by Murad and
colleagues51,52 were found, based on the same
South American study comparing UFT with 5-FU.
Two resource use studies were also identified, one
relating to medical resource use in the two
capecitabine trials53 and one to resource use in the
Carmichael UFT/LV trial.54 No published cost-
effectiveness evaluations were found for
capecitabine.
In addition to the published studies, an economic
evaluation was included as part of the sponsor
submissions from Roche45 and Bristol-Myers
Squibb.48
Review of existing economic evidence
Murad and colleagues, 199751,52
An economic evaluation was undertaken of the
treatment of patients with colorectal cancer in
Brazil and Argentina. This study estimated the
total cost of a course of treatment over 18 months
with UFT/LV compared with a course of treatment
with 5-FU. The treatment regimen with 5-FU was
not given. Therapeutic equivalence was assumed.
The study used a modified Delphi technique with
a panel composed of three physicians from Brazil
and three from Argentina. Costs were divided into
four categories: pre-chemotherapy care,
chemotherapy cycles, chemotherapy follow-up and
adverse event management. Cost per life year
gained (LYG) was not estimated. 
The results were divided by country and by
chemotherapy for metastatic disease or adjuvant
chemotherapy. The treatment cost in US$ for
metastatic colorectal cancer in Brazil was $10,179
(£6454) for UFT and $10,491 (£6652) for 5-FU.
The savings incurred through use of UFT
treatment were $312 (£198). In Argentina, the
treatment cost was $12,369 (£7483) for UFT and
$13,557 (£8596) for 5-FU. The savings incurred
through UFT treatment were $1188 (£753). The
cost savings came mainly in the area of adverse
event management. All other cost areas were fairly
similar. In Brazil, the pre-chemotherapy cost
favoured UFT, but all other cost areas (excepting
adverse events) favoured 5-FU. In Argentina, all
cost areas favoured UFT. A Monte Carlo sensitivity
analysis gave a range of cost savings between $250
(£159) and $410 (£260) for Brazil and $1500
(£951) and $875 (£555) for Argentina. The
authors of this study concluded that there was an
economic advantage for oral UFT over 5-FU in
the treatment of colorectal cancer in Brazil and
Argentina. 
A number of issues make this study difficult to
apply to the UK context. This study was not based
on an RCT, but rather on a panel of physicians
attempting to simulate a real-world situation, as
experienced in their practices. No information was
given on which resources were actually used in the
cost calculations, and whether the treatment
regimens were relevant to the UK setting. Also,
the small number of physicians on the panel
means that treatment options, particularly in the
treatment of adverse effects, will be biased towards
the preferences of these physicians. The study
noted that an improved adverse effect profile
could have a positive effect on QoL, but no QoL
data were collected. The authors concluded that
prospective economic research and quality of life
evaluations are needed to assess the economic
impact of UFT treatment. 
Ollendorf, 199954
This study examined the use of inpatient and
outpatient services in an international phase III
trial comparing UFT plus LV with 5-FU plus LV43
in patients with metastatic colorectal cancer. In
this trial, 5-FU/LV was given according to a
modified Mayo regimen with doses of 425 mg/m2
daily for 5 days every 5 weeks. All hospital and
nursing home admissions were recorded,
including hospitalisations for febrile neutropenia,
infection, tumour progression, drug toxicity and
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transfusion. Drug administration data were not
collected. Outpatient services included GP
consultations, hospitals, private nurses,
physiotherapists and home-help visits. 
The number of hospitalisations recorded was
higher among the 5-FU/LV group than the
UFT/LV group, as was the total number of days in
hospital. No difference was observed between the
groups in use of outpatient services. Among
patients who were employed at baseline, fewer
UFT/LV patients missed work owing illness than 
5-FU/LV patients, and the mean number of days
of work lost was lower in the UFT/LV group. The
author concluded that UFT with LV may be
associated with reductions in the use of inpatient
services and work loss due to illness among
patients with metastatic colorectal cancer. 
This study is useful but limited. It gives volumes of
resources used, but formal hypothesis testing was
not undertaken as the study was not adequately
powered to detect potentially important
differences between treatment groups in the
measures of interest and the comparator regimen
was not standard. Also, other resources used over a
course of treatment are not mentioned in this
study, and no benefits were calculated. 
Twelves and colleagues, 200153
This group analysed the resource use of 602
patients with advanced or metastatic colorectal
cancer in an international trial comparing
capecitabine treatment with Mayo regimen 
5-FU/LV treatment.41 Data were collected on
hospital visits required for drug administration,
hospital admissions, and drugs and unscheduled
consultations with physicians for the treatment of
adverse effects. Treatment-related resource use
included clinic visits, both number and duration,
and chemotherapy agents. Resource use related to
adverse event management included consultations,
hospitalisation days and treatments for the
management of adverse effects. 
The number of hospital visits per patient for drug
administration was 2109 for capecitabine patients
and 7625 for 5-FU/LV patients. The number of
hospital days for adverse event management was
368 for capecitabine patients and 477 for 5-FU/LV
patients. The number of consultations for the
treatment of adverse events was similar in the two
arms. Drug use for the management of adverse
events was analysed with emphasis on expensive
drugs that are likely to be economically important.
Increased quantities of expensive drugs were
required for the treatment of adverse events
stemming from 5-FU/LV treatment compared with
capecitabine treatment, where the most common
side-effect was hand–foot syndrome, which was
treated with inexpensive creams. No estimation of
benefit was made in this study. 
The authors concluded that capecitabine in
comparison with 5-FU/LV leads to a reduction in
medical resource use and improved response rate
and tolerability, and that the data support
capecitabine as the preferred fluoropyrimidine-
based regimen for the treatment of advanced
colorectal cancer. 
This study is not a cost-effectiveness analysis and
does not calculate costs or cost per LYG. However,
it is useful because the resource use is likely to be
similar to that of the UK, and UK prices
combined with international resource use would
give a good estimate of likely UK costs. 
Roche sponsor submission45
An unpublished sponsor submission received from
Roche used the Van Cutsem41 and Hoff40 trial
evidence in their calculations. They made no
mention of any other studies in terms of cost-
effectiveness. The submission included an
economic evaluation of first-line treatment with
capecitabine for patients with advanced colorectal
cancer. This evaluation is reviewed below. 
The Roche sponsor submission presents the
hypothesis that “capecitabine as a monotherapy
treatment in advanced colorectal cancer is at least
cost-effective, but most likely cost-saving compared
to the Mayo regimen using the England and Wales
perspective”.45 Roche used outcome and resource
use data from the Van Cutsem and Hoff trials,
which were funded by Roche. Roche were involved
as sponsors of the work and therefore may have
access to data that were not available to ScHARR. 
Cost estimates
Their costing took an NHS perspective, using a
time horizon spanning from start of treatment
until progression of the disease (4–5 months).
Therefore, drug costs and administration were
assumed to be incurred during this short time
period, and costs were not discounted. Costs
incurred after disease progression were not
included. Costs are summarised in Table 17. 
Drug doses were assumed to be the same as those
used in the clinical trials: capecitabine 1250 mg/m2
twice daily for 14 days every 3 weeks, as licensed
and recommended in the Summary of Product
Characteristics; and infusional 5-FU/LV given by
Economic analysis
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the Mayo regimen of calcium folinate 20 mg/m2
followed by 5-FU 425 mg/m2 for 5 days every 4
weeks. All doses were based on an average patient
of 1.7 m2. The report stated that the Mayo
regimen 5-FU/LV may be considered a suitable
comparator, since it is one of the many
intravenous regimens used widely in the UK. Costs
of calcium folinate and infusional 5-FU, and also
capecitabine, were the same as those on the
British National Formulary (BNF) website (BNF
No. 43).55 LV costs were not discounted, although
they are known to be in practice. 
The cost of administration was only calculated for
the Mayo regimen. The only administration costs
presented were the additional number of hospital
visits incurred by patients on the Mayo regimen.
Doctor and nurse time and the cost of infusions
were not included for either treatment regimen,
which means that the calculated administration
cost of capecitabine was zero. Five hospital
outpatient visits were assumed per cycle for most
patients, with a small proportion of trial
participants who required overnight visits for
infusion assigned the cost of an inpatient day. We
disagree with this method, since based on
consultation with clinicians we have assumed that
patients undergoing capecitabine treatment will
have at least one scheduled consultation with a
specialist each cycle, to discuss their treatment and
any adverse effects they might be experiencing
and receive their new prescription. The number of
scheduled consultations would likely be higher for
capecitabine patients than for Mayo patients, since
the cycle is shorter and adverse events would have
to be monitored more carefully. Therefore, the
non-hospitalisation costs of administration are
unlikely to be equivalent, and should have been
calculated for both arms. 
The cost of adverse event-related hospitalisations
was calculated using the average number of
hospitalisations per patient and the cost of an
inpatient hospital day from Netten and
colleagues56 This cost was similar across both arms
of the study (£434 for capecitabine treatment and
£503 for Mayo regimen). Unit costs and resource
use were not presented in the sponsor report, but
were available in the spreadsheet document that
accompanied the submission. Costs were also
calculated for unscheduled physician consultations
related to adverse events (£39 for capecitabine and
£28 for Mayo) and the drug costs of treating
adverse events (£166 for capecitabine and £681
for Mayo). There were errors in the spreadsheet
calculations of these drug costs, however, and the
numbers should have been lower for both arms. 
Return transportation ambulance costs (£333) were
included for a proportion of Mayo patients as
established by a survey conducted by Roche. No
transportation costs were included for capecitabine
patients since no administration costs were assumed. 
The total amount over the cost horizon used in
the analysis was £2713 for capecitabine treatment
and £4979 for Mayo regimen treatment. The main
differences came in the areas of drug cost, which
favoured Mayo, administration, which favoured
capecitabine, and the cost of drug therapy for the
treatment of adverse events, which favoured
capecitabine. The cost of capecitabine itself
accounted for the majority of the capecitabine
treatment cost. Administration made up the
largest proportion of Mayo regimen costs.
Treatment time was similar across both treatment
arms, so duration of treatment did not contribute
substantially to the cost difference. 
Outcomes
It seems that the intention was to use survival,
progression-free survival and quality-adjusted
survival as outcomes; however, since the survival
difference was negligible, a cost-minimisation
analysis was performed instead. Outcome results
were used from the trials mentioned above.40,41
Although capecitabine patients experienced a
higher response rate, there was no statistical
difference in time to progression or overall
survival, so therapeutic equivalence was assumed. 
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TABLE 17 Costs (£) used in Roche model
Component of healthcare utilisation Capecitabine Mayo regimen Net cost savings
Hospital use 434 503 68
Infusion administration (hospitalisation only) 0 2707 2,707
Transportation to hospital for treatment 0 333 333
Drug therapy 2072 725 –1347
Treating adverse events 166 681 515
Physician consultations 39 28 –11
Total costs 2713 4979 2266
Cost minimisation analysis
The incremental cost of the Mayo regimen over
capecitabine, according to the Roche analysis, is
£2266. Therefore, the use of capecitabine presents
a cost saving to the NHS. The authors conclude
that capecitabine is dominant over the Mayo
regimen owing to an improved side-effect profile
and more convenient administration. 
Sensitivity analysis
The main savings with capecitabine lie in the areas
of administration and adverse events. Since
capecitabine cannot be administered intravenously
and 5-FU/LV cannot be administered orally, the
administration costs were not tested in the
sensitivity analysis. Therefore, the sensitivity
analysis dealt only with variations in adverse event
rates. Three extreme scenarios were tested, one in
which neither arm experienced any side-effects,
one in which capecitabine patients did but Mayo
patients did not, and one in which Mayo patients
did but capecitabine patients did not. In every
scenario, capecitabine was cost saving, showing
that adverse event rates, although they contribute
to the cost difference, do not change the
advantage of capecitabine over Mayo. 
A threshold analysis was performed to find the
maximum average cost of a visit to the hospital for
Mayo administration. The authors found that this
cost would be £17, and concluded that since this
low figure was impossible to achieve, capecitabine
was clearly cost saving. 
No sensitivity analysis was performed for the cost
of either drug, despite the fact that this element
makes up a large proportion of total treatment
costs, and discounts are frequently given to
hospital pharmacies on the cost of calcium folinate. 
Discussion of Roche economic evaluation
Although the published paper on resource use
based on the capecitabine trials was well
constructed and comprehensive, the cost analysis
included in the sponsor submission was too brief
and included errors and omissions. 
Although the comparator chosen was suitable,
many different intravenous 5-FU regimens are
used in the UK, and it would be useful for
comparison to see the cost savings of capecitabine
over other commonly used regimens. The time
horizon of time to progression seems suitable,
since there is no evidence on which treatment
might be used as second-line therapy after
capecitabine treatment, or what proportion of
patients would receive any second-line treatment. 
The decision to perform a cost-minimisation
analysis was reasonable, since there was no
difference in survival outcomes. The cost
calculations themselves, however, were of poor
quality. No resource use data or unit costs were
given in the report, and the explanations of how
the costs had been categorised and collected were
unclear. The sensitivity analysis did not test
enough variables to show that the cost of
capecitabine was robust. 
No mention of QoL was made in the economic
evaluation, despite the fact that QoL data had been
collected from the trials by a well-validated method.
The results of the postal survey conducted by Roche
on society preferences were presented, however.
The authors concluded that the survey
demonstrated a societal preference for a description
of capecitabine treatment over a description of
Mayo treatment. The preference results for other
kinds of treatment were not presented. 
Despite these deficiencies, however, the cost
differences are small, and it is unlikely that in any
case capecitabine would become more expensive
than the Mayo regimen unless the drug price were
to be raised substantially. Therefore, the errors do
not impact the authors’ conclusion that
capecitabine provides a cost-saving option with
therapeutic equivalence to Mayo regimen 5-FU. 
Bristol-Myers Squibb sponsor submission48
The unpublished sponsor submission from Bristol-
Myers Squibb (BMS)48 reviewed the South
American study by Murad and colleagues51,52 and
also cost analyses by Avon, Somerset, Wiltshire
Cancer Services (November 2000) and Devon and
Cornwall Cancer Services (March 1999) as well as
a NICE rapid review of irinotecan, oxaliplatin and
raltitrexed for the treatment of advanced colorectal
cancer.24 It also included a brief summary of an
economic evaluation commissioned by BMS
comparing UFT/LV with intravenous 5-FU/LV
treatment. This economic evaluation used a Markov
model over a 5-year time horizon to estimate costs
of treatment with 5-FU/LV and UFT/LV. The model
included first- and second-line chemotherapy
costs, costs of palliative care, treatment of adverse
events, hospitalisations not due to adverse events
and monitoring. The results showed a minor cost
saving in favour of UFT/LV (£289 per patient),
with the majority of savings arising from decreased
hospitalisation costs for administration. 
The submission also included two economic
evaluations of UFT/LV as a first-line treatment for
advanced colorectal cancer, one based on each of
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the studies funded by BMS: Douillard and
colleagues42,46 and Carmichael and colleagues.43
The trials each used different infusional 5-FU/LV
regimens, one with a 4-week cycle and one with a
5-week cycle. The authors chose to present the 
5-week cycle trial43 in the main body of the report,
despite an irregular administration schedule and a
smaller patient population. The reasoning is that
because UFT/LV is given on a 5-week cycle the
difference in cycle lengths between the two
treatment arms has the potential to affect the
relative number of cycles received and therefore
the costs. Also, a number of patients in the
Douillard study46 received a reduced LV dose.
Although different resource use was recorded in
the two trials owing to different trial protocols, the
main cost areas of drugs and administration were
included in both trials, so the total cost-
effectiveness should be similar. 
Cost estimates
The costing took an NHS perspective with a time
horizon lasting the same length as treatment time
in the trials, since costs were based on actual
resource utilisation data from the trials. Since
treatment times were less than 1 year and costs
incurred outside of treatment were not counted,
no costs were discounted. Average costs are
summarised in Table 18 and 19.
Drug costs were calculated from the actual doses
prescribed in the trial. A standard dose consisted
of 300 mg/m2 daily UFT and 90 mg daily LV, both
for 28 days followed by a 7-day rest period. Dose
reductions and escalations were accounted for by
assuming an average dose of 250 mg/m2 for dose
reductions and 350 mg/m2 for dose escalations.
The mean body surface area of patients in this
trial was 1.83 m2, and all doses are based on this.
The expected cost per patient for UFT/LV
treatment was £2315 in the Carmichael trial. The
LV cost was discounted by 87% for both UFT and
5-FU/CV treatments, based on market research
conducted by BMS. The 5-FU/LV dose was 
425 mg/m2 5-FU with 20 mg LV daily for 5 days
every 5 weeks. The expected cost per patient on 
5-FU/LV treatment was £269. 
Administration resource use data were not
collected in the Carmichael study, but consultation
with an oncologist determined that UFT/LV
patients would visit an oncologist once a cycle so
that tests could be performed and another cycle
could be prescribed. 5-FU/LV patients visited a
chemotherapy unit each time their medication was
delivered. It was assumed that 5-FU/LV patients
would require more expensive day case visits
whereas UFT/LV patients would only require the
cost of a medical oncology outpatient follow-up
appointment. The costs of both appointments
were taken from NHS reference costs. The authors
took a conservative approach and assumed that
UFT/LV patients would visit a specialist once a
week for the first treatment cycle, and once each
cycle thereafter. The expected cost of
chemotherapy administration was £4160 for
patients treated with 5-FU/LV and £592 for
patients treated with UFT/LV. 
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TABLE 18 Average costs (£) per patient in the Carmichael trial,47 from the BMS submission48
Resource component UFT/LV 5-FU/LV Incremental cost
Chemotherapy medications 2315 269 2046
Chemotherapy administration 592 4160 –3568
Hospitalisations 272 387 –115
Concomitant medications 17 14 4
Other medical resources 50 69 –18
Total direct costs 3246 4897 –1651
TABLE 19 Average costs (£) per patient in the Douillard study,46 from the BMS submission48
Resource component UFT/LV 5-FU/LV Incremental cost
Chemotherapy medications 2471 293 2178
Chemotherapy administration 606 5279 –4673
Hospitalisations 314 346 –32
Healthcare visits 60 59 1
Diagnostic procedures 166 158 8
Concomitant medications 3 4 –1
Total direct costs 3620 6138 –2518
Adverse event costs were given in terms of number
and cost of hospital admissions. NHS reference
costs were used to estimate the average cost of an
admission of patients suffering from various
conditions. The admission cost was multiplied by
the number of admissions recorded for each
condition in the trials. Because many admissions
did not fall into any of the categories, the number
of admissions in the ‘Other’ category was 
more than all the specific categories combined. 
As the ‘Other’ category was so broad, it is possible
that there is a large margin for error in these 
cost estimates. All hospitalisations over the
treatment period were included in these
calculations, not only those resulting directly 
from treatment. 
The costs of concomitant medications and clinical
procedures were also included in the submission,
but contributed little to either the incremental cost
or the total cost. These medications and tests are
generally incurred with all treatments, leading to a
similar cost for capecitabine and Mayo as well as
UFT/LV. 
Indirect costs were also estimated in the sponsor
submission, in terms of the number of work days
lost by patients in the Carmichael trial. The value
of lost work time using the UK average weekly
wage and the friction-cost method was
approximately £799 per UFT/LV patient and
£1030 per 5-FU/LV patient.
Outcomes
The outcome used in this analysis is improvement
in toxicity end-points. UFT/LV was not inferior to
5-FU/LV in any toxicity end-point in the trial,
which led the authors to perform a cost-
effectiveness analysis. Because the authors had
decided to do a cost-effectiveness analysis, only
the end-points that favoured UFT/LV were
appropriate for the evaluation. The incremental
cost-effectiveness ratios derived from these clinical
end-points represent the extra cost of UFT/LV for
an additional patient to be free of the specified
adverse event. Only toxicity end-points that
significantly favoured UFT/LV were considered in
the economic evaluation. These outcomes
included both grades 1–4 and grades 3–4
stomatitis/mucositis, leucopenia and neutropenia,
and also thrombocytopenia of any grade, febrile
neutropenia and infection/fever. 
Cost-effectiveness analysis
Because the total cost of UFT/LV treatment was
lower than 5-FU/LV treatment and the only end-
points used favoured UFT/LV, UFT/LV was found
to be dominant in every case, and hence an
incremental analysis was not performed. 
Sensitivity analysis
A sensitivity analysis showed that the incremental
cost of UFT/LV is relatively robust, most sensitive
to chemotherapy administration costs and least
sensitive to adverse event hospital costs and other
medical resource costs. The only scenarios in
which UFT/LV cost more than 5-FU/LV were where
the cost of chemotherapy administration was £86
for both groups or if LV was acquired at BNF list
prices.55 The incremental cost of UFT/LV over 
5-FU/LV varied from –£2365 to +£866. 
Because cost is most sensitive to administration
costs, a threshold analysis was performed to test
the number and cost of specialist consultations
and outpatient visits for the administration of
UFT/LV. In the base case, UFT/LV patients
received an average of 1.775 specialist
consultations per cycle and each consultation costs
£86. To be equal in cost to 5-FU/LV patients, the
number of consultations each cycle would be
6.730. If the cost per consultation is £218, cost
equivalence would be achieved at 2.657
consultations per cycle. 
Discussion of Bristol-Myers Squibb economic
evaluation
BMS have presented a comprehensive economic
evaluation of UFT/LV as a first-line treatment of
advanced colorectal cancer. Their cost calculations
are detailed and relatively unbiased, as are the
calculations of administration costs. Although only
adverse events severe enough to require
hospitalisation were costed, the superior adverse
effect profile of UFT/LV would likely be reflected
by lower costs of adverse event-related
consultations and drug treatment, and hence
costing every element of adverse event
management would be unlikely to change the
results. 
The authors of this study chose not to perform a
cost-minimisation analysis as Roche did, but rather
a cost-effectiveness analysis. Since the only trials
comparing UFT/LV with a recognised regimen
(Mayo) were designed to show non-inferiority, the
only situation in which UFT/LV has a proven
superiority to 5-FU/LV is in selected adverse
events. By the nature of this selectivity, some of the
drawbacks associated with UFT/LV are overlooked,
namely significantly reduced time to progression
(although only amounting to 0.3 month), and a
statistically non-significant but possibly clinically
important reduced overall survival (1.0 month in
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the Douillard study46), and also adverse events
that are statistically equivalent between treatment
arms. Since the authors had chosen to perform a
cost-effectiveness analysis, it would have been
useful to have had an analysis of the incremental
cost-effectiveness (using different outcomes) of 5-
FU/LV over UFT/LV and of UFT/LV over 5-FU/LV.
Since UFT/LV has both a slight advantage in terms
of adverse events and a slight disadvantage in
terms of progression-free and overall survival, the
slight advantage is reflected in the economic
analysis, but not the slight disadvantage. 
The economic evaluation of UFT/LV made no
mention of QoL, although data had been collected
and were presented earlier in the report. The QoL
data show that the improved adverse effect profile
has no effect on QoL. 
As in the capecitabine analysis, the evaluation
showed that the main cost differences between
oral therapies and infusional regimens arise from
drug cost and administration. 
Since neither evaluation performed any kind of
sensitivity analysis in which outcomes were tested,
it is not known whether cost would be sensitive to
variation in outcome. 
Summary of existing economic
evidence
In summary, the existing economic evidence shows
that oral drugs may have an economic advantage
over the Mayo intravenous regimen, primarily
owing to their savings in administration, and
possibly also to improved adverse event profiles.
Although the quality of evidence is good in the
resource-use studies,53,54 these studies do not
report costs. Although the South American
economic evaluations51,52 claim to show cost
savings associated with UFT usage, the quality of
evidence is poor, as the resource-use data do not
come from trials or broadly based surveys, the rate
of resource use was not given and it is doubtful
whether the aggregated cost data are applicable to
current UK practice. Hence there are no
evaluations that can be directly translated to the
UK context. 
The analyses show that the increased drug
acquisition cost associated with oral therapies is
offset by the reduced cost of administration, and
as a result the cost differences between the oral
regimens and the Mayo regimen are small.
The major limitation of both submissions is that
there is no economic analysis presented
comparing oral drugs with any 5-FU regimen
other than the Mayo regimen. Many different 
5-FU intravenous regimens are currently used in
the UK, and therefore the submissions are only
partially relevant to current UK practice. 
Quality of life evidence
Capecitabine
Although QoL data were collected in the
capecitabine trials, the results have not yet been
published. Both trials used the EORTC QLQ-C30
questionnaire, assessed at baseline and at the start
of each treatment cycle. 
Results reported in the Roche sponsor
submission45 showed that there was no significant
difference in global QoL between capecitabine
and Mayo treatments, as measured by the EORTC
QLQ-C30, and that QoL was maintained for
patients in both arms of the studies. 
The Roche sponsor submission46 also included a
social preferences study (Appendix 5 in the
submission), conducted by post on randomly
chosen members of the public. These were not
people who had necessarily had any personal
experience of colorectal cancer. A detailed
questionnaire was used to determine social
preference weights associated with the different
treatment scenarios. The questionnaire was
extremely long and complex and may well have
been confusing to the respondents.
UFT/LV
QoL data for UFT/LV were collected and have
been published.46,47 In the Douillard study,46 QoL
was assessed with the FLIC 22-item questionnaire.
In the Carmichael trial,47 the EORTC QLQ-C30
was used. Like the capecitabine results, the
UFT/LV trials showed no significant difference in
favour of oral therapies. When adjusted for
baseline characteristics, the Douillard study46
revealed no statistically significant differences
between treatment arms. When the Carmichael
study was adjusted for baseline characteristics, the
subscale for diarrhoea remained statistically
different (p = 0.022) in favour of the 5-FU/LV
arm. This seems at odds with the safety analysis,
which showed no statistically significant higher
incidence of diarrhoea in the UFT/LV arm,
leading the investigators to hypothesise that the
timing of the questionnaire may have influenced
the results. 
Although both oral drugs showed an improved
adverse event profile, owing to lower frequency of
grade 3 and 4 adverse events, this was not
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reflected in improved QoL for the patients. This
may be because Mayo patients experience severe
adverse events during the middle of their cycle,
but they have mostly recovered by the time they
are receiving their next course of treatment. If
QoL questionnaires are administered at the
beginning of each treatment cycle, and (as in the
case of the EORTC) refer only to the preceding
week, then they are less likely to capture the
adverse effects on QoL of Mayo treatment. It is
also possible that QoL is improved through
intravenous treatment, owing to increased contact
with nurses and peer support of other patients. It
would be useful to investigate these possibilities
further in future trials.
Methods for economic evaluation
An economic evaluation was undertaken to
compare the cost-effectiveness of UFT/LV and
capecitabine with that of intravenous 5-FU/LV.
Intravenous 5-FU/LV is an appropriate
comparator because it is the most common first-
line treatment for metastatic colorectal cancer
currently in use in the UK. 
A number of intravenous 5-FU regimens are in
common use in the UK: the Mayo regimen, the de
Gramont (inpatient and outpatient regimens), the
modified de Gramont (MdG) regimen and
continuous infusion regimens. These are detailed
in Appendix 2. The decision as to which regimen
to use depends on the preferences of the physician
and the patient, the resources available at the local
treatment centre and the distances the patient may
have to travel in order to receive treatment. 
Estimation of net benefits
UFT/LV
Two phase III RCTs46,47 of UFT/LV were identified
(011 and 012). These are reviewed in full in the
section ‘Quantity and quality of research available:
UFT/LV’ (p. 20).
Douillard and colleagues, 200246
In the Douillard study46 (study 011) comparing
UFT/LV with the Mayo regimen, UFT/LV
demonstrated statistical equivalence in terms of
response rate (12 versus 15%) and median overall
survival (12.4 versus 13.4 months). UFT/LV had a
significantly inferior median progression-free
survival rate (3.5 versus 3.8 months, p = 0.011). 
Mean survival was calculated from the survival
curve published in the sponsor submission using
area under the curve (AUC) analysis. The area
under a survival curve gives the mean overall
survival experienced in the trial. Therefore, the
area between the UFT/LV survival curve and the 
5-FU/LV survival curve gives the mean survival
benefit of UFT/LV over 5-FU/LV. Calculated in this
way, the mean survival of UFT/LV was 15.3 months
and the mean survival of 5-FU/LV was 15.7 months. 
Carmichael and colleagues, 200247
In the Carmichael study47 (study 012), comparing
UFT/LV with a modified Mayo regimen, UFT/LV
demonstrated equivalence to infusional 5-FU/LV
in terms of response rate (11 versus 9%), time to
progression (3.4 versus 3.3 months) and overall
survival (12.2 versus 10.3 months). The values for
5-FU/LV are, however, lower than would be
expected compared with other 5-FU/LV trials.17
Mean survival was calculated from the survival
curve published in the sponsor submission using
AUC analysis. The mean time to progression was
4.3 months for UFT/LV and 4.6 months for 
5-FU/LV and mean survival was 14.0 months for
UFT/LV and 12.7 months for 5-FU/LV. 
Discussion of results. In the Carmichael study,47 the
5-FU/LV dose was reduced by 25% since it was
administered over 5-week intervals instead of 
4-week intervals to avoid a monitoring bias.
However, median doses were lower than the
protocol dosage level in both trials (median 
452 mg/m2/week versus protocol 531 mg/m2/week
5-FU in the Douillard study46 and median of 
418 mg/m2/week versus protocol 425 mg/m2/week
5-FU in the Carmichael trial), a difference of only
8%. 
The survival rate of the 5-FU/LV arm was lower in
the Carmichael study47 than in the Douillard
study,46 whereas the survival rate of the UFT/LV
arm remained the same. The regimen used in the
Carmichael study is, however, not considered to be
a good comparator, given that the protocol 5-FU
doses used in the modified Mayo arm were 20%
lower than standard Mayo regimens and the
survival rates from that trial are considerably lower
than expected for an efficient 5-FU regimen. The
survival rates in the Douillard study46 were similar
to those observed in other 5-FU trials.17
For the purposes of economic analysis, the results
of the Douillard study46 were used, since this study
involved a larger number of participants and used
the widely recognised 4-week Mayo regimen as its
comparator treatment. The UFT/LV results were
consistent between the two trials, so the choice of
the Douillard study46 does not bias the analysis. 
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Capecitabine
Two international RCTs40,41 with identical
protocols compared capecitabine with the Mayo
Clinic regimen. The data from these two trials
were also pooled in a report by Twelves.36 These
are reviewed in full in the section ‘Quantity and
quality of research available: capecitabine’ 
(p. 11).
Hoff and colleagues, 200140
In a published trial by Hoff and colleagues,40
capecitabine demonstrated equivalence with the
Mayo regimen in median time to progression (4.3
versus 4.7 months) and median survival (12.5
versus 13.3 months). Capecitabine had a superior
response rate (24.8 versus 15.5%). 
The survival and progression-free survival curves
were also published, and were used to calculate
mean time to progression (5.4 months for
capecitabine and 5.5 months for Mayo) and mean
survival (14.8 months for capecitabine and 15.1
months for Mayo). 
Van Cutsem and colleagues, 200141
In a published trial by Van Cutsem and
colleagues,41 comparing capecitabine with Mayo
regimen 5-FU/LV, capecitabine demonstrated an
improved response rate (26.6 versus 17.9%) as well
as equivalent survival (13.2 versus 12.1 months)
and progression-free survival (5.2 versus 4.7
months). The median survival and progression-free
survival rates were similar to those seen in other
studies of 5-FU/LV in the treatment of metastatic
colorectal cancer patients.20,19
The mean survival for the capecitabine regimen,
calculated through AUC analysis of the survival
curves, was 15.1 months and that for the Mayo
regimen was 14.1 months. The mean time to
progression was 5.4 months for the capecitabine
and 5.8 months for the Mayo regimen. 
Twelves, 200236
In a report36 using pooled data from Hoff and
colleagues40 and Van Cutsem and colleagues,41
capecitabine demonstrated a significantly superior
response rate (25.7 versus 16.7%, p < 0.0002) and
equivalent median progression-free survival (4.6
versus 4.7 months) and overall survival (12.9
versus 12.8 months). The mean survival, estimated
using AUC analysis, for the capecitabine regimen
was 15.7 months and that for the Mayo regimen
was 15.1 months. 
We chose to use the results published in the
Twelves paper36 in our analysis. The trials were
performed using identical protocols for the
purpose of pooling the data at a later date. The
pooled study includes a large number of patients
at a wide range of centres and provides high-
quality data for comparison. 
Choice of comparator regimen 
The Mayo regimen was used as a comparator in
the trials because it is internationally the most
widely used regimen. There is, however, no gold
standard therapy in the UK for the treatment of
advanced colorectal cancer. It is not known with
certainty to what extent different regimens are
used. However, a recent survey, based on responses
from 43 members of the British Oncology
Pharmacy Association, reported that 37% of
hospitals covered by the survey used low-dose FA
and 5-FU bolus (weekly or monthly) more often
than any other regimen for first-line
chemotherapy options for advanced colorectal
cancer. The proportions of hospitals using MdG,
de Gramont and PVI 5-FU regimens more often
than any other regimen were 26, 12 and 7%,
respectively.57
We therefore chose to compare the oral drugs
against the Mayo regimen and two infusional
regimens: the MdG regimen, given on an
outpatient basis, and the inpatient de Gramont
regimen. 
There is, however, no direct trial evidence
comparing oral drugs with infusional 5-FU
regimens. Therefore, to compare the oral drugs
against the MdG and inpatient de Gramont
regimens, it is necessary to consider an indirect
comparison of the Mayo regimen against
infusional regimens.
Efficacy of bolus versus infusional 5-FU regimens
A range of published survival estimates for the de
Gramont regimen are outlined in Appendix 5.
These range from 42 to 64 weeks. Case-mix
selection is an important determinant of survival
and may account for the variability in these
estimates. 
Little published evidence was identified on the
MdG regimen, although it is now widely used in
the UK. The MdG regimen preserves the main
elements of the de Gramont regimen: dose-
intensive exposure to FU with LV for 48 hours
every 2 weeks, with minimal haematological
gastrointestinal toxicity.21 The MRC have made the
decision to move over to the MdG regimen without
a large randomised equivalence trial because the
MdG regimen is more 5-FU dose-intensive and it
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has better non-randomised phase II response rates
than the old de Gramont regimen. (Seymour M,
Cookridge Hospital, Leeds: personal
communication, 2002). In addition, it is more
convenient for patients and hospitals. 
Evidence on the efficacy of bolus regimens (such
as the Mayo) against infusional regimens (such as
the de Gramont and the MdG) is limited. A small
number of studies have been identified and these
are considered below.
Meta-analysis Group in Cancer, 199815
(Appendix 3)
In a meta-analysis of trials comparing continuous
infusion 5-FU regimens with bolus 5-FU regimens,
continuous infusion regimens were found to be
slightly more effective. However, only two of the
trials involved regimens in which bolus or
continuous infusions were given alongside LV. In
these two trials no significant survival benefit was
demonstrated for continuous infusional regimens.
In addition, the meta-analysis used the results of
six trials, none of which involved the de Gramont
regimen and only one of which involved the Mayo
regimen. All of the continuous infusion arms of
these trials used prolonged infusions that
continued for a number of days without
interruption, and hence differ from the MdG
regimen used in the UK. This meta-analysis is
therefore not considered to provide high-quality
evidence on the relative effectiveness of the Mayo
and de Gramont regimens. 
De Gramont and colleagues, 199717
(Appendix 4)
A study by de Gramont and colleagues17
compared the Mayo regimen with the de Gramont
regimen. The de Gramont regimen had higher
response rates (32.6 versus 14.4%, p = 0.0004),
increased median time to progression (27.6 versus
22 weeks, p = 0.004) and insignificantly increased
overall survival (62 versus 56.8 weeks, p = 0.067).
Overall grade 3–4 toxicity was also lower on the
de Gramont regimen (11.1 versus 23.9%, 
p = 0.0004). 
Although overall survival rates were higher for the
de Gramont regimen, the difference was not
statistically significant. In addition, the survival
rates in the Mayo arm of the de Gramont trial
(56.8 weeks) are higher than those observed in the
capecitabine and UFT/LV trials. They are also at
the upper end of the published survival rates for
de Gramont regimen (Appendix 5). This suggests
that other factors are impacting on survival in the
de Gramont trial. These may include issues
relating to patient selection and possible early
diagnosis of metastatic disease.
Cheeseman and colleagues, 200221
A recently published phase II trial by Cheeseman
and colleagues21 to establish dose intensities for
the MdG regimen reported that the optimum
doses were 350 mg LV, 400 mg/m2 bolus 5-FU
followed by 2800 mg/m2 5-FU infusion given over
46 hours. This regimen was given on an outpatient
basis, with the bolus infusion being given during
an outpatient attendance and a district nurse
visiting the patient at home to disconnect the
patient’s line and flush it weekly. Forty-six patients
participated in the trial. At the optimum infusion
dose level, eight out of 22 (36%) patients
experienced a partial response, with disease
stability achieved in a further seven (32%). Median
failure-free survival was 9.3 months. Fifteen of the
22 patients went on to receive second-line
chemotherapy, and median overall survival from
starting treatment was 16.8 months. This survival
is similar to that reported by de Gramont and
colleagues.17 The toxicity profile is similar to de
Gramont regimen. The most common toxicities
observed were nausea or vomiting and lethargy,
with no adverse events worse than grade 3. No
hospitalisation data were reported. 
In conclusion, the limited evidence available
demonstrates that the de Gramont regimen is
superior to the Mayo regimen in terms of
progression-free survival and in relation to toxicity,
but that there is no statistically significant survival
benefit. 
For purposes of the economic analysis, we have
assumed that the survival benefits for the MdG and
de Gramont regimens are identical. In addition, it
is assumed that the de Gramont regimens offer the
same survival benefit as the Mayo regimen. This
assumption has been tested in sensitivity analysis.
Estimation of net costs
No published UK costs for the use of oral drugs in
advanced colorectal cancer were identified.
Cost estimates were divided into three categories:
drug acquisition cost, chemotherapy
administration costs and adverse event
management costs (including hospital admissions,
physician consultations and drug treatment). 
All costs are inflated to the year 2002 using the
Hospital and Community Health Service58 cost
index until 2001 and GDP from 2001 to 2002.
Unit costs are reported in Appendix 9.
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No discounting has been applied given that the
median survival times of patients with advanced
metastatic colorectal cancer are around 
12 months.
Drug costs
Drug acquisition costs were based on an individual
with a body surface area of 1.75 m2 undergoing
therapy at standard treatment doses as listed in
the Summaries of Product Characteristics.45,48 It
was assumed that doses remained at the
prescribed level for the duration of treatment.
This may result in a slight overestimate because in
the trials the average doses administered were
lower than the prescribed dose. The impact of this
assumption is tested in the sensitivity analysis.
The prescribed capecitabine dose was 4300 mg
daily: 4 × 500-mg tablets and 1 × 150-mg tablet
administered each morning and evening. The
prescribed UFT dose was five UFT capsules each
day, or 1680 mg/m2/week. The prescribed Mayo
dose was 425 mg/m2/day 5-FU with 20 mg/m2/day
LV. The de Gramont dose was assumed to be 
1000 mg/m2/day 5-FU with 200 mg/m2/day LV.
The MdG dose was assumed to be 350 mg LV, 
400 mg/m2 5-FU bolus then 2800 mg/m2 5-FU
infusion over 46 hours. 
Drug costs for 5-FU, LV and capecitabine were
taken from the BNF website (BNF No. 43).55 Drug
costs for UFT were taken from the letter
announcing price changes included in the sponsor
submission from BMS.48 Value added tax (VAT)
was calculated on all drug costs.
A sensitivity analysis was tested in which LV was
acquired at a discounted price, based on estimated
discounts (87% for tablets) established by market
research in the unpublished BMS submission.48 We
were able to verify from discussions with a number
of pharmacists that substantial discounts are often
offered to hospitals for this drug. As discounts are
kept confidential to hospitals, we were not able to
verify the estimated discount. The impact of the
discount of LV on the cost of the Mayo and de
Gramont regimens is substantial, given that LV
accounts for over 50% of the total drug cost for
these regimens.
Costs were calculated per cycle and then adjusted
to generate a cost per 28-day period to allow
comparison. The drug cost per 28-day period was
£464 for capecitabine, £892 for UFT/LV, £189 for
the Mayo, £563 for the de Gramont and £394 for
the MdG regimen. These costs include VAT, but
not discounts. 
Administration costs
Administration costs were divided into two groups:
costs that were incurred each cycle (cyclical costs)
and costs that were incurred only once over the
period of treatment (one-off costs). One-off costs
included education for patients on oral therapies
and line insertion and overnight admissions
associated with the outpatient de Gramont
regimens. Cyclical costs included inpatient and
outpatient hospital visits, a creatinine test for
capecitabine patients, preparatory drugs,
community nurse infusion administration and
home visits, infusion pumps, pharmacy
preparation and materials. 
The costs of outpatient appointments were taken
from the Christie Hospital (Hawkins R, Christie
Hospital, Manchester: personal communication,
2002). The cost of an outpatient appointment with
chemotherapy was assumed to be £150, whilst the
cost of an outpatient clinic appointment without
chemotherapy was assumed to be £80. The costs
of inpatient stays and other administration costs
were taken from the Personal and Social Services
Research Unit (PSSRU).58 The cost of outpatient
appointments were the key driver to the cost of
administration for capecitabine, UFT/LV, Mayo
and the MdG regimens. These costs were tested in
the sensitivity analysis.
Diagnostic tests have not been included in the
analysis. They are assumed to be similar across all
treatment arms. Costs of primary care and
transportation (in hospital ambulances) were
reported in the sponsor submissions but have not
been included as they make only a small
contribution to total incremental costs.
One-off costs
The costs of time and materials for patient
education were estimated following discussion with
a number of clinicians. Patients receiving oral
drugs are assumed to receive a 15-minute nurse
appointment at the beginning of their treatment
to discuss their role and responsibilities. They
were also given materials to take home with them.
The estimated cost of £7, based on 15 minutes of
nurse time, was assumed to be the same for both
capecitabine and UFT/LV treatments. The MdG
regimen was assumed to have a one-off cost of
£265 for line insertion.59 The Mayo regimen and
the inpatient de Gramont regimen were assumed
to have no one-off costs.
Cyclical costs
Patients undergoing oral therapies were assumed
to attend one outpatient appointment each cycle
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(Orr B, Weston Park Hospital, Sheffield: personal
communication, 2002). Patients on the Mayo
regimen incurred the costs of five outpatient
attendances to a cancer ward each cycle, in
addition to the cost of the infusions themselves.60
Patients on the MdG regimen incurred one
outpatient attendance to the cancer ward each
cycle and two community nurse home visits each
cycle to disconnect and maintain their infusion
lines.21 They also incurred the costs of infusion
pumps and materials associated with pump and
line maintenance. 
The 28-day cyclical administration costs were £113
for capecitabine, £64 for UFT/LV, £839 for Mayo
patients, £650 for MdG and £1500 for inpatient
de Gramont.
Management of adverse events
Both oral drugs have been reported to have
improved toxicity profiles compared with the
Mayo regimen. 
The costs of management of adverse events was
divided into three groups: hospitalisations,
physician consultations and drug treatment costs.
Capecitabine
For capecitabine, resources used relating to
hospitalisations and physician consultations were
taken from the study by Twelves and colleagues53
and combined with UK unit costs taken from the
PSSRU.56 Only hospitalisations directly related to
adverse events associated with treatment were
considered. Costs of drug treatment for adverse
events were taken from the Roche sponsor
submission45 and checked against common
treatments and costs according to clinicians and
the BNF. 
UFT/LV
The number of hospitalisations was consistent
between the two UFT/LV trials; however, the
hospitalisation rates appear to include all non-
administration related hospitalisations. This
includes adverse events associated with disease
symptoms and other illnesses in addition to
treatment-related adverse events. This is likely to
overestimate the cost of managing treatment-
related adverse events. An alternative estimate of
adverse events was considered.
Since the adverse event profile is equivalent or
superior to the Mayo regimen in nearly all
categories, it could be assumed that the resource
use rates for treatment-related adverse events
would be similar but slightly lower than those
incurred in Mayo treatment. Therefore, a
reasonable maximum cost would be the treatment-
related adverse event costs of Mayo treatment
calculated from the Twelves analysis,53 that is,
£851. Although this may still be an overestimate, it
is more reasonable than counting all non-
administration-related costs. 
Mayo regimen
Adverse event costs for the Mayo regimen were
calculated using the same methodology as for the
costs of adverse events for capecitabine. The cost
estimate obtained for Mayo treatment was very
close to the figure previously reported in a recent
NICE analysis of colorectal cancer drugs.24
De Gramont and MdG regimens
The de Gramont and MdG regimens are assumed
to have the same toxicity profile. They are
assumed to be less toxic than the Mayo regimen.17
The number of hospital days and drug treatment
costs were taken from a previous NICE analysis of
colorectal therapies24 and multiplied by the
PSSRU cost of a medical oncology inpatient day.
However, since different trials and hence different
patient groups are being considered, these costs
must be viewed with caution.
The cost of line complications needs to be taken
into account for patients on outpatient regimens,
such as the MdG regimen. Complications range
from minor to major, and may even require re-
siting of the line. Estimates of the frequency of
occurrence and cost of treating complications have
been provided by Professor James (James R, 
Mid Kent Oncology Centre, Maidstone: personal
communication, 2002). Based on 100 patients
receiving treatment, it is assumed that 20 patients
experience a minor complication at a cost of £50,
10 patients experience a major complication at a
cost of £250 and five patients require re-siting of
the line at a cost of £250, giving a total cost of
£4750 for 100 patients.
The 28-day cost of treating adverse events is £131
for capecitabine, £170 for the Mayo regimen (and
UFT), £29 for the MdG regimen and £22 for the
inpatient de Gramont regimen. Given the
uncertainty relating to the estimation of adverse
event costs, a sensitivity analysis was examined in
which adverse events were excluded and only drug
acquisition and administration costs were
considered.
Total treatment costs
Total treatment costs were derived by multiplying
the cost per 28-day period by the treatment
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duration and adding on the one-off
administration costs.
No consistent policy exists amongst UK clinicians
regarding duration of treatment for patients
receiving chemotherapy for advanced colorectal
cancer.61 Treatment for patients who are
responding or who have stable disease can be
continued until disease progression or stopped
after a fixed period of time, usually between 3 and
6 months. 
A recent study by Maughan and colleagues61 that
compared continuous or intermittent
chemotherapy for advanced colorectal cancer
suggested that there was no clear evidence of a
benefit in continuing therapy indefinitely. Patients
who were responding or had stable disease after
receiving 12 weeks of de Gramont, Lockich or
raltitrexed treatment were randomised to either
‘continue’ therapy until progression or ‘stop’, re-
starting on the same therapy on progression. Of
the 178 patients allocated to stop therapy, 39% re-
started treatment for a median time of 83 days.
There was no clear evidence of a difference in
progression-free survival or overall survival. In
addition, there appears to be a gain in QoL for
patients on intermittent therapy, supporting a
stopping policy for chemotherapy after 12 weeks.
For the purposes of economic evaluation, it was
assumed that all patients would be treated for 12
weeks. The survival results reported in the RCTs of
the oral drugs are based on patients treated until
disease progression. It was assumed that there was
no detrimental impact on survival resulting from
stopping treatment at 12 weeks. The assumption
that patients are treated for only 12 weeks may
underestimate total treatment costs given that,
based on the Maughan study,61 a proportion of
patients who stop treatment at 12 weeks may
continue treatment on first-line therapy at a later
stage. A sensitivity analysis was considered in which
patients were treated until disease progression. In
reality, treatment duration may well lie between
these two scenarios for many patients.
Treatment costs are likely to be overestimated
given that treatment may be stopped earlier for
some patients owing to toxic effects or
progression.
The estimated total treatment costs are given in
Table 20.
Discussion of results 
The costs of both capecitabine and UFT/LV were
estimated to be lower than the treatment costs for
the three intravenous regimens based on a
treatment duration of 12 weeks. The cost estimates
for UFT/LV, the Mayo regimen and the MdG
regimen were similar. The cost estimate for
inpatient de Gramont is substantially higher than
for the MdG regimen delivered on an outpatient
basis, in terms of both drug costs and
administration costs.
It should be noted, however, that the cost of
UFT/LV and the infusional regimens do not take
into account the substantial discount offered on
BNF prices on LV.
For capecitabine and UFT/LV, the relatively high
drug costs of the oral drugs were offset by lower
administration costs. 
A comparison of the costs estimates derived by
ScHARR and those provided in the sponsor
submissions is given in Table 21. The sponsor
submission costs have been converted into 28 day
costs for ease of comparison.
Comparison of treatment costs is not
straightforward. For instance, ScHARR’s estimates
for drug costs include VAT whereas the sponsor
submissions do not. In addition, the BMS
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TABLE 20 Total treatment costs (£)
Capecitabine UFT/LV Mayo MdG (outpatient) de Gramont (inpatient)
Drug cost 464 892 189 394 563
Administration 113 64 839 650 1500
Adverse events 131 170 170 29 22
Total 28-day costs 708 1126 1198 1073 2085
One-line costs 7 7 – 285
Treatment period (weeks) 12 12 12 12 12
Total treatment costs 2132 3385 3593 3485 6255
estimates for drug costs include a discount of 87%
on the BNF price of LV. When these were taken
into account there is little difference in the costs of
drugs between the ScHARR estimates and the
sponsor submissions.
The Roche submission presented the incremental
cost of administration over the Mayo regimen and
therefore did not include a cost for administration
of capecitabine. The BMS submission took a
conservative approach to estimating the cost of
administering UFT/LV by assuming that patients
visited a specialist weekly during the first 
cycle of chemotherapy, as opposed to once 
per cycle.
The ‘other’ category in the Roche cost estimates
includes transportation for hospital
administration. The ‘other’ category in the
estimation of BMS cost includes concomitant
medications and clinical procedures. These items
had little impact on the cost of medical resources.
Second-line treatment
The Carmichael study47 records the number of
participants who go on to receive second-line
treatment after treatment with the UFT/LV and
Mayo regimens. In this study, 41% of UFT/LV
patients and 39% of modified Mayo patients went
on to receive second-line treatment; 49% of the
UFT/LV patients and 47% of the Mayo patients
received 5-FU treatment, 28% of each arm
received irinotecan only and 13% of UFT/LV
patients and 16% of Mayo patients received either
oxaliplatin or irinotecan with oxaliplatin. The
effect of second-line treatment on survival was
similar across both arms. 
In the recent NICE rapid review of irinotecan,
oxaliplatin and raltitrexed for the treatment of
advanced colorectal cancer,24 it was estimated that
30–35% of patients who die of colorectal cancer
have received chemotherapy and, of these
patients, approximately 65% go on to have
second-line chemotherapy. The proportion of
patients who are likely to receive second-line
treatment in normal clinical practice is unknown.
If it is assumed that a similar proportion of
patients receiving oral therapies and intravenous
therapies will go on to receive second-line
treatment and that the duration of treatment is
similar for both, then the cost of second-line
therapy will not change between the different
therapies and will not influence the incremental
cost between therapies.
The cost of second-line treatment is not included
in the base-case scenario. It is included in a
sensitivity analysis to demonstrate the possible
costs incurred. 
Cost analysis
Methods
A cost-minimisation analysis was performed for
comparisons of capecitabine and UFT/LV with the
Mayo regimen, since the survival benefits have
been shown to be statistically equivalent. 
A cost-minimisation analysis was also performed
for comparisons of capecitabine and UFT/LV with
the infusional regimens. This was based on no
proven evidence of survival difference between the
Mayo and the infusional regimens and hence no
assumed survival difference between the oral
drugs and the infusional regimens (see the section
‘Efficacy of bolus versus infusional 5-FU regimens’,
p. 37).
Results
The results of the cost-minimisation analyses are
presented in Table 22.
Discussion of results
In comparison with the intravenous regimens,
both capecitabine and UFT/LV were shown to have
lower costs. Although the drug costs are higher,
oral drugs offer the advantage of a lower volume
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TABLE 21 Comparison of 28-day treatment costs (£)
Capecitabine UFT/LV Mayo
ScHARR Roche ScHARR BMS ScHARR BMS Roche
Drug cost 464 395 892 422 189 77 145
Administration 113 0 64 121 839 1100 541
Adverse event management 131 122 170 75 170 84 243
Other N/A 0 N/A 34 N/A 34 67
Total 28 day costs 708 517 1126 652 1198 1295 996
of hospital visits and avoid the need for line
insertions and their potential complications or
inpatient administration of chemotherapy. 
Fewer hospital visits may, however, be seen as a
disadvantage, as this scenario provides less
opportunity for symptom monitoring and
consultation with medical staff. Clearly, this has
potential implications for patient safety, and some
patients may need varying degrees of monitoring
in order to ensure their safety. Roche currently
offer a Hospital at Home service to patients on
capecitabine. This involves a trained nurse
contacting new patients by telephone twice within
the first 2 weeks to check patients are coping
adequately and also provides a support line for
patients with concerns or questions. If this service
is withdrawn by the manufacturer, it may be
necessary for hospitals or the community to
provide support to patients on oral chemotherapy.
Provision of this service has not been included in
the cost analysis.
The costs used in the economic evaluation were
not based on published studies and are subject to
uncertainty. Key uncertainties related to the price
of LV, which is known to be discounted
substantially below BNF prices, the treatment
duration for different therapies, which impacts on
their total treatment cost, the costs of managing
adverse events and the cost of outpatient
appointments. These issues are tested in the
sensitivity analysis.
The greatest uncertainty is based around the
comparison of oral drugs with the de Gramont
regimens. This is based on an indirect
comparison. The evidence comparing bolus and
infusional regimens is limited and subject to
debate. The study by de Gramont and colleagues19
comparing the Mayo regimen with the de
Gramont regimen reported that overall survival
rates were higher for the de Gramont regimen,
but that the difference was not statistically
significant (62 versus 56.8 weeks, p = 0.067). This
difference of 5.2 weeks may, however, be
considered clinically significant. A cost-
effectiveness analysis was therefore performed to
demonstrate the impact assuming a survival
difference between the de Gramont regimens over
oral drugs.
In addition, the use of a cost-minimisation
approach for comparing the de Gramont
regimens with the oral drugs ignores the
advantages offered by the de Gramont regimen
over the Mayo regimen in terms of response rates,
progression-free survival, toxicity and QoL. In the
de Gramont study,19 the de Gramont regimen had
increased median time to progression (27.6 versus
22 weeks, p = 0.004) and lower grade 3–4 toxicity
than the Mayo regimen (11.1 versus 23.9%, 
p = 0.0004). An additional cost-effectiveness
analysis was therefore performed to explore the
impact of these factors on the economic
evaluation.
Sensitivity analysis
A number of assumptions were made in the base
case methodology that could have an impact on
the final results. To study the potential impact of
these assumptions, they were tested in a sensitivity
analysis. 
Scenario A: base case
Scenario B: discounts on drug costs 
In the base case, the drugs were all costed
according to the list prices on the BNF website.55
In practice, many hospitals obtain discounts on
drugs, some of which can be substantial. There
was no indication that discounts were offered on
capecitabine, Uftoral or 5-FU; however, LV, which
accompanies UFT and both intravenous regimens,
is often discounted heavily. A sensitivity analysis
was tested in which LV was costed, based on
estimated discounts of 87% for tablets, as
established by market research in the unpublished
BMS submission.48 For consistency, the same
discount was applied to LV vials. The exact cost of
LV is likely to vary between institutions.
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TABLE 22 Cost savings from oral drugs (£)
Capecitabine Mayo MdG (outpatient) de Gramont (inpatient)
Total treatment costs 2132 3593 3485 6255
Cost saving from capecitabine –1461 –1353 –4123
UFT/LV Mayo MdG (outpatient) de Gramont (inpatient)
Total treatment costs 3385 3593 3485 6255
Cost saving from UFT/LV –209 –101 –2870
Scenario C: dose intensity
In the base case, doses were costed according to
the indications in the Summaries of Product
Characteristics.45,48 In practice, however, doses are
often adjusted owing to adverse effects. Median
doses prescribed in the trials were lower than the
indicated doses set out in the trial protocol. A
scenario was tested in which the average doses
were costed instead of the protocol doses. 
For UFT/LV, the median dose intensity in the
Douillard study46 was 1555 mg/m2/week (93%) and
in the Carmichael study47 1542 mg/m2/week (98%).
The average trial dose of 93% from the Douillard
study46 was used in the sensitivity analysis. For
capecitabine, an average of 81% was used in the
sensitivity analysis, based on the average
capecitabine dose intensity in the trials: 80% in
the Hoff trial40 and 82% in the Van Cutsem trial.41
For the Mayo regimen the delivered dose was 85%
in the Douillard study,42,46 86% in the Hoff trial40
and 95% in the Van Cutsem trial.41 An average of
90% was used in the sensitivity analysis. For studies
using the de Gramont and MdG regimens, only
the prescribed dosage was reported therefore no
dose adjustment was used in the sensitivity
analysis. 
Scenario D: cost of outpatient appointments
In the base case it was assumed that a cost
difference existed between outpatient
appointments with chemotherapy and outpatient
appointments without chemotherapy. The
outpatient costs were assumed to be £150 and £80,
respectively, and were supplied by Christie Hospital
(Hawkins R, Christie Hospital, Manchester:
personal communication, 2002). It is known that
these outpatient costs will vary between institutions.
A scenario was tested in which outpatient
appointments for infusional chemotherapy and
outpatient appointments for oral drugs were
assumed to incur the same costs, based on the cost
of medical oncology outpatient attendance of
£109 from Netten and colleagues.56 In addition,
the cost of a medical oncology outpatient follow-
up appointment, £86, and the cost of a day case
appointment, £218, from NHS reference costs
were also tested in the sensitivity analysis.
Scenario E: exclusion of costs of managing
adverse events
Owing to lack of resource-use information,
particularly regarding UFT/LV and MdG
treatments, many assumptions were made in the
calculation of the costs of treating adverse events.
Because of the resultant uncertainty, a scenario
was tested in which adverse event costs were not
included, and costs could be compared only on
the basis of drug costs and administration costs,
the two main cost drivers.
Scenario F: treatment until disease progression
The total cost of treatment was sensitive to the
length of treatment time. This may vary between
regimens. A scenario in which patients were
treated until disease progression was considered to
reflect possible variations in treatment period.
Time to progression for capecitabine, UFT/LV and
Mayo regimens were 4.6, 3.5 and 4.7 months,
respectively. It was assumed that the time to
progression for the MdG and de Gramont
regimens was the same as that for the Mayo
regimen. However, there is evidence available that
the de Gramont regimen offers advantages over
the Mayo regimen in terms of time to progression.
This is explored further in the section ‘Market
share of oral drugs’ (p. 47).
Scenario G: cost of second-line therapy included
There is little information regarding how
treatment would differ after disease progression
for patients on different treatment arms, and
therefore no costs after progression (tests, primary
care, palliative treatment, second-line treatment)
were estimated in the base case. 
A sensitivity analysis was undertaken in which
second-line treatment costs were included. It was
assumed that 40% of patients received second-line
chemotherapy and that all of these patients
received irinotecan. Patients undergoing second-
line therapy were assumed to be treated for 3
months after disease progression. The monthly
cost of second-line chemotherapy with irinotecan
was taken from the NICE rapid review of
irinotecan, oxaliplatin and raltitrexed.24 The cost
of second-line treatment per patient, based on
these figures, is £2125.
Treatment costs in scenarios B–G and incremental
costs are summarised in Table 23 and 24,
respectively.
Discussion of results of scenarios B–G 
The sensitivity analysis showed that the cost
estimates for capecitabine were robust to changes
in the cost parameters. Capecitabine offered cost
savings relative to all three intravenous therapies
under all scenarios. UFT/LV costs were lower than
those of all intravenous regimens except in scenario
D1 where outpatient appointments with and
without chemotherapy are assumed to have the
same cost. However, the majority of institutions do
appear to differentiate in cost terms between
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outpatient appointments for oral drugs and those
at which intravenous chemotherapy is
administered (often classified as day-case visits
rather than outpatient appointments) and
therefore this scenario is unlikely to reflect the
costing policy of most NHS Trusts.
The cost savings offered by capecitabine were
minimised in scenario B, in which a substantial
discount is assumed for LV. This discount reduced
the cost of all the intravenous regimens. In this
scenario, the cost difference between capecitabine
and the MdG regimen is less than £500. This
scenario may well reflect current costs to many
NHS institutions, although the exact size of the
discount received by individual institutions is not
known. This discount also reduces the cost of
UFT/LV and therefore the impact of this scenario
on the cost savings offered by UFT/LV were lower. 
Treatment costs are sensitive to treatment
duration. In the base case, all treatments were
assumed to be given for 12 weeks. Given that the
time to progression is assumed to be higher for
the de Gramont regimens than for oral therapies,
using the assumption that patients were treated
until progression substantially increased the cost
saving offered by oral therapies. Owing to lack of
evidence, no difference to the survival benefits
offered by the regimens was assumed whether
treatments were given for 12 weeks or until
progression.
Further sensitivity analysis – cost per
life year and cost per life year gained
Survival difference between the de Gramont
regimens and the oral drugs
A sensitivity analysis was carried out to
demonstrate the impact of assuming that the de
Gramont regimens offered a survival advantage
over the oral drugs. The base case assumed that
the survival outcomes for the de Gramont
regimens were equivalent to the outcomes from
the oral drugs.40,41 The survival difference
between the de Gramont regimen and the Mayo
comparator from the de Gramont trial17 was 5.2
weeks, although the difference was not statistically
significant. The impact of this survival difference
was assessed in terms of the cost per LYG for
illustrative purposes.
Capecitabine
The results of the cost-effectiveness analysis showed
that capecitabine offered a cost saving of £1461
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TABLE 23 Treatment costs (£) in scenarios B–G
Capecitabine UFT/LV Mayo MdG de Gramont 
(outpatient) (inpatient)
A: Basecase 2132 3385 3593 3485 6255
B: Discounted LV price 2132 2504 3296 2615 4852
C: Average dose intensities from trials 1867 3197 3536 3485 6255
D1: OP appointments have equal cost 2258 3460 3015 3254 6255
D2: OP appointments based on NHS reference costs 2164 3404 4687 3923 6255
E: Adverse events costs excluded 1738 2875 3084 3400 6188
F: Treatment until progression 3546 4288 6115 5745 10645
G: Cost of second-line therapy included 4257 5510 5718 5610 8380
OP, outpatients.
TABLE 24 Incremental costs (£) in sensitivity scenarios
Capecitabine UFT/LV
Mayo MdG de Gramont Mayo MdG de Gramont
(outpatient) (outpatient)
A: Basecase −1461 −1353 −4123 −209 −101 −2870
B: Discounted LV price −1164 −483 −2721 −792 −111 −2349
C: Average dose intensities from trials −1669 −1618 −4388 −339 −288 −3058
D1: OP appointments have equal cost −757 −996 −3997 445 206 −2795
D2: OP appointments based on NHS −2523 −1759 −4091 −1283 −519 −2851
reference costs
E: Adverse events costs excluded −1346 −1662 −4450 −209 −524 −3312
F: Treatment until progression −2569 −2199 −7099 −1827 −1457 −6357
OP, outpatients.
over the MdG regimen and £4123 over the
inpatient de Gramont regimen, but resulted in a
reduction in survival benefit of 5.2 weeks.
Expressed in terms of a cost per LYG, MdG
treatment over capecitabine treatment was
£13,571 and inpatient de Gramont treatment over
capecitabine treatment was £41,344. The
additional survival benefit of MdG over
capecitabine is therefore achieved at a reasonable
cost and the cost saving from oral drugs is not
sufficient to make it a more cost-effective option. 
UFT/LV
The results of the cost-effectiveness analysis
showed that UFT/LV offered a cost saving of £209
over the MdG regimen and £2870 over the
inpatient de Gramont regimen, but resulted in a
reduction in survival benefit of 5.2 weeks.
Expressed in terms of cost per LYG, the cost per
MdG treatment over UFT/LV treatment was £758
and that of inpatient de Gramont treatment over
UFT/LV treatment was £21,631. The additional
survival benefit of MdG and inpatient de Gramont
over UFT/LV is achieved at a reasonable cost and
therefore the cost saving from UFT/LV is not
sufficient to make it a more cost-effective 
option.
These numbers are illustrative only. Further
evidence is needed on the survival difference, if
any, between de Gramont regimens and the oral
drugs. However, it does illustrate that the cost
savings offered by the oral drugs, particularly in
relation to MdG, are not large and therefore if the
oral drugs do reduce the survival of patients by an
order of 5.2 weeks, they may not be considered a
cost-effective option relative to the MdG regimen.
It is difficult to draw any firm conclusions from
this cost-effectiveness analysis, given that it is
based on an indirect comparison of patients from
two different studies.
Difference in progression-free survival between
de Gramont regimens and oral drug regimens 
Progression-free survival is considered important
because disease progression may impair both
physical and emotional health. In addition,
progression-free survival is an important outcome
measure, given that the relationship between
progression-free survival and overall survival may
be confounded by the use of second-line treatment
following progression. 
Capecitabine
The progression-free survival difference between
the de Gramont regimen and the Mayo
comparator from the de Gramont trial17 was 5.6
weeks. The progression-free survival gain of MdG
over capecitabine was therefore assumed to be 5.6
weeks. The cost per progression-free LYG was
£12,567. The progression-free survival gain of
inpatient de Gramont over capecitabine was also
assumed to be 5.6 weeks. The cost per
progression-free LYG was £32,286.
UFT/LV
The progression-free survival gain of MdG over
UFT/LV was assumed to be 6.9 weeks. The cost
per progression-free LYG was £758. The
progression-free survival gain of inpatient de
Gramont over UFT/LV was also assumed to be 6.9
weeks. The cost per progression-free LYG was
£21,631.
These numbers are illustrative only. The results of
the cost-effectiveness analyses should be viewed
with caution, since the outcomes are based on an
indirect comparison of regimens from different
trials. However, they do show that the cost savings
offered by the oral drugs, particularly in relation
to MdG, are not large and therefore on the
assumption that oral drugs do reduce the
progression-free survival of patients by an order of
5.6 weeks, oral drugs cannot be considered a cost
effective option relative to the MdG regimen in
terms of the cost per progression-free LYG. 
Difference in quality-adjusted progression-free
survival between de Gramont regimens and oral
drug regimens
The purpose of chemotherapy for advanced
metastatic disease is as much palliation of
symptoms as relatively small survival benefits. It is
essential to ensure, therefore, that the burden of
treatment does not negate the palliative and
survival benefits.
None of the clinical trials measured utility values.
However, Petrou and Campbell62 have previously
assessed utility values for patients with advanced
colorectal cancer. Descriptions of 23 health states
representative of those for colorectal cancer,
including responding, stabilised and progressive
disease, with and without toxic side-effects of
treatment, were drawn up by a panel of experts.
Thirty nurses, all experienced in the care of
colorectal cancer patients, were used as proxies 
for patients, to estimate the utilities of the 
various health states using the standard gamble
technique. The results, given as median utility
score, are presented only for health states 
free of toxic effects, with some discussion of 
the effect of toxicities on reducing the utility
values of them.
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In order to estimate the effect of adjusting
progression-free survival for QoL, the following
assumptions were made. All days in hospital,
whether for chemotherapy (including outpatient
administration) or toxic effects, count as zero. The
value of zero is arbitrary and is tested in a
sensitivity analysis using the value 0.5. The
remaining days are multiplied by the quality-
adjusted life-year value shown by Petrou and
Campbell62 for stable disease of 0.95. The 
method outlined above has been used in a
previous NICE report41 and has similarities to the
Q-TWIST method described by Gelber and
colleagues.63
The progression-free survival gain of MdG over
capecitabine was previously assumed to be 1.3
months (5.6 weeks). Taking account of the
potential impact of QoL, the progression-free
survival gain fell to 1.2 months. The MdG
regimen involved higher hospitalisation for
administration but lower hospitalisation for
adverse events. In addition, the benefit of the
remaining time prior to progression was reduced
by the assumed utility value of 0.95. The overall
effect was, however, small.
The progression-free survival gain of MdG over
UFT/LV was previously assumed to be 1.6 months
(6.9 weeks). Taking account of the potential impact
of QoL, the progression-free survival gain rose to
1.7 months. The UFT/LV involved longer duration
of hospital stay for adverse events, which offset the
reduction in benefit of the remaining time prior to
progression by the assumed utility value of 0.95.
The overall effect was, however, small.
Impact on the NHS
Patient volumes
In 2003, it is estimated, based on current
colorectal cancer incidence rates, that the number
of new patients presenting with colorectal cancer
will be 29,643.5 Of these patients, it is estimated
that 29% (8596) will present with metastatic
colorectal cancer1 and 50% (10,524) of those
remaining will go on to develop metastatic
disease.56 This results in a pool of 19,120 patients
annually with metastatic colorectal cancer. 
Approximately 30% of those who die of metastatic
colorectal cancer have received chemotherapy
treatment.56 It has been suggested that not all
patients who could benefit from chemotherapy
currently receive treatment, with a further 15%
having the capacity to benefit from such
treatment.56 Based on these figures, 5736 patients
with colorectal cancer would therefore be treated
with first-line chemotherapy at current rates, with
the potential to treat up to 8604 patients. Since
some patients who currently refuse intravenous
therapy would accept oral therapy, it is likely that
widespread use of oral therapies will increase the
proportion of patients who are treated.
Market share of oral drugs
The proportion of patients currently receiving oral
drugs is not known.
Factors influencing the proportion of patients,
who are fit for treatment, likely to receive oral
agents as first-line therapy in the future include:
 proportion of patients not eligible for or who
refuse the FOCUS trial
 proportion of patients not eligible for
oxaliplatin downstaging of liver metastases
 proportion of patients experiencing line
complications with 5-FU.
Use of oral therapies will also be dependent on
patient preference and is therefore likely to vary
between providers. 
It is assumed that 45% (8604) of patients with
metastatic colorectal cancer receive chemotherapy.
Of these, it is assumed that 10% enter the FOCUS
trial and that 10% receive oxaliplatin. The
remaining patients could then receive either oral
drugs or intravenous 5-FU. 
The maximum number of patients who are
receiving oral drugs would be 6883 (36% of all
patients with metastatic cancer), assuming that no
patients receive intravenous 5-FU.
Impact on the drugs budget
An increase in the proportion of patients on oral
drugs will result in an increase in expenditure on
drugs. 
It is assumed that 6883 patients receive
intravenous 5-FU. The additional drug cost to the
NHS of these patients switching to capecitabine
treatment would be £0.6 million. The additional
drug cost of these patients switching to UFT/LV
treatment would be £3.5 million. This cost will be
an overestimate, given that some patients are
already receiving oral drugs.
Impact on total costs
The cost of drug prescriptions is the only resource
that will directly impact on the NHS budget.
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However, other resource use will change, including
costs relating to chemotherapy infusions and
hospitalisations. In particular, oral drugs required
one outpatient visit per cycle rather than day-case
or inpatient visits for intravenous regimens.
Assuming that 6883 patients currently receive
intravenous 5-FU, divided evenly between Mayo
and MdG and inpatient regimens, the total cost
saving to the NHS of these patients switching to
capecitabine treatment would be £12.6 million.
The cost savings of these patients switching to
UFT/LV treatment would be £4.0 million. This
cost saving will be an overestimate, given that
some patients are currently receiving treatment
with oral drugs. 
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Work days lost
The study by Ollendorf54 includes number of work
days missed by patients employed at baseline
(25%), and concludes that patients undergoing
UFT/LV therapy miss fewer days of work than
patients undergoing Mayo regimen treatment. In
the BMS sponsor submission,48 the value of these
lost days is calculated using the friction-cost
method. The cost of work days lost was £799 per
patient employed for the UFT/LV arm and £1030
for the modified Mayo arm, resulting in a cost
saving of £231 per employed patient. 
Support of families and friends
Costs are also incurred by the patient’s family and
friends. They may also miss work through caring
for patients or taking them to hospital. Regimens
with many hospital visits are likely to require more
support from friends and families, as are regimens
with serious adverse events. Also, some patients
may not be competent enough on their own to
take oral medications reliably, but may be
prescribed them if they have someone to help
them comply with their therapy. 
Transportation
In the Roche sponsor submission,45 the cost per
patient of transportation to and from hospital,
only including transportation by hospital
ambulances, for infusion administration was
estimated (£333, for Mayo regimen patients only).
It could be assumed to be much higher if it were
also to include private costs. While the Roche
estimate can only be illustrative as it did not count
any administration costs incurred by capecitabine
patients, it demonstrates the possible costs of
transportation, which will of course be greater for
patients who have to visit the hospital more
frequently, that is, patients on the Mayo regimen
in particular, but also MdG patients, who visit once
every 2 weeks instead of once every 3 weeks. 
Chapter 5
Implication for other parties
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Outreach clinics
Oral chemotherapeutic agents offer the advantage
of delivery outside a specialist cancer centre.
Outreach clinics, for example, may be a
particularly useful place for delivery of oral
chemotherapeutic agents for patients who are
either geographically isolated or prefer not to
travel to a cancer centre. This raises many issues
with regard to patient education and the
monitoring of adverse events which normally take
place within the specialist cancer centre.
Therefore, the needs of patients with regard to
education and support must be considered if
patients are to receive oral chemotherapeutic
agents in an outreach clinic. The provision of staff,
such as chemotherapy nurses, to provide for these
needs must be taken into account when planning
such a service.
Cost incentives within the NHS
A shift towards the greater use of oral drugs within
the NHS may exert cost pressures on NHS Trusts,
as a result of existing contracting arrangements.
An oral prescription is classed as an outpatient
visit, whereas outpatient intravenous
chemotherapy is classed as a day-case expense. A
shift towards using oral drugs is therefore likely to
provide less income to the Trust and may also
result in the Trust failing to meet activity targets
under existing contracts. Further cost pressures
may be exerted on Cancer Centres in terms of
reduced activity, if oral drugs are made available
to patients via local outreach units rather than
patients travelling into Cancer Centres to receive
intravenous therapy. Consideration will therefore
need to be given to methods of activity
measurement in future NHS Trust contracts.
Pharmacy and nursing time
Oral therapies can be prescribed and monitored
during an outpatient appointment with an
oncologist and dispensed without procedure at the
hospital pharmacy. In contrast, infusional
regimens are costly not only in terms of nurses
and doctors administering the infusions, but also
in terms of pharmacy time and resources.
Infusional drugs need to be prepared in a special
isolated area, and other costs such as bags, pumps
and tubing are also incurred. Although pharmacist
time and disposables have been included in this
analysis, the costs imposed by the necessity of
dedicated isolator cabinets situated in
pharmaceutical clean rooms has not been counted,
nor has the cost of training specialist pharmacists
to deal with cytotoxic drugs. Oral therapies offer
the opportunity to reduce the pressure on these
services, which are currently overstretched in many
hospitals. More specialist staff are needed in all
areas of administration for infusional regimens, as
radiologists and radiographers may also be
needed for line insertion, and specialist
pharmacists and nurses are needed for the
preparation and administration of drugs. 
Training for doctors and nurses
The introduction of oral therapies may necessitate
additional training for doctors and nurses in
patient identification and education. Since it is
very important for the safety of the patients that
they are well-enough informed to assume
responsibility for their treatment and physically
and mentally competent to take it reliably, it is
therefore vital that physicians offer oral treatment
only to patients who are able to take it, and that
they have a suitable relationship with patients to
encourage them to report any problems. The same
is also true of the nurses charged with educating
patients on the risks of non- and over-compliance. 
Concordance
Concordance is a key factor when using oral
chemotherapeutic agents. Concerns have been
raised by the FDA concerning the use of an oral
formulation of a cytotoxic anticancer drug over a
parenteral formulation because of the uncertainty
of the amount actually taken by the patient and
the narrow safety margin. This uncertainty is less
important with drugs for other conditions where
the safety margin is much greater.49 The majority
of dangers with these drugs lies in over-
compliance rather than under-compliance, as
Chapter 6
Factors relevant to the NHS
patients may be motivated to take medication even
when they are experiencing adverse effects. 
There may therefore be a need for patient support
in the community to ensure patient safety, for
example, an oncology nurse who is available for
telephone contact or who initiates contact with the
patient at regular intervals. GPs may also become
more closely involved with the treatment of
patients and monitoring of adverse events. People
with colorectal cancer are often elderly and
therefore may have problems with confusion and
home support. 
Place of oral chemotherapy in
combination therapy
It has been suggested that in future,
chemotherapy for metastatic colorectal cancer may
consist of a combination of therapies including
potentially irinotecan or oxaliplatin.64 If this is the
case, it is important to consider that these drugs
may still need to be administered in a parenteral
manner and the place of oral chemotherapies in
combination with these treatments must be
carefully considered as much of the saving on
administration cost would no longer apply.
Factors relevant to the NHS
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Main results
Capecitabine
Two trials were identified40,41 that compared
capecitabine with 5-FU/LV administered via the
Mayo regimen. An additional study was
identified36 that pooled the data from these two
trials. No studies were identified that compared
capecitabine treatment with the de Gramont or
MdG 5-FU/LV regimens. 
One study41 reported only investigator-assessed
overall response rates to be significantly greater in
the capecitabine group than the 5-FU/LV group.
The other trial40 and the pooled data both found
that investigator-assessed and IRC-assessed overall
response rates were significantly greater in the
capecitabine group than the 5-FU/LV group.
Duration of response, time to disease progression
or death, time to treatment failure and overall
survival were found not to be significantly different
between the capecitabine groups and the 5-FU/LV
groups in the two trials and in the pooled data.
With regard to toxicity, patients in the
capecitabine groups reported less diarrhoea,
stomatitis, nausea and alopecia of all grades than
those in the 5-FU/LV groups. Those in the
capecitabine group also had significantly less
grade 3–4 neutropenia and less frequent
hospitalisation for adverse events. Hand–foot
syndrome and grade 3 hyperbilirubinaemia were
significantly greater in the capecitabine group.
UFT/LV
Two trials comparing treatment with UFT/LV with
5-FU/LV46,47 were identified in the literature
searches. These two trials are not comparable for two
main reasons. First, the comparator in the Douillard
study46 is the standard Mayo 5-FU/LV regimen
whereas the comparator in the Carmichael study47
is a modification of the Mayo 5-FU/LV regimen
that has not been tested for efficacy. Second, the
Douillard study46 uses two different doses of
leucovorin, depending on the study site, whereas
the Carmichael study47 uses only one dosage.
There were no significant differences with regard
to overall response rates, duration of response or
survival between UFT/LV and 5-FU/LV in either
trial. Time to disease progression was inferior for
the UFT/LV group compared with the 5-FU/LV
group in the Douillard study.46 There was no
difference in time to disease progression between
the two groups in the Carmichael study,47
although this is possibly due to the use of a non-
standard Mayo regimen. The use of this less dose-
intensive regimen may make it less effective,
thereby obscuring any deficit in the effectiveness
of UFT/LV.
In the Douillard study46 (study 011), UFT/LV was
associated with significantly less diarrhoea,
nausea/vomiting, mucositis, neutropenia and
thrombocytopenia than 5-FU/LV for all grades and
mucositis, neutropenia, thrombocytopenia and
anaemia for grades 3–4. Increased bilirubin,
without other liver function abnormalities was
significantly more common in UFT/LV patients
than those treated with 5-FU/LV (p < 0.001). In
the Carmichael study47 (study 012), UFT/LV
treatment resulted in significantly fewer episodes
of stomatitis/mucositis, neutropenia,
thrombocytopenia and anaemia of any grade.
With regard to grade 3–4 adverse events, UFT/LV
treatment resulted in significantly less
stomatitis/mucositis and neutropenia.
Patient preference
Studies50,65 have shown that patients prefer oral
over intravenous therapies if efficacy is not
compromised. However, other factors apart from
patient preference must be taken into account.
Although oral chemotherapeutic agents offer
greater convenience and avoidance of problems
related to venous access among others, oral
administration may be associated with over- or
under-compliance and control of side-effects may
be difficult.66
Liu and colleagues65 administered a structured
questionnaire to 103 patients with advanced cancer
who would be undergoing palliative treatment.
The purpose of the questionnaire was to determine
preferences regarding route of administration of
treatment. Of those responding, 89% preferred
oral therapy but 70% were unwilling to accept a
lower response rate and 74% were unwilling to
accept a shorter duration of response.
Chapter 7
Discussion
One study50 measuring patient preference for
UFT/LV treatment was identified. The results of
this small study found that patients preferred the
UFT/LV regimen to the 5-FU/LV regimen. No
studies of patient preference involving
capecitabine were identified.
Quality of life
Both capecitabine trials and both UFT/LV trials
included health-related QoL data, although the
capecitabine QoL data have not been published
and were available in the sponsor submissions
only.45,48 Neither UFT/LV or capecitabine therapy
was associated with an improvement in health-
related QoL.
Economic results
Two economic studies55,54 and two resource-use
studies57,58 were identified. The economic studies
were not relevant to the UK context. 
The two unpublished sponsor submissions
compared the oral drugs with the Mayo regimen,
a bolus 5-FU/LV regimen. In both sponsor
submissions, the economic analysis presented
showed that the oral drugs may have an economic
advantage over the Mayo regimen, primarily due
to savings in administration costs. 
However, a number of different intravenous 
5-FU/LV regimens are currently in use in the UK.
No cost analysis was presented in the sponsor
submissions comparing oral drugs with 5-FU/LV
regimen other than the Mayo regimen. An
economic evaluation was therefore undertaken to
compare the cost-effectiveness of UFT/LV and
capecitabine with three intravenous 5-FU/LV
regimens widely used in the UK: the Mayo
regimen, the MdG regimen (outpatient) and the
inpatient de Gramont regimen. 
A cost-minimisation analysis was performed for
comparisons of capecitabine and UFT/LV with the
Mayo regimen, since the survival benefits have
been shown to be statistically equivalent. The costs
of capecitabine and UFT/LV were estimated to be
£2132 and £3385, respectively, based on a 
12-week treatment period. The cost of the Mayo
regimen was estimated to be £3593. The estimated
cost savings of the oral therapies relative to the
Mayo regimen were £1461 and £209 for
capecitabine and UFT/LV, respectively. Drug
acquisition costs were higher for the oral therapies
than for the Mayo regimen, but were offset by
lower administration costs. Adverse event
treatment costs were similar across the three
regimens. 
A cost-minimisation analysis of the oral therapies
against the MdG and the inpatient de Gramont
was performed on the basis of no proven survival
benefit of the de Gramont regimen over the Mayo
regimen. The oral therapies were once again
shown to be cost saving. The cost of the MdG
regimen and the de Gramont regimen were
estimated to be £3485 and £6255 respectively. 
However, the only randomised trial identified
which compared the de Gramont regimen with the
Mayo bolus regimen found that the de Gramont
regimen had an increased overall survival (62
versus 56.8 weeks, p = 0.067).19 This survival
difference of 5.2 weeks was not statistically
significant but is considered clinically significant.
In addition, the infusional regimens, such as the
de Gramont regimens, have been shown to be
more effective in terms of progression-free survival
and toxicity.19 The impact of these differences in
outcome was explored in the sensitivity analysis in
terms of cost per LYG and cost per progression-
free LYG of the oral drugs relative to the de
Gramont regimens. 
Based on a survival difference of 5.2 weeks
between the oral therapies and the MdG and the
de Gramont regimens, the cost per LYG of MdG
treatment over capecitabine treatment was
£13,571 and that of inpatient de Gramont
treatment over capecitabine treatment was
£41,344. On this basis, the cost saving from oral
drugs is not sufficient to make it a more cost-
effective option. The cost per LYG of MdG
treatment over UFT/LV treatment was £758 and
that of inpatient de Gramont treatment over
UFT/LV treatment was £21,631. These numbers
are illustrative only. However, they do show that
the cost savings offered by the oral drugs,
particularly in relation to MdG, are not large and
therefore if the oral drugs do reduce the survival
of patients by an order of 5.2 weeks, they cannot
be considered a cost-effective option relative to the
MdG regimen. It is difficult to draw any firm
conclusions from this cost-effectiveness analysis,
given that it is based on an indirect comparison of
patients from two different studies.
Likewise, provisional estimates of the cost per
progression-free LYG of MdG and inpatient de
Gramont over capecitabine and UFT/LV showed
that the cost savings offered by the oral drugs,
particularly in relation to MdG, are not large. On
the assumption that oral drugs do reduce the
progression-free survival of patients by an order of
5.6 weeks, oral drugs cannot necessarily be
considered a cost-effective option relative to the
Discussion
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MdG regimen in terms of the cost per
progression-free LYG. Further work is needed in
this area.
Assumptions, limitations and
uncertainties
The RCT evidence for oral drugs compares
capecitabine and UFT/LV against the Mayo
regimen. However, a number of different
intravenous 5-FU/LV regimens are currently in use
in the UK. No direct comparisons of the oral
drugs and infusional regimens were identified. For
purposes of economic evaluation, an indirect
comparison was therefore required.
The costs used in the economic evaluation were
not based on published studies and are subject to
uncertainty. Key uncertainties related to the price
of LV, which is known to be discounted
substantially below BNF prices, the treatment
duration for different therapies, which impacts on
their total treatment cost, the costs of managing
adverse events and the cost of outpatient
appointments. These issues are tested in sensitivity
analysis.
In addition there is no trial evidence on utility data.
Cost and benefit assumptions
There is considerable uncertainty in the economic
analysis, particularly in relation to the indirect
comparison of the oral drugs with the infusional
regimens.
Costs
The drug costs were based on an assumed
individual with a body surface area of 1.75 m2
undergoing treatment with no dose reductions,
and assuming that all drugs were supplied at BNF
list prices. Drug discounts were not included in
the base case. Substantial discounts are, however,
currently available on LV, although the precise
scale of the discount is confidential and will vary
between hospitals.
The cost of a hospital outpatient appointment was
assumed to differ for patients on oral therapy and
patients receiving intravenous therapy. Cost data
from a local provider were used but are likely to
vary between institutions.
No published data were available relating to the
cost of managing adverse events. Resource use
data were taken from the unpublished sponsor
submissions. However, a number of assumptions
had to be made and therefore these cost data are
open to uncertainty.
Benefits 
A cost-minimisation analysis was performed for
comparisons of capecitabine and UFT/LV with the
Mayo regimen, since the survival benefits have
been shown to be statistically equivalent. 
However, no direct comparisons of the oral drugs
and the de Gramont regimens (MdG and
inpatient de Gramont) were identified and
therefore an indirect comparison was undertaken
for the purposes of economic evaluation. Evidence
on the survival benefits of the Mayo regimen
versus the de Gramont regimen was reviewed. On
the basis that there is no proven survival
difference between the Mayo and the de Gramont
regimens, it was inferred that there was no survival
difference between the oral drugs and the de
Gramont regimens. Therefore, a cost-minimisation
analysis was also performed for comparisons of
capecitabine and UFT/LV with the de Gramont
regimens. 
Evidence on the efficacy of the MdG regimen is
limited. There are no randomised trials of MdG
versus the traditional de Gramont regimen. The
MRC have made the decision to move over to
MdG without a large randomised equivalence trial
because the MdG regimens are more 5FU dose-
intensive and they have better non-randomised
phase II response rates than the old de Gramont
regimen (Seymour M, Cookridge Hospital, Leeds:
personal communication, 2002). In addition, they
are more convenient for patients and hospitals.
The economic analysis assumes that de Gramont
and MdG regimens are equally effective and that
they have similar adverse event profiles, but this is
not proven. 
Although there is no proven survival benefit of
infusional regimens, such as the de Gramont
regimen, over bolus regimens, such as the 
Mayo regimen, in advanced colorectal cancer,
infusional regimens have been shown to be more
effective in terms of progression-free survival,
tumour response and toxicity.19 The impact of a
potential difference in progression-free survival
between the oral drugs and the infusional
regimens was explored in terms of the impact on
the cost per progression-free year gained. 
No significant differences in QoL were found
between the oral drugs and the Mayo regimen.
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Values from a previous study on colorectal cancer
using nurses as proxy subjects have been used to
explore the potential impact of utility on
estimated benefits in terms of quality-adjusted
progression-free life-years. These are shown for
illustrative purposes only.
Need for further research
The following points have been identified as areas
requiring further research:
 QoL data should be included in trials of
colorectal cancer treatments. Well-validated
instruments should be used and this research
should be conducted by independent
researchers. It may be necessary to use more
than one instrument in order to identify
differences in QoL. It may also be necessary to
identify the components of QoL that vary with
different treatments.
 More research is needed to determine the place
of effective oral treatments in the treatment of
colorectal cancer. This should focus on when
such treatments should be given alone and
when they should be given in combination with
other chemotherapeutic agents. Research is
needed on the combination of oral agents with
other chemotherapy agents (notably irinotecan
and oxaliplatin) and novel agents.
 Some types of patients may benefit more from
oral treatment than others. Research is needed
to determine what safety mechanisms are
needed in order to ensure compliance and the
monitoring of adverse effects.
 The optimum duration of treatment needs to be
determined, for example, with respect to
disease progression, response, unacceptable
toxicity or death. Intermittent treatment with a
pause after 12 weeks for those with stable or
responding disease also needs to be considered.
 The issue of patient preference must be given
careful consideration in future trials and all
trials should incorporate the measurement of
patient preference.
 In order to make a precise estimate of the cost-
effectiveness of capecitabine and UFT/LV versus
MdG treatment, a phase III comparative trial
would be necessary to determine whether there
was any survival advantage. This would also give
clinicians clear information on survival to
present to patients, who can then make an
informed choice with regard to treatment.
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There is good evidence to suggest thatcapecitabine is effective in improving overall
response rates compared with Mayo regimen 
5-FU/LV therapy in the treatment of metastatic
colorectal cancer. Duration of response, time to
disease progression or death, time to treatment
failure and overall survival were found to be
equivalent. Capecitabine use was associated with
fewer adverse events apart from hand–foot
syndrome and hyperbilirubinaemia. 
There is some evidence to suggest that UFT/LV is
equivalent to the Mayo regimen 5-FU/LV and
some evidence to suggest that UFT/LV treatment
is associated with inferior time to disease
progression. UFT/LV was associated with fewer
adverse events than the 5-FU/LV regimen. 
There was no evidence that either capecitabine or
UFT/LV affects health-related QoL. No studies
were identified regarding patient preference for
capecitabine. One small cross-over trial found that
patients preferred UFT/LV treatment over
treatment with 5-FU/LV.
Given that the survival benefits of therapy have
been shown to be similar for the oral and the
Mayo regimens, a cost-minimisation analysis was
undertaken. The results of the economic analysis
showed that both capecitabine and UFT/LV offer
cost advantages over the Mayo regimen. The cost
savings offered by capecitabine and UFT/LV in
relation to the Mayo regimen were estimated to be
£1461 and £209, respectively. Savings in the cost
of administration more than offset the higher
drug costs of the oral therapy regimens. 
There is no direct evidence to compare the
survival benefits of MdG or inpatient de 
Gramont regimens with the oral regimens. No
evidence was identified that showed a significant
survival advantage of de Gramont regimens over
the Mayo regimen and therefore a cost-
minimisation analysis was undertaken. The results
of the economic analysis showed that both
capecitabine and UFT/LV offer cost advantages
over the MdG regimen and the inpatient de
Gramont regimen. However, infusional regimens
have been shown to be more effective in terms of
progression-free survival, tumour response and
toxicity.17 Preliminary analysis undertaken to
explore the impact of these factors on cost-
effectiveness suggests that oral drugs cannot
necessarily be considered a cost-effective option
relative to the MdG regimen in terms of the cost
per progression-free LYG. Further evidence in
terms of both benefits and costs is needed in this
area.
Costs and cost-effectiveness are sensitive to
discounts on the drug acquisition cost of LV, the
cost of outpatient appointments and the treatment
time.
In order to make a precise estimate of the cost-
effectiveness of capecitabine and UFT/LV versus
MdG treatment, a phase III comparative trial
would be necessary to determine whether there
was any survival advantage. This would also give
clinicians clear information on survival to present
to patients, who can then make an informed
choice with regard to treatment.
Chapter 8
Conclusions
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Bidimensionally or unidimensionallymeasurable disease.
Complete response 
Disappearance of all known disease, determined
by two observations not less than 4 weeks apart.
Partial response
In the case of bidimensionally measurable disease,
a decrease by at least 50% of the sum of the
products of the largest perpendicular diameters of
all measurable lesions as determined by two
observations not less than 4 weeks apart. For
unidimensionally measurable disease, a decrease
by at least 50% in the sum of the largest diameters
of all lesions as determined by two observations
not less than 4 weeks apart.
It is not necessary for all lesions to have regressed
to qualify for partial response, but no lesion
should have progressed and no lesion should
appear. Serial evidence of appreciable change
must be obtained and available for subsequent
review. The assessment must be objective.
Minor response
In the case of bidimensionally measurable disease,
a decrease by at least 25% but less than 50% of the
sum of the products of the largest perpendicular
diameters of all measurable lesions as determined
by two observations not less than 4 weeks apart.
For unidimensionally measurable disease, a
decrease by at least 25% but less than 50% in the
sum of the largest diameters of all lesions as
determined by two observations not less than 4
weeks apart. It is not necessary for all lesions to
have regressed to qualify for minor response, but
no lesion should have progressed and no lesion
should appear. Serial evidence of appreciable
change must be obtained and available for
subsequent review. The assessment must be
objective.
No change
For bidimensionally measurable disease, a <25%
decrease and <25% increase in the sum of the
products of the largest perpendicular diameters of
all measurable lesions. For unidimensionally
measurable disease, a <25% decrease and <25%
increase in the sum of the diameter of all lesions.
No new lesions should appear.
Progressive disease
A >25% increase in the size of at least one
bidimensionally or unidimensionally measurable
lesion (in comparison with the measurements at
nadir), or appearance of a new lesion. The
occurrence of pleural effusion or ascites is also
considered as progressive if this is substantiated by
positive cytology.
Appendix 1
WHO criteria for evaluation of response67,68
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Appendix 2
5-FU-based treatment regimens
Regimen Schedule
Bolus 5-FU:
Mayo 5-FU 425 mg/m2/day + FA 20 mg/m2/day for 5 days every 4 weeks
Infusional 5FU:
AIO 2-hour infusion of FA (500 mg/m2) followed by a 24-hour infusion of 5-FU (2600 mg/m2), weekly for 
6 weeks; cycle time 8 weeks
de Gramont 2-hour infusion of FA (200 mg/m2) + bolus 5-FU (400 mg/m2) followed by a 22-hour infusion of 5-FU
(600 mg/m2) on days 1 and 2 of each fortnight11
MDG FA (350 mg) + bolus 5-FU (400 mg/m2) followed by a 46-hour infusion of 5-FU (2800 mg/m2)
fortnightly44
Lokich 5-FU 250–300 mg/m2 as prolonged continuous i.v. infusion until progression/toxicity
AIO, Arbeitsgemeinschaft Internische Onkologie.
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Appendix 3
Continuous infusion versus bolus 5-FU 
regimens – meta-analysis
Study Research question No. of trials Searches Study selection
Meta-analysis Group in
Cancer, 199815
To compare the
administration of 5-FU
by continuous
intravenous infusion
with bolus
administration in
patients with advanced
colorectal cancer
Six randomised clinical
trials
MEDLINE 1984–94,
Proceedings of major
congresses, personal
contacts with
investigators
Seven trials were
identified, one was
excluded because
original patient data
could not be retrieved
and the randomisation
procedure was based
on hospital record
numbers
Study details
Study details continued
A
ppendix 3
7
0
Study Trial characteristics Predicted cumulative doses of 5-Fu in 5-FU bolus arm and in 5-FU ci arm (doses expressed in mg/m2)
Trial Treatment arm After week 1 4 8 12
Meta-analysis Group in
Cancer, 199815
ECOG was a three-arm trial with one arm
receiving 5-FU ci plus cisplatin. This arm was
not included in the meta-analysis. The SWOG
trial had seven arms, three of which were not
included in the meta-analysis
In the ECOG and MAOP trials, ci 5-FU was
administered without a rest period. In the
SWOG trial, 5-FU infusion was maintained
over 80% of the time. In the NCIC and the
French trial, duration of 5-FU infusion was
between 33 and 50% of the time
ECOG 5-FU ci 2100 8400 16,800 25,200
5-FU bolus 2500 3700 6100 8500
NCIC 5-FU ci 2450 4900 9800 14,700
5-FU bolus 2250 2250 4500 6750
SWOG 1 5-FU ci 2100 8400 14,700 21,000
5-FU bolus 2500 2500 5000 7500
MAOP 5-FU ci 2100 8400 16,800 25,200
5-FU bolus 2500 2500 5000 7500
France 5-FU ci 5250 10,500 15,750 21,000
5-FU bolus 2500 2500 5000 7500
SWOG 2 5-FU ci 1400 5600 9800 14,000
5-FU bolus 2125 2125 4250 6375
Jerusalem 5-FU ci 3000 6000 9000 12,000
5-FU bolus 3000 6000 9000 12,000
Study Included trials Treatment schedules and number of patients
Study 5-FU ci 5-FU bolus No. of patients
ECOG, Eastern Cooperative Oncology Group. 
Meta-analysis 
Group in Cancer,
199815
ECOG, 1996
National Cancer Institute of Canada
(NCIC), 1992
Southwest Oncology Group (SWOG1),
1995
Mid-Atlantic Oncology Program
(MAOP), 1989
France, 1992
Southwest Oncology Group (SWOG2),
1995
Jerusalem, 1989
ECOG 5-FU 300 mg/m2/d without interruption 5-FU mg/m2 dl–d5 324
then 5-FU 600 mg/m2d, q7d
NCIC 5-FU 350 mg/m2 dl–d15, q28d 5-FU 400–450 mg/m2/dl–d5, q28d 185
SWOG 1 5-FU 300 mg/m2 dl–d28, q35d 5-FU 500 mg/m2/dl–d5, q35d 181
MAOP 5-FU 300 mg/m2/d without interruption 5-FU 500 mg/m2/dl–d5, q35d 173
France 5-FU 750 mg/m2 dl–d7, q21d 5-FU 500 mg/m2/dl–d5, q28d 155
SWOG 2 5-FU 200 mg/m2 dl–d28, q35d+ 5-FU 425 mg/m2 + folinic acid 175
Folinic acid 20 mg/m2 i.v., q7d 20 mg/m2 i.v. d1–d5, q28d×2, then q35d
Jerusalem 5-FU 600 mg/m2 + folinic acid 5-FU 600 mg/m2 + folinic acid 26
15 mg/6 h orally d1–d5, q21d 15 mg/6 h orally d1–d5, q21d
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Patient characteristics
Study Patient characteristics
Trial Accrual period Treatment arm No. of patients Primary colon (%) PS < 2 (%) Metastases (%)
Liver only Lung only
A total of 1219 patients were considered in the meta-analysis. The median patient age was 63 years and 61% of patients were male. At the time of analysis, 91% of patients had died.
Meta-analysis Group in
Cancer, 199815
ECOG 1987–90 5-FU ci 162 81 94 23 8
5-FU bolus 162 80 89 23 7
NCIC 1986–89 5-FU ci 95 68 85 49 5
5-FU bolus 90 78 89 49 4
SWOG1 1989–92 5-FU ci 88 85 88 NA NA
5-FU bolus 93 72 89 NA NA
MAOP 1984–86 5-FU ci 88 76 90 34 5
5-FU bolus 85 74 91 34 8
France 1987–90 5-FU ci 77 66 92 44 12
5-FU bolus 78 64 90 51 12
SWOG2 1989–92 5-FU ci 86 70 92 NA NA
5-FU bolus 89 72 88 NA NA
Jerusalem 1984–86 5-FU ci 11 38 82 45 18
5-FU bolus 15 80 93 33 13
Total 1984–92 5-FU ci 607 75 91 35 7
5-FU bolus 612 75 90 36 7
A
ppendix 3
7
2
Study quality
Results
Study Agreement between reviewers Similarity of included studies Tests for homogeneity
Meta-analysis Group in
Cancer, 199815
Data were extensively checked and discussed
with all collaborators at a plenary meeting of the
Meta-analysis Group
Studies use different regimens of 5-FU both
continuous and bolus and two (SWOG2 and
Jerusalem) add LV
Tests for heterogeneity were calculated for
tumour response odds ratios and survival
hazards ratios (both NS)
Study Outcomes measured Tumour response Survival Prognostic factors
Meta-analysis Group in
Cancer, 199815
Tumour response and survival A total of 1103 patients were
included in the tumour response
analysis as 116 patients in the SWOG
trial had non-measurable disease
5-FU ci 22% (CR 3%, PR 19%)
5-FU bolus 14% (CR 2%, PR 12%).
Overall response odds ratio (OR)
was 0.55 (95% CI: 0.41 to 0.75),
indicating a highly significant
advantage for 5-FU ci (p = 0.0002),
equivalent to a risk reduction of 45%
with a standard error of 12%.
However, advantage of 5-FU ci over
5-FU bolus was only statistically
significant in three individual trials
(ECOG, MAOP, French).
A logistic regression model showed
that treatment and performance
status were the only independent
prognostic factors with no interaction
between the two
Median duration of tumour response
5-FU ci 7.1 months (95% CI: 5.7 to
8.5 months)
5-FU bolus 6.7 months (95% CI: 5.7
to 8.5 months)
No individual trial showed a benefit
of 5-FU ci but their combination
showed a small but statistically
significant advantage for 5-FU ci over
5-FU bolus [hazards ratio (HR): 0.88,
95% CI: 0.78 to 0.99; p = 0.04)]
Median survival duration
5-FU CI: 12.1 months (95% CI: 11
to 13.1)
5-FU bolus: 11.3 months (95% CI:
10.5 to 12)
LV modulation
5-FU/LV (SWOG2 and Jerusalem)
overall survival was not significantly
better for 5-FU ci compared with 5-
FU bolus (HR 1.03; 95% CI: 0.77 to
1.38; p = 0.84) but based on too few
patients to be informative.
Cox regression model stratified for
trial showed that treatment,
performance status and primary
tumour site were independent
prognostic factors for survival
Randomised treatment, age
(continuous), sex, performance status
(ECOG), primary tumour location
(rectum or colon) and site of
metastases (liver only or not) were
considered in the prognostic factor
analyses.
Randomised treatment and
performance status were
independent prognostic factors for
haematological toxicity. Patients
assigned to 5-FU bolus (p < 0.0001)
and patients with a poor
performance status (p = 0.03) had a
significantly higher risk of
haematological toxicity.
Age, sex and performance status
were independent prognostic factors
for non-haemotological toxicity.
Older patients (p = 0.01), female
patients (p = 0.03) and patients with
good performance status (p = 0.007)
had a significantly higher risk of
toxicity.
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Toxicity
Study Outcomes measured Tumour response Survival Prognostic factors
5-FU/LV (SWOG2 and Jerusalem)
found the difference between 5-
FU/LV and bolus 5-FU/LV did not
reach statistical significance tumour
response, OR = 0.82 (95% CI: 0.33
to 2.07), but only 145 patients were
included in this group
Duration of treatment
Tumour response OR was 0.55 (95%
CI: 0.37 to 0.81) when duration of 5-
FU infusion was >80% of the time
(ECOG, MAOP, SWOG1), compared
with 0.48 (95% CI: 0.26 to 0.89)
when 5-FU infusion was between 33
and 50% of the time χ2 for
interaction 0.14; p = 0.70)
Randomised treatment, age and sex
were independent prognostic factors
for hand–foot syndrome. 
Survival duration was added to the
logistic regression model and found
to be unrelated to haematological
toxicity (p = 0.99), marginally related
to non-haematological toxicity 
(p = 0.08) and strongly related to
hand–foot syndrome (p < 0.0001).
Study Haematological toxicity Non-haematological toxicity Hand–foot syndrome
d, days; q, every; i.v., intravenous; h, hours, ci, continuous infusion; OR, odds ratio; PS, performance status; NA, not available; SWOG 1 and SWOG 2 refer to two different arms of
one SWOG trial.
Meta-analysis Group in
Cancer, 199816
Overall proportion of grade 3–4 haematological
toxicity was 4% for patients assigned to 5-FU ci
(23 of 607) and 31% for patients assigned to 5-
FU bolus (191 of 612).
Adjusted haematological toxicity rate ratio (RR)
was 0.14 (95% CI: 0.09 to 0.21), indicating that
patients receiving 5-FU ci were on average seven
times less likely to experience a grade 3–4
haematological toxicity than patients receiving 5-
FU bolus (p < 0.0001)
Overall grade 3–4 non-haematological toxicity
occurred in 13% of patients in 5-FU ci (79 of
607) and in 14% of those in 5-FU bolus (84 of
612). 
Adjusted non-haematological toxicity RR was
0.96 (95% CI: 0.72 to 1.28; p = 0.78). 
Risks of severe diarrhoea, nausea/vomiting and
mucositis were not different in the 5-FU ci and
5-FU bolus groups: 4 vs 6%, 3 vs 4% and 9 vs
7% respectively
Overall proportion of hand–foot syndrome was
34% for 5-FU ci patients (206 of 607) and 13%
for 5-FU bolus patients (977 of 612). The
adjusted RR was 1.87 (95% CI: 1.50 to 2.34),
which indicates that the risk of hand–foot
syndrome is almost doubled when 5-FU is given
by ci (p < 0.0001).
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Appendix 4
Continuous infusion versus bolus 5-FU 
regimens – RCTs
A
ppendix 4
7
6
Study design
Study Study site Comparators, dosage and procedure Type of study Numbers 
randomised Funding
de Gramont et al.,
199717
70 centres in France Arm A (Mayo): Monthly 5-FU bolus, low-dose LV for 5
consecutive days. LV given by i.v. bolus at 20 mg/m2/day and
immediately followed by 5-FU bolus at 425 mg/m2/day, repeated
for 5 consecutive days. Cycles every 4 weeks.
Arm B (de Gramont): Bimonthly high-dose LV with 5-FU bolus
and continuous infusion for 2 consecutive days. LV was given at
200 mg/m2/day as a 2-hour infusion followed by i.v. bolus 5-FU
at 400 mg/m2/day and 22- hour infusion 5-FU 600 mg/m2/day all
repeated for 2 consecutive days. Cycles at 2-week intervals.
The full regimen was administered until disease progression
[neutrophils were >1500/mm3, platelet count was
>100,000/mm3, and toxicity remained tolerable (WHO grade
0–2)]. Study regimens were stopped when disease progression
occurred and second-line chemotherapy, including 5-FU
continuous infusion, could be administered in both trial arms
RCT 448 total patients Wyeth-Lederle laboratories
(Paris, France)
Study Length of study Inclusion criteria Exclusion criteria Power calculation Baseline comparability
de Gramont et al.,
199717
Patients assigned to
treatment from
February 1991 to
April 1994; follow-up
time for the whole
cohort was 43.5
months
Adenocarcinoma of the colon or rectum, progressive or
histologically proven non-resectable metastases at
presentation, no central nervous system metastasis, no
exclusive bone metastases, no secondary malignancy (except
adequately treated in situ carcinoma of the cervix or non-
melanomic skin cancer), life expectancy over 2 months, age
between 19 and 75 years, WHO performance status 0–2, no
previous therapy for metastatic disease, no previous adjuvant
therapy if completed less than 6 months before inclusion or if
it included LV, metastases outside the radiation field in patients
who had previously had radiation therapy, initial evaluation 2
weeks or less before inclusion, neutrophils >1500/mm3,
platelets greater than 100,000/mm3, serum creatinine <300
mol/L and partial thrombin time >50%
As stated in
inclusion criteria
Yes, to detect
difference in
survival
Yes
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Patient details
Quality assessment
Outcomes
Study Randomised/method Blinding/appropriate method Description of withdrawals Jadad score
and dropouts
de Gramont et al., 199717 Yes, method not described.
Patients were stratified according to
performance status, measurable disease,
synchronous vs metachronous metastases and
institution
No blinding described Withdrawals and dropouts
adequately described
2/5
Study ITT analysis Primary end-points Secondary end-points Duration of treatment
de Gramont et al., 199717 No, 348 of 448 original randomised patients
were included in the analysis of response rates
and 433 of 448 in other analyses
Survival Tumour response Patients in Arm A received a
median of 5 cycles (range: 1–21)
and in Arm B a median of 12
cycles (range: 1–42)
Study Sex (M/F) Age Performance score Primary site Sites of metastasis
de Gramont
et al., 199717
Arm A: 145/71
Arm B: 135/82
Mean SD:
Arm A: 61.7 ± 9.6
Arm B: 60.9 ± 9.5
WHO performance status
Arm A (%) Arm B (%)
WHO status 0 98 (45.4) 97 (44.7)
WHO status 1–2 118 (54.6) 120 (55.3)
Arm A (%) Arm B (%)
Colon 142 (65.7) 139 (64.1)
Rectum 68 (31.5) 73 (33.6)
Multiple or 
non-specified 6 (2.8) 5 (2.3)
Arm A (%) Arm B (%)
Liver 172 (80.7) 176 (81.5)
Lung 34 (16) 34 (15.7)
Other 40 (18.8) 40 (18.5)
1 site 182 (85) 182 (84.3)
≥ 2 sites 32 (15) 34 (15.7)
No. of 
sites not 
specified 2 1
A
ppendix 4
7
8
Results
Study Response rate Duration of response Median time Survival
to disease 
progression 
or death
de Gramont et al., 199717 Overall objective tumour responses;
number of patients (%)
Arm A Arm B
CR 4 (2.3) 10 (5.7)
PR 21 (12.1) 47 (26.9)
Stable 68 (39.3) 62 (35.4)
Progression 80 (46.2) 56 (32)
CR + PR 25 (14.45)* 57 (32.57)*
*p = 0.0004
Median duration of response
was 48.5 weeks in Arm A and
47 weeks in Arm B (p = 0.78)
Not reported Progression-free survival
Arm B (bimonthly regimen) had significantly longer
median progression-free survival than those in Arm A
(monthly regimen), 27.6 vs 22 weeks (p = 0.0010; 
OR = 0.72)
Median survival
Arm B (bimonthly regimen) had slightly longer median
survival than Arm A (monthly regimen) (62.0 vs 56.8
weeks p = 0.067). 
Patients with measurable disease had a median survival of
63 vs 46 weeks in patients with non-measurable disease
(p = 0.0186). Interaction test between treatment arms
and measurable/non-measurable diseased showed
borderline significance (p = 0.07). OR ratio was
significant only for patients with measurable disease
treated with the bimonthly regimen compared with the
monthly regimen (OR = 0.75, p = 0.015). 
Median survival in patients with measurable disease was
72 weeks in Arm B and 58.4 weeks in Arm A
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Toxicity
Study Types of side-effects Treatment-related deaths
a Comparisons are for grade 3–4 toxicity Arm A vs Arm B; those in parentheses in the comparison column refer to grade 1–2 toxicities.
de Gramont et al.,
199717
Toxicity per patient:
Arm A (monthly) (n = 205) Arm B (n = 208) (bimonthly) Comparisona
Grade 1–2 (%) Grade 3–4 (%) Grade 1–2 (%) Grade 3–4 (%)
Neutrophils 14 (6.8) 15 (7.3) 20 (9.6) 4 (1.9) 0.0052
Platelets 1 (0.5) 1 (0.5) 1 (0.48) 2 (1.0) 1.00
Infection 14 (6.8) 8 (3.9) 11 (5.3) 2 (1.0) 0.095
Nausea 72 (35.1) 7 (3.4) 80 (38.5) 8 (3.9) 0.95
Diarrhoea 54 (26.3) 15 (7.3) 59 (28.4) 6 (2.9) 0.039
Mucositis 38 (18.5) 26 (12.7) 42 (20.2) 4 (1.9) 0.0001
Angina pectoris 2 (1.0) 0 8 (3.8) 0 (0.14)
Cutaneous 25 (12.2) 0 31 (14.9) 2 (1.0) (0.59)
Alopecia 26 (12.7) 3 (1.5) 25 (12.0) 1 (0.5) 0.37
Epistaxis 7 (3.4) 0 19 (9.1) 0 (0.019)
Conjunctivitis 10 (4.9) 0 29 (13.9) 0 (0.003)
Neurological 3 (1.5) 0 7 (3.4) 1 (0.5) 1.00
Maximal 90 (43.9) 49 (23.9) 119 (57.2) 23 (11.1) 0.0004
One therapy-related death
in the study in Arm A
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Appendix 5
Summary of de Gramont study results
Study Response rates (%) Progression-free survival Median overall survival
de Gramont et al., 199717 32.6 27.6 weeks 62 weeks
de Gramont et al., 200019 28.6; 22.3a; 21.9 (ITT) 26.9 weeks; 26.1 weeksa 63.9 weeks
Douillard et al., 200020b 22 (ITT); 31 4.4 months (17.6 weeks) 14.1 months (56.4 weeks)
[de Gramont alone: [de Gramont alone: [de Gramont alone: 13.0 months]
21.0 (ITT)] 3.7 months (14.8 weeks)]
Maughan et al., 200218 23 25 weeks 294 days (42 weeks)
a Independent assessor.
b In this trial, both de Gramont and AIO regimens included.

WHO scale for performance
status
Karnofsky performance scale
Eastern Cooperative Oncology
Group (ECOG) performance
status
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Appendix 6
Performance status scales
0 Fully active, able to carry on all predisease
performance without restriction
1 Restricted in physically strenuous activity but
ambulatory and able to carry out work of a light or
sedentary nature, e.g. light housework, office work
2 Ambulatory and capable of self-care but unable to
carry out any work activities. Up and about more
than 50% of waking hours
3 Capable of only limited self-care, confined to bed or
chair more than 50% of waking hours
4 Completely disabled. Cannot carry out any self-
care. Totally confined to bed or chair
5 Dead
Status Patient findings
0 No symptoms
1 Patient symptomatic but ambulatory
2 Patient bedridden less than half the day
3 Patient bedridden half the day or longer
4 Patient chronically bedridden and requires
assistance with activities of daily living
% Description
100 Normal; no complaints; no evidence of disease
90 Able to carry out normal activity; minor signs or
symptoms of disease
80 Normal activity with effort; some signs or
symptoms of disease
70 Cares for self; unable to carry on normal activity
or do active work
60 Requires occasional assistance, but is able to care
for most of his/her needs
50 Requires considerable assistance and frequent
medical care
40 Disabled; requires special care and assistance
30 Severely disabled; hospitalisation is indicated
although death is not imminent
20 Very sick; hospitalisation necessary, active
supportive treatment necessary
10 Moribund; fatal processes progressing rapidly
0 Dead
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Electronic bibliographic
databases searched
1. BIOSIS previews (the new online version of
Biological Abstracts)
2. CancerLit
3. CCTR (Cochrane Controlled Trials Register)
4. CDSR (Cochrane Database of Systematic
Reviews)
5. CINAHL
6. EBM Reviews – ACP Journal Club
7. EMBASE
8. HEED (Health Economic Evaluations
Database)
9. MEDLINE
10. NHS DARE (Database of Assessments of
Reviews of Effectiveness)
11. NHS EED (Economic Evaluations Database)
12. NHS HTA (Health Technology Assessment)
13. PreMedline
14. Science Citation Index
15. Social Sciences Citation Index
Other sources searched
1. Adverse Event Reporting System
2. AHRQ (Agency for Healthcare Research and
Quality), USA
3. Bandolier
4. Beating Bowel Cancer
5. British Geriatrics Society – Gastro Special
Interests Group
6. British Oncological Association
7. British Psychosocial Oncology Society
8. Cancer BACUP
9. Cancer Research UK
10. CCOHTA (Canadian Coordinating Office for
Health Technology Assessment)
11. CenterWatch
12. CHE (Centre for Health Economics), York
13. Clinical Evidence
14. CliniWeb
15. CMA (Canadian Medical Association)
InfoBase
16. COIN (DoH)
17. Colon Cancer Concern
18. Current Controlled Trials
19. CriB (Current Research in Britain)
20. Drug Safety Research Unit
21. DES Reports (West Midlands Health
Technology Assessment Collaboration)
22. DoH
23. eBNF (electronic British National Formulary)
24. eGuidelines
25. EMEA (European Agency for the Evaluation
of Medicinal Products)
26. eMedicines Compendium
27. European Society for Medical Oncology
28. GOOGLE
29. Health Evidence Bulletin, Wales
30. HSRU (Health Services Research Unit),
Aberdeen
31. INAHTA (International Network of Agencies for
Health Technology Assessment) Clearinghouse
32. Index to Theses (Sheffield University)
33. ISI Proceedings (Web of Science)
34. Long Term Medical Conditions Alliance
35. Macmillan Cancer Relief
36. Marie Curie Cancer Care
37. MEDLINEplus Drug Information
38. MeRec
39. MRC Trials Register
40. National Assembly for Wales
41. National Cancer Alliance
42. National Cancer Research Institute
43. National Guidelines Clearinghouse
44. National Research Register (2002 Issue 2)
45. NCCHTA (National Coordinating Centre for
Health Technology Assessment)
46. NHS CRD (Centre for Reviews and
Dissemination), University of York
47. OMNI
48. POINT (DoH)
49. RAND
50. ReFeR (Research Findings Register)
51. Royal College of General Practitioners
52. Royal College of Nursing
53. Royal College of Physicians
54. Royal College of Radiologists
55. Royal College of Surgeons
56. Royal Pharmaceutical Society
57. ScHARR Library catalogue
58. SIGN (Scottish Intercollegiate Guidelines
Network)
59. SEEK (Sheffield Evidence for Effectiveness
and Knowledge)
60. Toxline
61. Trent Working Group on Acute Purchasing
Reports
Appendix 7
Search strategies
62. TRIP (Turning Research into Practice) Database
63. Wessex DEC (Development and Evaluation
Committee) Reports
64. WHO
Search strategies used
Biological Abstracts
1985–2002
SilverPlatter WebSPIRS
Search undertaken April 2002
#1. Capecitabine*
#2. Xeloda
#3. 154361-50-9
#4. EU?1?00?163?001
#5. EU?1?00?163?002
#6. Ro09?1978
#7. Fluoropyrimidine*
#8. Tegafur*
#9. 17902-23-7
#10. Uftoral
#11. PL?11184?0087
#12. #1 or #2 or #3 or #4 or #5 or #6 or #7 or
#8 or #9 or #10 or #11
#13. Carcinoma* or neoplasia* or neoplasm* or
adenocarcinoma* or cancer* or tumor* or
tumour* or malignan* or disease*) near3
(colorectal* or colon* or rect* or intestin* or
bowel*)
#14. #12 and #13
CDSR and CCTR
2002, Issue 1 
The Cochrane Library, Update Software 
(CD ROM version)
Search undertaken April 2002 
#1. COLORECTAL-NEOPLASMS*:ME
#2. NEOPLASMS*:ME
#3. CARCINOMA*:ME
#4. ADENOCARCINOMA*:ME
#5. #2 OR #3 OR #4
#6. COLONIC-DISEASES*:ME
#7. RECTAL-DISEASES*:ME
#8. COLON*:ME
#9. RECTUM*:ME
#10. #6 OR #7 OR #8 OR #9
#11. #5 AND #10
#12. ((CARCINOMA* OR NEOPLASIA* OR
NEOPLASM* OR ADENOCARCINOMA*
OR CANCER* OR TUMOR* OR
TUMOUR* OR MALIGNAN*) NEAR
(COLORECTAL OR COLON* OR RECT*
OR INTESTIN* OR BOWEL*))
#13. #1 OR #11
#14. #12 OR #13
#15. CAPECITABINE*
#16. XELODA*
#17. 154361-50-9
#18. EU100163001
#19. EU100163002
#20. RO091978
#21. FLUOROPYRIMIDINE*
#22. TEGAFUR*
#23. 17902-23-7
#24. UFTORAL
#25. PL111840087
#26. #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR
#25
#27. #14 AND #26
CINAHL
1982–2002
Ovid Biomed
Search undertaken April 2002
#1. Exp Colorectal Neoplasms/
#2. Neoplasms/
#3. Carcinoma/
#4. Adenocarcinoma/
#5. or/2-4
#6. Colonic Diseases/
#7. Rectal Diseases/
#8. Exp Colon/
#9. Exp Rectum/
#10. or/6-9
#11. 5 and 10
#12. ((Carcinoma$ or neoplasia or neoplasm$ or
adenocarcinoma$ or cancer$ or tumor$ or
tumour$ or malignan$) adj3 (colorectal or
colon$ or rect$ or intestin$ or bowel$)).tw
#13. 1 or 11 or 12
#14. Capecitabine.af
#15. Xeloda.af
#16. 154361-50-9.af
#17. EU#1#00#163#001.af
#18. EU#1#00#163#002.af
#19. Ro09?1978.af
#20. Fluoropyrimidine$.af
#21. Tegafur.af
#22. 17902-23-7.af
#23. Uftoral.af
#24. PL?11184?0087.af
#25. Or/14-24
#26. 13 and 25
Citation Indexes (Science and Social
Sciences)
1981–2002
Web of Science
Search undertaken May 2002
Database limits:
DocType=All document types; All languages;
Databases=SCI-EXPANDED, SSCI; Timespan=All
years
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((Capecitabine or Xeloda) and (colorectal or
colon* or rect* or intestin* or bowel*))
((154361-50-9 or EU?1?00?163?001 or
EU?1?00?163?002) and (colorectal or colon* or
rect* or intestin* or bowel*))
((Ro09?1978 and (colorectal or colon* or rect* or
intestin* or bowel*))
((Fluoropyrimidine* or tegafur or uftoral) and
(colorectal or colon* or rect* or intestin* or
bowel*)) 
((17902-23-7) and (colorectal or colon* or rect* or
intestin* or bowel*)) 
((PL?11184?0087) and (colorectal or colon* or
rect* or intestin* or bowel*)) 
CRD databases (NHS DARE, EED,
HTA)
CRD Web site – complete databases
Search undertaken April 2002
Capecitabine/all fields
Xeloda/all fields
Tegafur/all fields
Uftoral/all fields
Fluoropyrimidine/all fields
EMBASE
1980–2002
SilverPlatter WebSPIRS
Search undertaken April 2002
#1. Explode ‘colorectal-cancer’ / all 
subheadings
#2. Explode ‘colorectal-carcinoma’ / all
subheadings
#3. Explode ‘colorectal-tumor’ / all 
subheadings
#4. #1 or #2 or #3
#5. Explode ‘neoplasm-’ / all subheadings
#6. Explode ‘carcinoma-’ / all subheadings
#7. Explode ‘adenocarcinoma-’ / all 
subheadings
#8. #5 or #6 or #7
#9. Explode ‘colon-disease’ / all subheadings
#10. Explode ‘rectum-disease’ / all subheadings
#11. Explode ‘colon-’ / all subheadings
#12. Explode ‘rectum-’ / all subheadings
#13. #9 or #10 or #11 or #12 
#14. #8 and #13
#15. ((Carcinoma* or neoplasia* or neoplasm* or
adenocarcinoma* or cancer* or tumo* or
malignan*) near3 (colorectal or colon* or
rect* or intestin* or bowel*))
#16. #4 or #14 or #15
#17. Capecitabine*
#18. Xeloda*
#19. 154361-50-9
#20. EU?1?00?163?001
#21. EU?1?00?163?002
#22. Ro09?1978
#23. Fluoropyrimidine*
#24. Tegafur*
#25. 17902-23-7 
#26. Uftoral
#27. PL?11184?0087
#28. #17 or #18 or #19 or #20 or #21 or #22
or #23 or #24 or #25 or #26 or #27
#29. #16 and #28
HEED (Office of Health Economics
Health Economic Evaluation Database)
CD ROM version
Search undertaken May 2002
Search terms:
Capecitabine
Xeloda
Tegafur
Uftoral
Fluoropyrimidine
Fields searched: 
Quick search – All data
MEDLINE
1966–2002
Ovid Biomed
Search undertaken April 2002
Exp Colorectal Neoplasms/
#1. Neoplasms/
#2. Carcinoma/
#3. Adenocarcinoma/
#4. or/2-4
#5. Colonic Diseases/
#6. Rectal Diseases/
#7. Exp Colon/
#8. Exp Rectum/
#9. or/6-9
#10. 5 and 10
#11. ((Carcinoma$ or neoplasia or neoplasm$ or
adenocarcinoma$ or cancer$ or tumor$ or
tumour$ or malignan$) adj3 (colorectal or
colon$ or rect$ or intestin$ or bowel$)).tw
#12. 1 or 11 or 12
#13. Capecitabine.af
#14. Xeloda.af
#15. 154361-50-9.af
#16. EU#1#00#163#001.af
#17. EU#1#00#163#002.af
#18. Ro09?1978.af
#19. Fluoropyrimidine$.af
#20. Tegafur.af
#21. 17902-23-7.af
#22. Uftoral.af
#23. PL?11184?0087.af
#24. Or/14-24
#25. 13 and 25
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MEDLINE – for the epidemiology of
colorectal cancer only
1966–2002
Ovid Biomed
Search undertaken May 2002
Exp Colorectal Neoplasms/
#1. Neoplasms/
#2. Carcinoma/
#3. Adenocarcinoma/
#4. or/2-4
#5. Colonic Diseases/
#6. Rectal Diseases/
#7. Exp Colon/
#8. Exp Rectum/
#9. or/6-9
#10. 5 and 10
#11. ((Carcinoma$ or neoplasia$ or neoplasm$
or adenocarcinoma$ or cancer$ or tumor$
or tumour$ or malignan$) adj3 (colorectal
or colon$ or rect$ or intestin$ or
bowel$)).tw
#12. 1 or 11 or 12
#13. Colorectal neoplasms/ep
#14. 13 and 14
#15. Limit 15 to yr=1990-2002
#16. (Epidemiolog$ or incidence$ or
prevalence$).ti
#17. 16 and 17
MEDLINE – for further references
specifically on the two 5-FU regimens
(de Gramont and Mayo Clinic)
1966–2002
Ovid Biomed
Search undertaken June 2002
#1. Gramont.tw
#2. Mayo.tw
#3. 1 or 2
#4. Exp Fluorouracil/
#5. 3 and 4
Methodological search filters
used in Ovid MEDLINE
Systematic reviews/meta-analyses
#1. Meta-analysis/
#2. Exp review literature/
#3. (Meta-analy$ or meta analy$ or
metaanaly$).tw
#4. Meta analysis.pt
#5. Review academic.pt
#6. Review literature.pt
#7. Letter.pt
#8. Review of reported cases.pt
#9. Historical article.pt
#10. Review multicase.pt
#11. or/1-6
#12. or/7-10
#13. 11 not 12
Randomised controlled trials
#1. Randomized controlled trial.pt
#2. Controlled clinical trial.pt
#3. Randomized controlled trials/
#4. Random allocation/
#5. Double blind method/
#6. Single blind method/
#7. or/1-6
#8. Clinical trial.pt
#9. Exp clinical trials/
#10. ((Clin$) adj25 (trial$)).ti,ab
#11. ((Singl$ or doubl$ or trebl$ or tripl$) adj25
(blind$ or mask$)).ti,ab
#12. Placebos/
#13. Placebos.ti,ab
#14. Random.ti,ab
#15. Research design/
#16. or/8-15
#17. Comparative study/
#18. Exp evaluation studies/
#19. Follow up studies/
#20. (Control$ or prospective$ or
volunteer$).ti,ab
#21. Prospective studies/
#22. or/17-21
#23. 7 or 16 or 22
Economic evaluations
#1. Economics/
#2. Exp “costs and cost analysis”/
#3. Economic value of life/
#4. Exp economics, hospital/
#5. Exp economics, medical/
#6. Economics, nursing/
#7. Economics, pharmaceutical/
#8. Exp models, economic/
#9. Exp “fees and charges”/
#10. Exp budgets/
#11. Ec.fs.
#12. (Cost or costs or costed or costly or
costing$).tw
#13. (Economic$ or pharmacoeconomic$ or
price$ or pricing).tw
#14. or/1-13
Guidelines
#1. Guideline.pt
#2. Practice guideline.pt
#3. Exp guidelines/
#4. Health planning guidelines/
#5. or/1-4
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Quality of life
#1. Exp quality of life/
#2. Quality of life.tw
#3. Life quality.tw
#4. Hql.tw
#5. (Sf 36 or sf36 or sf thirtysix or sf thirty six
or short form 36 or short form thirty six or
short form thirtysix or shortform 36).tw
#6. Qol.tw
#7. (Euroqol or eq5d or eq 5d).tw
#8. Qaly$.tw
#9. Quality adjusted life year$.tw
#10. Hye$.tw
#11. Health$ year$ equivalent$.tw
#12. Health utilit$.tw
#13. Hui.tw
#14. Quality of wellbeing$.tw
#15. Quality of well being.tw
#16. Qwb.tw
#17. (Qald$ or qale$ or Qtime$).tw
#18. Or/1-18
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Appendix 8
National Cancer Institute common 
toxicity criteria67,69
Toxicity
0 1 2 3 4
White blood cell
count (WBC)
>4.0 3.0–3.9 2.0–2.9 1.0–1.9 <1.0
Infection None Mild Moderate Severe Life threatening
Nausea None Able to eat
reasonable intake
Intake significantly
decreased but can
eat
No significant
intake
Vomiting None 1 episode in 
24 hours
2–5 episodes in 24
hours
6–10 episodes in
24 hours
>10 episodes in
24 hours or
requiring
parenteral support
Diarrhoea None Increase of 2–3
stools/day
Increase of 4-6
stools/day, or
nocturnal stools or
moderate
cramping
Increase of 7–9
stools/day, or
incontinence or
severe cramping
Increase of >10
stools/day, or
grossly bloody
diarrhoea or need
for parenteral
support
Stomatitis None Painless ulcers,
erythema or mild
soreness
Painful erythema,
oedema or ulcers,
but can eat
Painful erythema,
oedema or ulcers,
and cannot eat
Requires
parenteral or
enteral support
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Appendix 9
Unit costs used in economic evaluationa
Cost (£) Year Source
Inpatient day 359 2001 PSSRU
Outpatient day 109 2001 PSSRU
Outpatient clinic appointment with chemotherapy 150 2002 Christie Hospital
Outpatient clinic appointment without chemotherapy 80 2002 Christie Hospital
Medical oncology outpatient follow-up 86.07 2001 NHS reference costs
Day-case 218 2001 NHS reference costs
District nurse home visit 20 2001 PSSRU
GP home visit 59 2001 PSSRU
GP telefon consultation 22 2001 PSSRU
Day-care visit 125 2001 PSSRU
GP surgery consultation 19 2001 PSSRU
GP clinic consultation 26 2001 PSSRU
A and E visit 61 2001 PSSRU
Other hospital visits 74 2001 PSSRU
Line insertion 498 2002 Christie Hospital
Line insertion 537 2001 Revised Christie Hospital cost
Line insertion 250 1996/7 Iveson, 199959
Line insertion-peripherally inserted central catheter 20 2002 Line insertion by nurse
Pumps 65 2002 Christie Hospital
Pumps 62 1996/7 Iveson, 199959
Consultant hour 86 2001 PSSRU
District nurse hour 43 2001 PSSRU
Grade D pharmacist hour 13.25 2000 Avon, Somerset and Wiltshire Cancer
Services Cancer Drug Therapy Forum60
MTO 3 pharmacy technician 9.6 2000 Avon, Somerset and Wiltshire Cancer
Services Cancer Drug Therapy Forum60
Staff nurse hour 27 2001 PSSRU
5-FU 1000-mg vial 12.80 2002 BNF
5-FU 5000-mg vial 64.00 2002 BNF
5-FU 500-mg vial 6.40 2002 BNF
5-FU 250-mg vial 3.20 2002 BNF
LV 50-mg vial 19.41 2002 BNF
LV 350-mg vial 90.98 2002 BNF
a All costs are adjusted to 2002 prices for use in the economic evaluation.
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